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Introduction and outline of the  thesis

IN T R O D U CTIO N  A N D  O U TLINE OF THE THESIS
Introduction
Hem atopo ie tic  stem cell transp lan ta tion  (SCT) is h igh ly e ffec tive  fo r trea ting  
hem atological malignancies, and o th e r disorders. However, p repara tion  fo r  SCT is 
still accom panied by s ign ifican t m o rb id ity  and m o rta lity  resu lting from  uncon tro lled  
in flam m ato ry  cond itions th a t occur at several stages o f the  tre a tm e n t 1. These 
in flam m ato ry  cond itions consist o f mucosal ba rrie r in ju ry  (MBI), m anifesting 
c lin ica lly  as m ucositis, acute and chronic gra ft-ve rsus-host disease (GvHD), 
id iopa th ic  pneum onia syndrom e and in fections. The pathogenesis o f MBI 2;3 and 
gastro in testina l acute GvHD 4;5 have s trik ing  s im ila rities  w ith  in flam m ato ry  bowel 
diseases, includ ing Crohn's disease, in which the  host-m icrob ia l hom eostasis in the 
gastro in testina l tra c t becomes d is tu rbed resu lting  in uncon tro lled  mucosal 
in flam m ation  6-9.
The skin and gastro in tes tina l tra c t are fascinating organs, because th e ir  ep ithe lia l 
barriers are norm ally  in a s tate o f im m unolog ical to le rance, and hom eostasis is 
present, despite the  constant exposure to  b illions o f m icroorganism s and fore ign 
antigens (e.g. food, drugs, po llu tan ts), fo r  which s tr ic t and carefu l regulation o f the 
im m une system is essential 9;10. There has to  be a balance betw een to le rance to  the 
'no rm a l' commensal flo ra  and in to le rance to  pathogenic m icroorganism s, which 
requires the  generation o f an e ffec tive  and s w ift im m une response. Exciting new 
discoveries have been made in recent years, p rov id ing  greater insight in the 
com plex regu la to ry  mechanisms fac ilita tin g  "b a rrie r hom eostasis". It appears th a t 
constant in te rac tion  and "cross-ta lk" be tw een in testina l ep ithe lia l cells (lECs), 
im m une cells (m onocytes, macrophages and de nd ritic  cells) on the  one hand and 
m icrobes (norm al flo ra  and pathogens) on the  o th e r hand are necessary to  
de te rm ine  exactly w ha t is going on at the  mucosal surface and to  d irec t im m une 
activ ity .
The innate im m une system plays a centra l ro le in keeping the  balance, since it is the 
f irs t to  come in con tact w ith  and to  react to  m icroorganism s, and also orchestrates 
the  adaptive im m une system. In th is  regard pa tte rn  recogn ition  receptors (PRRs), 
the  "sensors" o f innate im m une cells, are key players in the  regu la tion  o f mucosal 
im m un ity  11;12. In add ition , an tim icrob ia l peptides (AMPs) play an im p o rta n t role, as 
they are w ide ly  expressed by the  skin and gastro in testina l tra c t and regulate the 
com position  and qu a n tity  o f the  m icrob ia l flo ra  present at the  barriers.
Studies on in flam m ato ry  bowel diseases and psoriasis have id en tified  several 
fac to rs  involved in the  d isrup tion  o f ep ithe lia l homeostasis, includ ing altered 
m icrobia l com position , ove r-activa tion  o f certa in  cy tok ine pathways (in te rleuk in  
(IL-) 12/Th1, IL-23/Th17), and de fective  PRRs, au tophagy and AMPs 8;13-15. These 
insights have already allow ed the deve lopm ent o f new the rapeu tic  and preventive 
in te rven tions fo r these au to-im m une diseases, such as cy tok ine m odu la tion ,
11
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pre -b io tics  and p ro -b io tics  16, PRR m odu la tion  17-20 and the  use o f AMPs. The 
s im ila rities  in pathogenesis be tw een in flam m ato ry  bowel diseases and MBI and 
acute GvHD, suggest th a t these benefic ia l developm ents m ight be transla ted to  the 
se tting  o f SCT and to  am e lio ra te  m o rb id ity  and reduce m orta lity .
Innate immunity
The im m une system has h is to rica lly  been divided in to  the  innate ( 'na tu ra l') and 
adaptive ('acqu ired ') im m une system to  h igh ligh t the  d iffe rence  in p rim itive  and 
m ore sophisticated responses. Current know ledge suggests th a t the  division 
between the  innate and adaptive im m une systems is b lu rred as the re  is considerable 
overlap in fun c tion , and both are highly in te rlinked . Im p o rta n tly  it is now clear th a t 
the  innate im m une system actually  orchestrates the  adaptive im m une system, 
which, in tu rn , con tro ls  and m odulates the  innate im m une responses 21;22. 
Nevertheless, the  d icho tom y is still useful if on ly fo r  the  sake o f c larity.
Innate im m u n ity  is a prim ary  highly conserved im m une system which can been 
found in m ost liv ing organisms, from  plants, insects, fish, birds, and mammals 23. 
Indeed innate im m u n ity  is the  only im m une system many organisms have. It is only 
the  m ore developed organisms, such as mammals, tha t also harbor an adaptive 
im m une response. The innate im m une system brings abou t the  f irs t  con tact w ith  
m icroorganism s and fore ign m olecules and in itia tes  a prim ary  response to  react 
qu ickly to  externa l th rea ts. Besides speed, the  response is characterized by being 
coarse, non-specific , and lacks "m e m ory " so th a t on re-challenge the  same 
response ensues. In contrast, the  adaptive im m une system is re fined, recognizes 
specific fo re ign  molecules, and shows a b e tte r response w ith  every re-challenge. 
The innate im m une system consists o f several hum oral and ce llu la r com ponents 23. 
It com prises the  ep ithe lia l surfaces wh ich resu lt in a d irec t physical ba rrie r th a t has 
also been re ferred to  as the  in tegum ent. Hum oral fac to rs  consist o f the  com plem ent 
systems, AMPs, acute phase pro te ins (e.g. C-reactive pro te in) and mucosal 
secretions (mucins, saliva). Cellu lar com ponents consist o f natural k ille r cells (NK) 
and phagocytic cells such as m onoyctes, macrophages, po lym orphonuclear 
neu troph ils  (PMN) and de nd ritic  cells (DC). These classical im m une cells, are, in 
fact, com plem ented by ep ithe lia l cells, endo the lia l cells and fib rob las ts  which are 
now recognized as being essential ce llu la r com ponents o f the  innate im m une 
system. For instance, IECs recognize m icrobes, produce cytokines and AMPs, 
phagocytize and present antigens 24-26.
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Pattern recognition receptors: key players of the innate immune system
The im portan t discovery in the  drosophila f ly  o f the patte rn  recognition receptor 
named Toll receptor led the  way to  the discovery o f the Toll-like receptors (TLRs) 
which explained how innate im m une cells recognize foreign molecules 27;28. This gave 
a m ajor boost to  the  research in innate im m un ity  which resulted in the discovery of 
many d iffe re n t PRRs in humans. Several fam ilies o f PRR have been iden tified , the 
most im portan t ones being the TLRs, the Nod-like receptors (NLRs), RIG-like receptors 
(RLRs), and the  fam ily  o f C-type lectin receptors (CLRs) (Table 1) 11;29;30.
PRRs are expressed on nearly every human cell ranging from  blood cells to  ep ithe lia l 
and endo the lia l cells and recognize the  so called m icrobe-associated m olecu lar 
pa tte rns (MAMPs; lip ids, p ro te ins and nucleic acids) th a t are evo lu tiona ry  conserved 
m olecu lar pa tte rns o f the  cell w all o f m icrobes (Figure 1). Some PRRs are present 
on the  cell surface, e.g. TLR1, TLR2, TLR4, TLR6, dectin-1 and the  mannose receptor, 
w h ile  o thers reside in the  endosom e/lysosom e com partm en t o r the  cytosol, e.g. 
TLR3, TLR7, TLR9 and NOD2 11. The site and degree o f expression is highly regulated 
and, fa r from  being constant, increases in the  face o f in fec tion  and under 
in flam m ato ry  conditions. The spatial d is tr ib u tio n  is also im p o rtan t, fo r  instance, 
s tim u la tion  o f TLR9 at the  apical o r basolateral site o f ep ithe lia l cells respective ly 
inh ib its  or activates NF-kB 31. M icrob ia l com ponents possess d iffe re n t m o tifs  th a t 
are recognized by d iffe re n t PRRs, w ith  a certa in  degree o f specific ity , which is 
actua lly  advantageous as the  system is s till capable o f p reventing in fection  even 
when a given PRR fa ils to  fun c tion . PRRs were o rig ina lly  tho ugh t to  d iscrim inate 
"se lf" from  "n on -se lf" 32, bu t they also recognize endogenous ligands, released 
a fte r tissue damage includ ing heparan-su lphate, h igh -m o b ility  group box 1 
(HMGB-1), fib rinogen , uric acid and heat shock pro te ins (HSPs), so called danger- 
associated m olecu lar pa tte rns (DAMPs) 33. This enables the  innate im m une system 
to  respond to  "danger" in general, w h e the r or no t it stems from  in fec tion  34.
PRRs exercise broad regu la to ry  functions in hom eostasis and disease 12;35. 
In homeostasis sensing o f commensal flo ra  con tribu tes  to  the  m aintenance o f 
ba rrie r in te g rity  (m ediated by TLR2) 36 and m atura tion  o f the  im m une system e.g. 
by p rom oting  the  deve lopm ent o f IgA+ plasma cells (TLR5) 37, lym phoid fo llic les 
(NOD1) 38 and Peyer's patches (NOD2) 39. W hen faced w ith  pathogenic 
m icroorganism s, or ba rrie r d is rup tion , PRRs sense MAMPs and DAMPs to  e lic it 
pow erfu l p ro tec tive  im m une responses in an a tte m p t to  restore homeostasis. 
W hen in fec tion  develops or tissue damage occurs, the  ensem ble o f activa ted PRRs 
and subsequently activa ted in trace llu la r signaling pathways results in the  release 
o f a cockta il o f cytokines and the activa tion  o f d iffe re n t signaling pathways. The 
resu lting "c y to k in e -p ro file "  defines the  in flam m ato ry  response and orchestrates 
the  deve lopm ent o f the  adaptive im m une response tow ards T-helper 1 (Th1), Th2, 
Th17 o r regu la to ry  T cell a c tiv ity  22;40;41. The s im ultaneous activa tion  o f m u ltip le
13
Table 1 Overview o f pattern recognition receptors, ligands, and characteristics.
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TLR-5 MyD88 Membrane Flagellin Flagellated bacteria -
TLR-7 MyD88 Endosome/lysosome ssRNA Viruses -
TLR-8 MyD88 Endosome/lysosome ssRNA Viruses -
TLR-9 MyD88 Endosome/lysosome CpG DNA Bacteria and mycobac­
teria
Viruses, fungi
Nod-like NOD-1 RIP-2 (RICK) Cytoplasmic DAP (PGN) Gram-negative bacteria -
receptors (NLR) NOD-2 RIP-2 (RICK) Cytoplasmic MDP(PGN) Gram-negative and 
positive bacteria, 
mycobacteria
NLRP-1-14 Asc, caspase-1 
(inflammasome)
Cytoplasmic MDP (NLRP1, NLRP3) 
p-glucan (NLRP3)?
Many bacteria, viruses 
and fungi




IPAF Cytoplasmic Flagellin Pseudomonas, 
Legionella 
Flagellated bacteria






Membrane p-glucan Fungi, mycobacteria -
Dectin-2 Syk/CARD9 Membrane Mannan (N-linked) Fungi -
DC-sign RAF-1 Membrane Mannan (N-linked) Fungi, mycobacteria Glycoproteins
Mannose receptor 
(MR)
? Membrane Mannan (N-linked) Fungi, mycobacteria Glycoproteins
RIG-like RIG-1 Cardif Cytoplasmic dsRNA Viruses -
receptors (RLR) MDA-5 Card if Cytoplasmic dsRNA Viruses -
Secreted PRR MBL - Secreted Mannan Fungi -
PGRP - Secreted PGN Bacteria -


























c h a p t e r  1
Figure 1 Microbe-associated m olecular patterns (MAMPs) o f gram -negative 
and gram -positive bacteria.
TLR = Toll-like receptor. Figure adapted from  van der Poll and Opal Lancet Infect Dis 2008 1
PRRs provides endless possib ilities fo r ta ilo rin g  th is  response against a broad range 
o f m icrobes. However, overw helm ing in fec tion , deregulated expression or 
ac tiva tion  o f PRRs, and fa iling  negative feedback mechanisms can resu lt in the 
collapse o f th is fine ly  tuned system resulting in in fectious disease as w e ll as 
uncon tro lled  in flam m ato ry  responses th a t become m anifest as au to-im m une 
diseases, the  acute resp ira to ry  distress syndrom e (ARDS) and the system ic 
in flam m ato ry  response syndrom e (SIRS) 42-45.
Antimicrobial peptides: nature's antibiotics
A ntim ic rob ia l peptides are evo lu tiona rily  conserved elem ents o f innate im m un ity  
and probably evolved along w ith  the  host and its commensal m icroorganism s and 
pathogens, by exercising s tr ic t con tro l over the  pathogenic m icrobes w h ile  
preserving benefic ia l commensal bacteria. M ore than 700 AMPs have been 
id en tifie d  and they are w ide ly  d is tribu te d  in nature, being found in plants, insects, 
and mammals 46. In general AMPs are small (peptides conta in ing 12-50 am ino acids), 
am phipatic  (having hydrophob ic and hydrophilic  charged patches), and contain at 
least 2 positive ly  m oieties (arginine o r lysine residues). AMPs are produced m ainly
16
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by ep ithe lia l cells, in pa rticu la r the  Paneth cells o f the  small in testine , as well as by 
PMNs, and can be con s titu tive ly  expressed or induced by the  activa tion  o f PRRs 
and p ro -in fla m m ato ry  cytokines. The defensins and cathe lic id ins are the  best 
characterized in humans and are o f m ajor im portance in the  mucosal host defenses 
(Table 2).
P le io trop ic  functions o f AMPs have been dem onstra ted in the  con text o f host 
im m unity , a lthough no t all AMPs share the  same set o f ac tiv ities  46;47. D irect 
an tim icrob ia l a c tiv ity  is re lated to  the  charge and am phipatic  s truc tu re  o f these 
peptides fa c ilita tin g  in te rac tion  w ith  m icrobia l cell m em branes u ltim a te ly  resulting 
in pore fo rm a tio n  and subsequent cell death 48. O ther mechanisms o f action have 
also been described, and some AMPs increase m icrob ia l clearance by opsonization, 
fac ilita tin g  chem otaxis, and by activa ting  phagocytes. O ther im m unom odu la to ry  
ac tiv ities  such as increased p roduc tion  o f cytokines by s tim u la ting  PRRs, and 
increased d iffe re n tia tio n , m atu ra tion  and antigen presen ta tion  o f DCs have been 
described 46;48. Notably, defic iencies in, and dysfunction  of, AMPs have been 
associated w ith  an increased risk o f in fections 49;50 and the  occurrence o f 
au to -im m une diseases o f the  skin and gastro in testina l tra c t 51;52 
The func tiona l p ro file  o f AMPs makes them  a ttra c tive  fo r  fu r th e r investigations as 
po ten tia l agents fo r trea tin g  in fectious com plica tions th a t arise from  trea ting  
patien ts fo r solid tum ors and hem atological m alignancies 46. Several AMPs are now 
under investigation as an tim icrob ia l and im m unom odu la to ry  agents in an a ttem p t 
to  stave o f f  the  increasing resistance o f m icroorganism s to  im p o rta n t an tim icrob ia l 
drugs includ ing quinolones, azoles and cephalosporins, wh ich hampers e ffec tive  
con tro l o f bacteria l and fungal in fections in cancer pa tien ts (Table 2).
Innate immunity and SCT
It is im p o rta n t to  understand the  ro le o f innate im m u n ity  in the  se tting  o f SCT, 
because m ost com plica tions resu lt from  tre a tm e n t e ffec ts  on host im m u n ity  and 
consist o f in fectious com plica tions and in flam m ato ry  syndromes. These con tribu te  
to  bo th the  m o rb id ity  and m o rta lity  o f SCT recip ients and trea tin g  these 
com plica tions generates considerable costs 53-56. T here fore  exp lo ring ways to  
m odulate the  innate im m une com ponents involved in these patholog ical processes 
could prove to  be benefic ia l by im proving SCT outcom e and reducing costs.
Infections
A fte r cond ition ing  w ith  chem otherapy and rad io therapy the  human im m une system 
is severely pertu rbed. Condition ing aims to  achieve m yeloablation to  reduce disease 
burden, and, tog e the r w ith  im m unosuppression, a ttem p ts  to  create 'ro o m ' fo r  the
17
Table 2 O v e rv ie w  o f a n tim icro b ia l p e p tid e s and th e ir p ro p e rtie s .
n
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•■p 2  ai u
Group Name Source Antimicrobial activity Pleiotropic effects
a-defensins HNP-1,2,3,4 Neutrophil granules Broad spectrum antibacterial 
Antiviral activity




a-defensins HD-5,6 Epithelial cells (intestinal 
(Paneth cells), urogenital)
Broad spectrum antibacterial Induction IL-8 
Decreased IL-lp  release 
LPS neutralization?
Classical complement pathway 
inhibition
ß-defensins HBD-1,2,3,4 Epithelial cells (intestinal, 
respiratory, urogenital, skin)
Broad spectrum antibacterial 
Anti-Candida activity




Cathelicidins LL-37 Neutrophil granules, monocytes 
Epithelial cells (skin and lung)
Broad spectrum antibacterial 
Anti-Candida activity
Chemotactic activity, induction of 
IL-8
Production of mucins 
LPS and LTA neutralization 
Promotion of phagocytosis 
Differentiation ¡DCs from monocytes
H ¡statins Histatin-5 Salivary glands Antibacterial 
Anti-Candida activity
Group Derivative Intended use Antimicrobial activity Pleiotropic effects
Human lactoferrin hLFl-11,
LFcinH
Treatment of bacteremia and 
fungal infections in SCT (hLFl-11)
Broad spectrum antibacte­
rial, antifungal, and antiviral 
activity
Promotion of phagocytosis 








Indolicidin Omiganan Prevention catheter infections
Protegrin Iseganan Oral mucositis
BPI rBPI21 Endotoxin neutralization in SCT
I DR = innate defense regulator, BPI = bactericidal/perm eability-increasing protein.
Broad spectrum antibacte­
rial, antifungal, and antiviral 
activity
LPS and CpG DNA neutralization 
Classical complement pathway 
inhibition
Broad spectrum antibacterial, 
however indirect
Induction IL-8 and MCP-1 
Increased IL-10 production
Broad spectrum antibacterial 
and antifungal activity
Broad spectrum antibacterial 
and antifungal activity
-
Gram-negative bacteria LPS neutralization
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stem cell g ra ft and prevent its re jec tion . Consequently, the re  is a pro longed period 
o f severe im m une fa ilu re . Use o f im m unosuppressants fo r acute GvHD prophylaxis 
con tribu tes fu r th e r to  th is  im m unocom prom ised state, pa rticu la rly  w ith  respect to  
the  acquired im m une system. A fte r a llogeneic SCT reco ns titu tio n  o f acquired 
im m u n ity  occurs slowly, and can last up to  a year o r even longer 57;58. During th is 
period patien ts are at risk o f developing in fections due to  bacteria, viruses, fungi, 
and o th e r op po rtu n is tic  pathogens 59-61.
Acquired im m unity  is effective ly absent fo r a prolonged period leaving only the 
remnants o f the innate immune system to defend patients against infection 62. However, 
the innate immune system also suffers damage from  conditioning tha t results in 
neutropenia, epithelia l barrier damage, and lower production of AMPs and salivary 
secretions, although its duration is much shorter, lasting m ostly 3-4 weeks 58;63;64. 
The risk o f developing in fectious com plications is at its highest during th is tim e. 
Current know ledge is lim ited  as to  which com ponents o f the  im m une system remain 
su ffic ie n tly  in tac t to  con tribu te  to  the  an tim icrob ia l defenses a fte r SCT, a lthough it 
is generally believed th a t the  macrophages and antigen presenting cells (APCs) th a t 
reside in the  tissues remain a fte r cond ition ing . Furtherm ore, Paneth cells in the 
small in tes tine  are m ostly  spared from  chem otherapy-induced damage, how w ell 
they s till fun c tion  is no t known 65. W hat exactly happens at the  ep ithe lia l barriers 
o f gastro in testina l tra c t and the lung remains largely speculative, as investigations 
o f the  mucosal surfaces during SCT in humans have no t been pe rfo rm ed p rim arily  
because o f technica l d ifficu lty .
An essential question remains w hy the re  is so much d iffe rence  in in te r-ind iv idua l 
risk fo r in fectious com plica tions even to  patien ts trea ted  w ith in  the  same protocols. 
This probably relates to  d ifferences in the damage in flic ted  upon the innate immune 
system, the  m agnitude o f MBI, pa tien t fac to rs  such as age, gender and co­
m orb id ities , p rio r trea tm ents , bu t also d iffe rences in in te rven tions  such as the  use 
o f p rophy lactic  an tim icrob ia ls . However, d iffe rences in innate im m une genes m ight 
also explain, in part, the  apparent suscep tib ility  o f ind iv idual pa tien ts 62;66.
Inflammatory complications
In flam m ato ry  com plica tions occurring during SCT con s titu te  a group o f overlapping 
and successive d isorders designated MBI 2, sepsis, acute GvHD 67, id iopath ic  
pneum onia syndrom e 68, and en g ra ftm en t syndrom e 69. The induction  by the 
cond ition ing  tre a tm e n t o f tissue damage, especially o f ep ithe lia l barriers o f the  gut 
and lung, appears centra l to  the  pathogenesis th a t leads to  the  unrestra ined 
in flam m ation  resu lting from  excessive release o f p ro -in fla m m ato ry  cytokines 
e lic ited  by activa tion  o f PRRs by various m icrobia l m otifs  and endogenous ligands 
(Figure 2  and 3). The ro le o f innate im m u n ity  and PRR-induced in flam m ation  has 
also been im p lica ted in the  process o f g ra ft re jec tion  70.
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Mucosal barrier injury
Chem otherapy and rad io therapy damage the  oral and gastro in testina l mucosa 
in itia tin g  an in flam m ato ry  cascade th a t culm inates in MBI, w h ich m anifests itse lf 
c lin ica lly  as m ucositis. The pathogenesis o f MBI is tho ugh t to  consist o f five  phases 
2;3;71: 1) the  activa tion  o f nuclear factor-KB d ire c tly  by chem o/rad io therapy and 
in d ire c tly  from  fo rm a tio n  o f reactive oxygen species (ROS), DNA, and non-DNA 
damage 72, 2) p roduction  and release o f p ro -in fla m m ato ry  cytokines and chemokines 
(IL-1, IL-6, IL-8, tu m o r necrosis fa c to r (TNF) a, IL-23, in te rfe ron  (IFN) y) by 
macrophages, lECs and endo the lia l cells 72-77, 3) positive feedback loop o f TNFa, 
ep ithe lia l cell apoptosis and increased mucosal pe rm eab ility  78;79, 4) transloca tion  
o f m icrobes or m icrob ia l wall com ponents aggravating in flam m ation  ("cy tok ine 
s to rm ") 80-82, and 5) repair and healing. A lthough the im pact o f m icrobes and th e ir 
cell wall com ponents on the  in flam m ato ry  response is o f secondary im portance, 
s tim u la tion  o f PRRs by MAMPS transloca ting  the  d isrupted mucosal barrier, o r the 
invasion o f m icroorganism s leading to  bacterem ia and endotoxem ia, appear to  
aggravate in flam m ation  (Figure 2). This could also so be the  case fo r  DAMPs, which 
are released as a resu lt o f tissue damage, and in th is  regard the  endogenous ligands 
HMGB-1 and HSP m ight be o f pa rticu la r in te rest (Figure 2) 83.
Graft-versus-host disease
Acute GvHD results from  an allo-im m une response directed at host antigens after 
engraftm ent and is accompanied by the activation of alloreactive T lymphocytes tha t 
attack the host tissues. However, MBI fo llow ing conditioning is also thought to  play an 
im portan t role in the in itia tion phase of acute GvHD 5;74. Chemotherapeutic agents, 
radiation, p ro-in flam m atory cytokines (IL-ip, TNFa, IFNy) and stim ulation o f PRRs by 
DAMPs and MAMPs activate both APCs and epithelia l cells which increase the ir 
expression of co-stim ulatory cytokines, m inor h istocom patib ility  complex antigens 
(miHags) and major h istocom patib ility  complex (MHC) molecules 70;82;84-89. Furthermore, 
chemokines (CXCL10, CXCL8) are released to  a ttrac t alloreactive T- and NK-cells to  the 
secondary lymphoid tissues of target organs 90;91. In the second phase activated host 
APCs, and to  a lesser extent, donor APCs, present host antigens to  alloreactive 
T-lymphocytes 84;92-94. Activation and pro life ra tion of T lymphocytes, predom inantly 
Th1 lymphocytes and probably Th17, then ensues and is crucial to  the pathogenesis of 
GvHD. In addition, APCs im prin t alloreactive T-cells w ith  more or less tissue specific 
homing molecules 95. During the last phase tra ffick ing  o f alloreactive T- and NK-cells to 
inflamed tissues occurs 91;96 leading to  the ir damage as result o f the cytotoxic effects 
and the release o f Th1 and Th17 type cytokines 67;93. Subsequently, at least in intestinal 
GvHD, mucosal damage again leads to  am plification of in flam m ation, through 
translocation o f bacterial products, increasing cytokine release and stim ulating Th1 
and Th17 responses 70;82;97;98 (Figure 2 and 3).
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Figure 2 Mucosal barrier and innate im m unity.
In health there is a tightly  contro lled immune balance at the mucosal barriers w ith  tolerance to 
commensal flora, and absence of tissue damage. PRRs sensing MAMPs play an im port role in maintaining 
this homeostasis. The m icrobial flora is kept in check, fo r instance through the release of AMPs, and 
immune responses are dampened by preservation o f the physical barrier, selective expression o f PRRs, 
and beneficial properties o f commensal microorganisms. There is a low  state o f immune activation and 
inflam m ation ('physiological inflam m ation'), that contributes to the developm ent o f a healthy local and 
systemic immune system and keeps the immune system on stand-by (left panel). During health, innate 
immune responses m odulate the acquired immune responses towards a tolerogenic profile contributing 
to  the homeostasis.
22
IN TRODUCTION A N D  OUTLINE OF THE THESIS
Due to  MBI resulting from  cytotoxic therapy and mucosal damage resulting from  GvHD the mucosal 
barriers and immune homeostasis are perturbed. Microorganisms and MAMPs are able to  translocate 
and induce inflam m ation by activating PRRs. This is aggravated by the release o f DAMPs released on the 
occurrence of tissue damage. The m icrobial flora is not kept in check w ith  an increase in pathogenic 
microorganisms (dysbiosis) (righ t panel). Deregulated innate immune responses contribute to  the 
developm ent o f inflam m atory com plications by eliciting pro-in flam m atory acquired immune responses 
which can fu rthe r damage the mucosal barriers. TLR = Toll-like receptor, NLR = Nod-like receptor, 
TSLP = thym ic stromal lym phopoietin, TGF-0 = transform ing grow th facto r beta, TNFa = tum or necrosis 
factor alfa, IFNy = in terfe ron  gamma, IL = interleukin, HMGB-1 = high m ob ility  group box 1, 
HSP = heat shock protein, LPS = lipopolysaccharide, LTA = lipote ichoic acid, MDP = muramyl dipeptide, 
Th = T helper lymphocyte, Treg = regulatory T cell, PAMP = pathogen-associated molecular pattern, 
DAMP = danger-associated molecular pattern, and AMP = antim icrobia l peptide. Illustration by Tine 
Thorig wetenschappelijke illustraties.
The in flam m ato ry  cond itions m ainly involve the  gastro in testina l trac t, h igh lighting 
the  im portance o f host-m icrob ia l in te ractions in creating the  risk and de fin ing  the 
m agnitude o f these com plica tions. Some patien ts su ffe r from  severe in flam m ation  
and acute GvHD w h ile  others do not. These in te r-ind iv idua l d iffe rences resu lt from  
varia tion  in the  m agnitude o f damage in flic ted  on the  innate im m une system, the 
com position  o f the  m icrob ia l flo ra  99;100, m ism atches in MHC and miHags, the 
severity  o f MBI 101, and also d iffe rences in the  genes fo r  innate im m u n ity  and o ther 
non-HLA genes involved in the  expression and fu n c tio n  o f PRRs, cytokines, and NK 
cell ac tiva tion .
Non-HLA immunogenetics in SCT
Ind ividual d iffe rences in transp lan t-re la ted  com plications, has stim u la ted  the 
grow ing in te rest in the  im pact o f single nucleotide  po lym orphism s (SNPs) in 
non-HLA im m une genes on the  occurrence o f in fections, MBI and acute GvHD in 
SCT 102-105. The genes o f pa rticu la r in te rest are those involved in the  p roduc tion  and 
a c tiv ity  o f cytokines and chem okines, innate im m une genes such as the  PRRs and 
AMPs, and k ille r cell im m unog lobu lin -like  receptor (KIR) genes in NK cells. The 
concept o f env ironm en ta lly  de term ined genetic expression (EDGE) was in troduced 
by Kallianpur et al. to  account fo r  the  observations 106. EDGE is based on the 
fo llow ing  observa tions: 1) genetica lly encoded varia tions in expressed prote ins 
have d iffe re n t e ffec ts  in d iffe re n t environm enta l contexts; 2) a disease phenotype 
is de term ined by both the  func tiona l m agnitude o f the  genetic change and the 
severity  o f the  environm enta l change; 3) rare genetic d isorders (e.g. inborn errors 
o f m etabolism ) represent one extrem e w ith  l i t t le  con tribu tion  from  the  environm ent, 
w h ile  massive env ironm enta l insults resu lt in phenotypes independent o f genetic 
varia tion ; and 4) m ost diseases/phenotypes fa ll be tw een these extrem es (Figure 4).
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Figure 3 Hypothesis on the  relationship between MBI and in flam m atory 
com plications post SCT.
Chem otherapy and radio therapy induce tissue damage in particu la r to  the mucosal barriers o f the oral 
and intestinal tracts. Activation of NF-kB, ROS form ation , release of DAMPs and increased mucosal 
perm eab ility  resulting in translocation o f MAMPs which activate PRR-pathways u ltim a te ly  result in a 
systemic in flam m atory response which is associated w ith  the occurrence o f com plications including 
the systemic in flam m atory response syndrome, acute lung injury, and graft-versus-host disease. SIRS 
= systemic in flam m atory response syndrome, BOOP = b ronch iolitis  obliterans organizing pneumonia, 
PRR = pattern recognition receptor, MAMP = m icrobe-associated m olecular pattern, DAMP = danger- 
associated m olecular pattern
Exposure to  high-dose chem otherapy presents a considerable insu lt th a t may 
unmask the  e ffec ts  o f no rm ally  s ilent genetic po lym orphism s.
M any studies have been pe rfo rm ed on the  im pact o f SNPs in non-HLA genes in SCT, 
especially regarding cytokines, PRRs, and the  com plem ent system (mannose- 
b ind ing lec tin  (MBL)) 102-104. However, con tra d ic to ry  results and a lack o f consistency 
make draw ing firm  conclusions d iff ic u lt ,  and im pede the  deve lopm ent o f strategies 
to  am e lio ra te  SCT-related com plica tions in clinical practice. This arises from  
problem s associated w ith  research in to  genetic linkage, includ ing sample size, 
selection bias, genetic d ive rs ity /he te rog ene ity  betw een popu lations, and clinical 
con text 107;108. Nevertheless, at least fo r  the  tim e  being, s tudying these po ly­
m orphism s provides insight in to  the  pathogenesis o f the  com plex im m unolog ical 
processes tha t take place a fte r SCT. In the fu tu re  de tection o f genetic polym orphism s 
th a t are consis ten tly  associated w ith  disease could resu lt in the ra pe u tic  and 
preventive approaches, such as a lte red donor selection, risk adapted an tim icrob ia l 
prophylaxis, and use o f agents m odula ting  PRR-pathways. Then, screening fo r  SNPs
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Figure 4 The concept o f environm enta lly  de term ined genetic expression 
(EDGE).
The role o f genetic defects on the developm ent o f diseases depends at the one hand on the degree of 
functional consequences of a particu la r defect and on the o the r hand on environm enta l factors and 
confounders. Figure adapted from  Kallianpur et al. Bone M arrow  Transplant 2005 106.
in non-HLA genes should be im p lem ented in clinical practice. A t present, the  m ost 
prom ising candidates are gene po lym orphism s in NOD2/CARD15 109, TLR4, the  IL-2 3 
receptor 110, MBL 111;112, IL-10 and TNFa 113-115. However, many others genes remain 
to  be evaluated and investigated in SCT as new PRRs, cytokines, and com plem ent 
m olecules are discovered every year.
A t the  same tim e, developm ents in genetic research in o th e r areas o f m edicine 
should be fo llow ed  closely. For instance, new in te resting  SNPs and m uta tions have 
been found in various diseases w ith  the  help o f genom e-w ide association studies 
108;116. Since many genes are re lated to  host im m u n ity  any new find ings m ight be o f 
in te rest in the  se tting  o f SCT.
Antimicrobial peptides in SCT
In cu rren t practice, supportive  care measures in SCT are aim ed at p reventing and 
trea ting  in fections and in flam m ato ry  com plica tions using an tim icrob ia l agents, 
granulocyte colony-stimulating factors (G-CSF), corticosteroids, and other immuno- 
m odulators. Using reduced in tens ity  cond ition ing  regimens, mucosal p ro tectan ts
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or g ro w th  fac to rs  such as ke ra tinocyte  g row th  fac to rs  (KGF) 117 are also ways of 
a ttenua ting  the  tissue damage resu lting from  cond ition ing , a lthough w ith  variab le 
success. Strategies are o ften  ra the r a rtific ia l, o r at best rem edies, so approaches in 
w hich the  physio logical state o f innate im m u n ity  is preserved, im proved or restored 
are pre fe rred . The app lica tion  o f g ro w th  fac to rs  such as G-CSF and KGF is a good 
exam ple o f this.
In troducing AMPs in the  se tting  o f SCT w ould  be o f pa rticu la r in te rest fo r  several 
reasons 46;118;119. Firstly, decreased expression o f AMPs has been shown to  be linked 
to  the  occurrence o f human diseases 120;121. For instance, SNPs in genes o f the 
Paneth cells, the  m ost im p o rta n t source o f AMPs in the  in testine , resu lt in decreased 
p roduc tion  o f both a-defensins (HD-5 and 6) and p-defensins (hBD2) and have been 
linked to  the  pathogenesis o f in flam m ato ry  bowel diseases 122;123. This has been 
con firm ed fo r SNPs in NOD2, the  PRR fo r  m uram yl d ipeptide , and SNPs in the  W nt 
signaling pathway, a pathway im p o rta n t in Paneth cell deve lopm ent and homeostasis 
i24;i25. There fore, adm in is tering  AMPs to  correc t the  de fic it, especially in those 
indiv iduals w ho have a genetic disadvantage, m ight be the rapeu tica lly  valuable. 
Secondly, these na tu ra lly  occurring peptides possess several im p o rta n t a ttr ibu tes  
th a t could be exp lo ited  in the  se tting  o f SCT. The broad spectrum  an tim icrob ia l 
a c tiv ity  o f AMPs w ith  an tibacte ria l, an tiv ira l, and an tifungal ac tiv ity , even against 
m u lti-res is tan t m icroorganism s, w ou ld  be o f great im portance in the  tre a tm e n t o f 
in fections a fte r SCT. A t the  same tim e  AMPs can dampen po ten tia lly  harm fu l pro- 
in flam m ato ry  responses by scavenging MAMPs, th a t transloca te  across the 
damaged gastro in testina l tra c t during MBI and acute GvHD. In add ition , the  im m une 
enhancing a c tiv ity  o f AMPs m ight con tribu te  to  the  preven tion  o f in fections and 
help accelerate im m une recons titu tion .
M any cation ic AMPs have been developed and stud ied extensive ly in vitro; however 
few  have been stud ied in vivo and even few er in humans (Table 2). One o f the 
exceptions, iseganan, an analog o f p ro tegrin , has been tested in phase III clinical 
tria ls  fo r  the  preven tion  and tre a tm e n t o f rad io therapy- and chem othe rapy-in ­
duced oral m ucositis, bu t the  results w ere d isappo in ting  126;127. In fact, despite th e ir 
prom ise in vitro, none o f the  com m ercia lly  developed AMPs has ye t proved safe 
and e fficacious in the  tre a tm e n t o f any human diseases. So, th e ir  in tro du c tion  in to  
clinical practice is likely a long way away as studies are ju s t s ta rting  to  be designed 
to  generate the  answers we need before we can em ploy AMPs as new clinical 
therapeutics.
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Aims and outlines of this thesis
The thesis consists o f th ree  com p lem entary  parts addressing the  them e o f innate 
im m un ity  and host-m icrob ia l in te ractions in the  se tting  o f hem atopo ie tic  SCT w ith  
a special focus on in fectious and in flam m ato ry  com plica tions.
In the f irs t part 'the  stage was set' by investigating the factors tha t con tribu te  to  the 
in flam m ato ry  response and the com plications seen a fte r cond ition ing w ith  chemo- 
and rad io therapy to  prepare fo r a SCT. Historically, the focus has been on neutropenia 
and the resulting in fectious com plications, but in recent years the role of MBI and 
alterations in host-m icrob ia l in teractions at mucosal barriers have gained prom inence. 
Our hypothesis was tha t the degree o f MBI, ra ther than neutropenia, determ ines the 
onset and extent o f in flam m ation and influences the incidence of com plications 
post-SCT. We also wanted to be tte r define the role o f bacterem ia in this process. We 
describe the results o f tw o  retrospective studies o f patients who had received an 
autologous or allogeneic SCT in our hospital (chapter 2 and 3).
In the  second pa rt o f the  thesis we explored the  im pact o f SNPs in tw o  d iffe re n t 
innate im m une genes, namely, NOD2 and dectin-1, on the  outcom e o f SCT recip ients. 
Both NOD2 and dectin-1 are PRRs involved in the  sensing o f m icroorganism s and 
MAMPs at ep ithe lia l and mucosal surfaces o f the  human body. In previous studies 
it has been shown th a t the  presence o f NOD2 polym orphism s, which were orig ina lly  
described in Crohn's disease, exerted a s ign ificant im pact on the  incidence o f 
severe acute GvHD and trea tm e n t-re la te d  m o rta lity  (TRM). Besides supporting  the 
ro le fo r host-m icrob ia l in te ractions in SCT, these results suggest tha t looking fo r  
these po lym orphism s m ight have clinical consequences w ith  respect to  an tim icrob ia l 
the rapy and prophylaxis. One pa rticu la r problem  w ith  SNP studies has been tha t 
docum ented associations are very much con text dependent and th e re w ith  o ften  
d iff ic u lt  to  con firm  and reproduce. There fore, we set ou t to  con firm  the  im pact o f 
NOD2 polym orphism s on severe acute GvHD and TRM, especially as we perfo rm  
partia l T ce ll-dep le tion , and looked fo r the  im pact o f NOD2 po lym orphism s on 
bacterem ia. We analyzed the  data from  a hom ogenous coh o rt o f pa tien ts w ho all 
had received m yeloabla tive cond ition ing  conta in ing idarubic in  fo r SCT (chapter 4). 
The dectin-1 po lym orphism  Y238X was shown to  resu lt in a "loss -o f-fun c tion " w ith  
de fective  Candida b ind ing and cytok ine p roduc tion  and had been recently  
discovered in a Dutch fam ily  w ith  several subjects su ffe ring  from  recu rren t 
m ucocutaneous candidosis. We investigated the  im pact o f th is  po lym orphism  on 
Candida co lon ization, system ic Candida in fections, and invasive m ould in fections 
occurring a fte r SCT (chapter 5) to  see w h e the r it was possible to  b e tte r ta ilo r 
prophylaxis to  the  ind iv idual pa tien t's  needs. SNPs associated w ith  the  occurrence 
o f fungal in fections, if consisten t and con firm ed, could be used to  pe rfo rm  risk 
s tra tifica tio n .
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Dectin-1 is activa ted by the  fungal cell wall com ponent p-glucan which results in 
both innate and acquired im m une responses. There fore, we stud ied the  im pact o f 
the  dectin-1 status as well as Candida co lon ization on the  occurrence o f acute and 
chronic GvHD, relapse, re lapse-re la ted m o rta lity , and overall survival (chapter 6). 
In the  th ird  pa rt we investigated the  ro le o f the  an tim icrob ia l p ro te in  human 
la c to fe rrin  and a peptide de riva tive  - human la c to fe rrin  1-11 (hLF1-11) - in the 
tre a tm e n t o f SCT recip ients. Human la c to fe rrin  is a natural defense p ro te in  present 
in body flu ids  and secretions as w ell as neutroph ils , and has p le io trop ic  functions 
includ ing an ti-m icrob ia l ac tiv ity , a n ti- tu m o r activ ity , regulation o f cell g row th  and 
d iffe re n tia tio n , and m odu la tion  o f in flam m ato ry , hum ora l and ce llu la r im m une 
responses. Levels o f la c to fe rrin  are decreased fo llow ing  SCT, con tribu ting  to  the 
overall im m une deficiency, so correcting  th is  d e fic it m ight enhance im m un ity  in 
SCT recip ients. Preclinical studies showed prom ising an tim icrob ia l a c tiv ity  o f 
hLF1-11 even in im m unode fic ien t mice, and being a de riva tive  o f a 'n a tu ra l' p ro te in  
it m ight have few e r disadvantages like side e ffec ts  and occurrence o f an tim icrob ia l 
resistance. We f irs t  described the  theo re tica l background, sum m arizing the 
po ten tia l roles o f lac to fe rrin , deriva tives and o th e r AMPs in the  tre a tm e n t o f 
SCT-related com plica tions, includ ing in fections, MBI and GvHD (chapter 7). Next, 
a fte r con firm ing  th a t the  drug was safe in healthy vo lunteers, we investigated the 
to le ra b ility  and safe ty o f a single dose o f hLF1-11 in a clinical tr ia l invo lv ing patients 
receiving an autologous SCT (chapter 8). A t the  same tim e  in vitro  studies were 
pe rfo rm ed to  de te rm ine  the  im m unom odu la to ry  a c tiv ity  o f hLF1-11, and establish 
the  presence o f any o f the  p le io trop ic  activ ities  possessed by la c to fe rrin  and o ther 
AMPs (chapter 9).
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CHAPTER 2
Abstract
We unde rtook  a re trospective  analysis o f a coh o rt o f sixty-seven patien ts w ith  
m u ltip le  m yelom a w ho had received an autologous HSCT fo llo w in g  high dose 
m elphalan to  exp lore the  im pact o f m ucositis  on the  system ic in flam m ato ry  
response. A hom ogenous group o f 16 patien ts w ith o u t a docum ented in fec tion  and 
a group o f 30 pa tien ts w ith  bacterem ia were id en tified  fo r whom  com ple te data on 
neutropen ia, an in flam m ato ry  response, in fectious com plica tions and m ucositis 
were available. All pa tien ts showed a s im ilar course o f events w ith  an in flam m ato ry  
response coincid ing w ith  the  occurrence o f s ign ificant m ucositis, regardless the 
presence o r absence o f in fection . The only d iffe rences between the tw o  groups 
were s ign ifican tly  higher maxim um  C-reactive p ro te in  (CRP) levels and low er 
c itru llin e  levels fo r  pa tien ts w ith  bacterem ia, suggesting a causative ro le fo r 
m ucositis in the  occurrence o f bacterem ia. S tatistica l analysis showed a s ign ificant 
association over tim e  between c itru llin e  levels, to  a lesser exten t bacterem ia, but 
not neutropen ia, and the  in flam m ato ry  response measured by CRP. These data 
suggest th a t the  in flam m ato ry  response a fte r cond ition ing  fo r  a HSCT is the  result 
o f the  chem otherapy-induced m ucositis and independent o f neutropen ia. Though 
prim ary  in flam m ation  appeared due to  m ucositis, in fections resu lting from  mucosal 
ba rrie r in ju ry  and neutropen ia  aggravated the  in flam m ato ry  response.
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Introduction
Four decades have passed since Bodey et al. 1 reported  th a t neutropen ia 
accom panied by subsequent in fectious com plica tions was the  main de te rm inan t of 
fever during neutropen ia  ("feb rile  neu tropen ia "). However, they  also showed th a t 
th is re la tionsh ip  did no t hold fo r  feb rile  patien ts w ho were no t in fected, suggesting 
tha t neutropen ia  was no t the  sole de te rm inan t o f fever 1. Nonetheless, feb rile  
neutropen ia has been regarded one o f the  m ost im p o rta n t com plica tions o f cancer 
therapy and the re fo re  preven tion  and tre a tm e n t w ith  an ti-m icrob ia l drugs and 
g ranu locyte  colony s tim u la ting  fac to rs  have been stud ied extensive ly 2-5. However, 
many o f these studies also repo rted  th a t a substantia l num ber o f pa tien ts rem ained 
feb rile  w ith o u t a in fec tion  ever being docum ented 2. Hence, such episodes o f fever 
were designated "unexpla ined fe ve r" 6.
Fever is a consequence o f the  release o f cytokines. Many d iffe re n t inducers of 
these cytokines exist in hem atopo ie tic  stem cell transp lan ta tion  (HSCT) recip ients, 
and by no means are all o f these re lated to  in fections. Chem otherapy and 
rad io therapy used in cond ition ing  the rapy damage the oral and gastro in testina l 
mucosa in itia tin g  an in flam m ato ry  cascade, cu lm ina ting in mucosal ba rrie r in ju ry  
(MBI), which m anifests itse lf c lin ica lly  as m ucositis. The pathogenesis o f MBI is 
tho ugh t to  consist o f five  phases: 1) the  activa tion  o f nuclear factor-KB, 2) release 
o f p ro -in fla m m ato ry  cytokines, 3) ep ithe lia l cell apoptosis and increased mucosal 
perm eability , 4) trans loca tion  o f m icrobes o r m icrob ia l wall com ponents and 5) 
repair and healing 7-9. D isruption o f the  mucosal ba rrie r is also an im p o rta n t risk 
fa c to r fo r  the  occurrence o f bacterem ia 10-12 and candidem ia 13. However, the  im pact 
o f m icrobes on the  in flam m ato ry  response may no t be necessary since MBI alone 
appears able to  e lic it a system ic in flam m ato ry  response evidenced by elevated 
C-reactive p ro te in  (CRP) levels and fever. This is supported by clinical data showing 
tha t pa tien ts receiving chem otherapy experience m ore fever w ith  o r w ith o u t 
in fections in the  presence o f severe m ucositis 14. This suggests m ucositis to  be a 
s ign ificant independent risk fa c to r fo r  the  occurrence o f feve r and in fections of 
HSCT recip ients.
In o rder to  de te rm ine  the  im pact o f m ucositis on the  system ic in flam m ato ry  
response, and the  occurrence o f " fe b rile  neutropen ia", a re trospective  analysis was 
conducted in a cohort o f rec ip ients o f an autologous HSCT fo llow ing  high dose 
m elphalan the rapy (HDM) w ho had no id en tifiab le  in fectious com plica tions. We 
com pared the  course o f in flam m ato ry  events in th is  group w ith  those having a 





We pe rfo rm ed a re trospective  analysis o f 67 consecutive patien ts w ith  m u ltip le  
m yeloma w ho had been given an autologous HSCT fo llow ing  HDM in our hospita l 
from  May 2004 to  December 2006. Data on m ucositis, in flam m ation  and in fections 
had been prospective ly  gathered from  the  day o f s ta rting  chem otherapy (day 1) 
un til discharge.
All pa tien ts were trea ted  according to  the  same pro toco l and managed w ith  a 
centra l venous ca the te r (CVC). The prepara tive  regim en consisted o f HDM (200 
m g/m 2) adm in is tered over tw o  days on days 1 and 2. On day 4, all pa tien ts were 
given an autologous HSCT conta in ing at least 2.0 x 106 CD34+ cells per kg. Patients 
did no t receive hem atopo ie tic  g ro w th  fac to rs  and an ti-m icrob ia l prophylaxis 
consisted o f 500 mg c ip ro floxacin  given tw ice  da ily and 500 mg va lac ic lov ir given 
th ree  tim es daily. Fluconazole was given at 200 mg a day on ly  to  those w ho were 
colonized w ith  Candida albicans. Blood (10 ml) was drawn fo r aerobic cu ltu re  each 
M onday and Thursday from  each lum en o f the  CVC. A blood cu ltu re  was considered 
positive if one or m ore bo ttles  yie lded a m icroorganism , except fo r  coagulase- 
negative staphylococci, fo r  w h ich tw o  separate positive blood cu ltu res y ie ld ing the 
same stra in were required to  be considered to  represent bacterem ia 15.
Plasma was ob ta ined on the  same days to  de tect Aspergillus ga lactom annan- 
antigen (Platelia Aspergillus EIA test; Biorad Laboratories, Veenendaal, The 
Netherlands). A x illa ry  tem pe ra tu re  was recorded fo u r tim es a day and fever was 
defined by a single ax illa ry  tem pe ra tu re  > 38.5oC. A t the  onset o f feve r 40 ml o f 
periphera l b lood was ob ta ined fo r cu ltu re  tog e the r w ith  10 ml from  each lum en o f 
the  catheter, the  patien ts w ere  exam ined fo r any signs o f local in fection , em pirica l 
the rapy was s ta rted  w ith  2000 mg ceftaz id im e given th ree  tim es da ily in travenously, 
and a chest X-ray was ordered. Blood cultu res w ere ob ta ined again on the  4th day 
o f em pirica l the rapy and a tho rough  clinical exam ination was done. A high-resolu- 
tion  com puterized tom ography scan o f the  lungs was undertaken fo r pa tien ts who 
were s till feb rile  w ith o u t the re  being an obvious cause to  de tect any signs of 
invasive fungal disease. W here possible, bronchoscopy was carried ou t if indicated 
to  ob ta in  a bronchoa lveo lar lavage, w h ich was then subjected to  a com prehensive 
m icrob io log ica l exam ination includ ing de tection  o f Aspergillus antigen.
Neutrophil count
The absolute neu troph il count (ANC) was de term ined da ily and neutropen ia  was 
de fined as an ANC < 0.5 x109/ l,  w ith  pro found  neutropen ia being defined as an ANC 
< 0.1 x109/ l.  The duration and depth o f neutropenia was recorded fo r each patient.
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Inflammatory response
CRP levels (m g/l) were de term ined every day and the maxim um  CRP (CRP max) and 
day o f CRP max were recorded.
Mucosal barrier injury assessment
Oral m ucositis was graded da ily according to  the  valida ted N ijm egen Nursing 
M ucositis  Scoring System (NNMSS) 16. Also the  maxim um  value and day o f maximum 
value were recorded. Plasma c itru llin e  was de term ined to  estim ate gu t m ucositis 
be fore the  s ta rt o f HDM and th ree  tim es w eekly th e re a fte r un til discharge 17. The 
day o f nadir and the  lowest c itru llin e  levels w ere recorded fo r each patien t.
Study group selection
Two pa tien t groups were selected. The f irs t  group consisted o f pa tien ts fo r  whom  
no m icrob io log ica lly  de fined o r a c lin ica lly  de fined in fection  had been iden tified  
according to  the  Consensus de fin itions  o f Im m unocom prom ised Host Society 6. The 
second group consisted o f pa tien ts w ith  bacterem ia according to  the  same 
consensus de fin itions .
Data analysis
We em ployed descrip tive statis tics fo r  fever, neu troph il count, CRP level, NNMSS 
and c itru llin e  levels w h ich w ere expressed as mean values tog e the r w ith  the  95% 
confidence in te rva l, w ith  the  use o f SPSS v 14.0. Comparison o f the  variables was 
done using the  independent t-tes t, M ann-W hitney U-test, x2-tes t o r Fisher's exact 
tes t when appropria te .
C itru lline  was measured th ree  tim es weekly; the re fo re  the  real c itru llin e  nadir 
m ight be a tta ined  between tw o  m easurem ents and hence rem ained unobserved. 
To study the  mean o f the  possibly unobserved c itru llin e  nadirs and the day o f 
occurrence we stud ied the  course o f c itru llin e  as a fun c tion  o f tim e  during the  firs t 
18 days by developing a cubic linear m ixed model w ith  f irs t, second and th ird  power 
o f tim e  as pred ictors.
To describe the  re la tionsh ip  o f neu troph il count, m ucositis (NNMSS and c itru lline ) 
and bacterem ia on CRP we used several linear mixed m odels fo r  the  f irs t  18 days 
and im p lem ented the  loga rithm ic  transfo rm ed ou tcom e variab le log10 CRP. The 
covariance s truc tu re  could adequate ly be m odeled w ith  the  heterogeneous 
com pound sym m etry.
Because the  c itru llin e  levels were measured th ree  tim es weekly, th is  variab le had 
missing values. The mechanism o f these missing data was considered to  be 
com ple te ly  at random . There fore, we used the  SAS procedure PROC MIXED, which 
handles missing data w ith o u t in troduc ing  bias.





In the to ta l cohort o f 67 subjects 19 patients had no documented in fection (Table 1). 
However, data on c itru llin e  levels were lacking fo r 3 patien ts, leaving 16 patients 
e lig ib le  fo r  analysis. A to ta l o f 40 pa tien ts had a m ic rob io log ica lly  de fined in fec tion , 
37 w ith  bacterem ia due to  Gram positive bacteria (Table 1). Data on c itru llin e  levels 
w ere missing in 7 cases resu lting in a fina l coh o rt o f 30 pa tien ts w ith  bacterem ia. 
There were no s ta tis tica lly  s ign ificant d iffe rences in age, body mass index, gender 
d is tr ib u tio n  o r dose per kg o f m elphalan (Table 2).
Table 1 Study population.
T o ta l s tu d y  p o p u la t io n N = 67
No in fe c t io n N = 19
M ic ro b io lo g ic a lly  d e fin e d  in fe c t io n * :
- OVS b a c te re m ia .
- OVS and CoNS b a c te re m ia .
- CoNS b a c te re m ia .
- B a c te re m ia  (Aerococcus, Gemella, Bacillus).
- Fusariosis.
- C an d ide m ia .
- G en e ra lized  he rpes  zo s te r in fe c t io n .
N = 40
-  N = 17






C lin ica lly  d e fin e d  in fe c t io n * :
- P n e um o n ia .
- T h ro m b o p h le b it is .
N = 7
- N = 6
- N = 1
N o n - in fe c tio u s  in f la m m a to ry  c o n d it io n . N = 1
*D efin itions according to  the Immunocompromised Host Society defin itions 6. 
OVS = o ral viridans streptococcus and CoNS = coagulase negative staphylococcus.
Neutrophil count
All pa tien ts experienced neutropen ia fo r  a mean du ra tion  o f 9 days, which was 
pro found in all cases fo r a mean du ra tion  o f 6 days (Figure 1a). No s ign ificant 
d iffe rences existed be tw een patien ts w ith o u t in fections and those w ith  bacterem ia 
(Table 2). N eutropenia w ith  ANC < 0.5 x 109/ l  occurred a mean o f 9 days a fte r 
s ta rting  chem otherapy (5 days post-HSCT).
Inflammatory response, fever and bacteremia
The course o f mean da ily CRP levels during HSCT is illus tra ted  in Figure 1b. CRP 
levels were elevated fo r all pa tien ts in both study groups s ta rting  on average on
42
FEBRILE M u c o s i T i s  IN sTE M  cELL T R A N s p LANTATIo N
2Table 2 Patient characteristics and results.
No infection Bacteremia
Characteristics N=16
M ean (95% CI) Unless 
stated otherwise
N=30
M ean (95% CI) 
Unless stated  
otherwise
P-value
Age (years) 57 (53-61) 55 (52-58) 0.343a
Gender: male 56.3% 63.7% 0.639c
HDM mg/Kg 4.9 (4.7-5.1) 5.0 (4.8-5.2) 0.373a
BMI 26.3 (24.7-27.9) 26.6 (25.0-28.2) 0.922a
Fever(%) 69% 100% 0.003d
Day fever 11.9 (10.9-12.9) 12.0 (11.5-12.5) 0.799"
Neutrophils < 0.5 x109/ l  (days) 9.2 (8.4-10.0) 8.6 (8.1 -9.2) 0.240a
Neutrophils < 0.1 x109/ l  (days) 6.0 (5.5-6.5) 5.6 (5.2-6.0) 0.228"
Day neutrophils < 0.5 x109/ l 8.9 (8.5-9.3) 8.5 (8.2-8.8) 0.144"
Day CRP max 14.2 (13.3-15.1) 14.1 (13.5-14.6) 0.768"
Mean CRP max (mg/l), median (range) 94 (30-153) 193 (54-384) 0.003b
Day peak mucositis 11.9 (10.9-12.8) 11.8 (11.4-12.2) 0.898"
Mean max mucositis 8.3 (6.9-9.7) 8.4 (7.8-8.9) 0.950"
Day nadir citrulline (observed) 13.6 (12.4-14.7) 13.5 (12.9-14.2) 0.827"
Day nadir citrulline (predicted) 14.1 (13.7-14.5)* 14.1 (13.8-14.4)* 1.0e
Citrulline nadir (^m ol/l) (observed) 7.3 (5.8-8.7) 5.2 (4.6-5.9) 0.004"
Citrulline nadir (^m ol/l) (predicted) 6.9 (6.0-7.8) 5.4 (4.7-6.1) <0.0001e
a: independent t-test, b: Mann-W hitney U-test, c: x2-test, d: Fisher's exact test, e: P-value resulting from  
linear mixed model. *Confidence intervals based on bootstrap percentiles (150 replications). A P-value 
of <0.05 was considered statistically significant. HDM = high dose melphalan, CRP = C-reactive protein, 
BMI = body mass index.
day 10 (6 days post-HSCT), and reaching a maxim um  on day 14 (10 days post-HSCT). 
The course was s im ilar bu t the re  was a s ign ificant d iffe rence  in the  mean CRP max 
(193 vs. 94 m g /l (P =0.003)) (Table 2).
All pa tien ts w ith  bacterem ia became feb rile  as did 69% o f pa tien ts w ith o u t 
in fections (P =0.003), though the  mean onset o f feve r was 12 days (8 days post-HSCT) 
in both cases. A lthough not feb rile  according to  our d e fin itio n  five  patien ts w ith o u t 
fever had an elevated body tem pe ra tu re  from  baseline up to  38 .0oC.
Bacterem ia occurred a mean o f 12 days a fte r s ta rting  chem otherapy in the  cohort 
o f in fected patien ts, m ostly 2 days a fte r the  s ta rt o f the  in flam m ato ry  response.
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Figure 1 Course o f neutroph il count, mucositis and in flam m atory response 
fo llow ing HSCT after HDM conditioning in patients w ith ou t infectious 
com plications (closed lines) and in patients w ith  bacterem ia 
(dashed lines).
Course o f neutroph il count (x109/l)  (a), C-reactive prote in  (CRP) levels (m g/l) (b) mucositis score 
according to  the Nijmegen Nursing Mucositis Scoring System (NNMSS) (c) and c itru lline  levels (^.mol/l) 
(d) fo llow ing  HSCT a fte r cond ition ing  w ith  HDM. Day 1 is the day o f s ta rt o f chem otherapy. Day 4 is the 
day o f transplantation. Values are expressed as mean values w ith  95% confidence interva l (CI).
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2Figure 1 Continued.
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Patients in both groups suffered from  oral m ucositis w ith  a mean maxim um  score 
o f 8.3 and 8.4, bo th on day 12 (8 days post-HSCT, Figure 1c).
In both study groups mean baseline c itru llin e  levels were 25.5 and 23.8 |amol/l fo r 
those w ith o u t in fections and those w ith  bacterem ia respectively, and the re  was a 
marked decrease w ith  nadir occurring on day 14 (10 days post-HSCT, Figure 1d, 
Table 2). Im portan tly , in bo th study groups on day 10 m ost pa tien ts had already 
passed the  c itru llin e  th resho ld  o f 10 ^ m o l/ l ind ica ting  severe mucosal a trophy 18. 
Furtherm ore, the re  was a s ta tis tica lly  s ign ificant d iffe rence  in the  nadir o f c itru llin e  
between the  tw o  groups (6.9 vs. 5.4 ^m o l/l) , w ith  a P-value o f <0.0001.
Relationship variables and CRP
In long itud ina l un iva ria te  analysis, c itru llin e  and NNMSS score were s ign ificantly  
associated w ith  log10 CRP (both P <0.0001), as opposed to  neu troph il count 
(P =0.11). However, in the  model w ith  both c itru llin e  and NNMSS as pred ic to rs  fo r 
log10 CRP, on ly c itru llin e  con tribu ted  s ign ifican tly  (P <0.0001 vs. P =0.69). M odels 
w ith  neu troph il count com bined w ith  c itru llin e , NNMSS, o r both, came up w ith  
non-s ign ifican t estim ates o f the  regression coe ffic ien ts  fo r  neu troph il count. We 
concluded th a t the  best model to  pred ic t the  CRP values in a pa tien t from  day 1 
un til 18 on ly uses c itru llin e  levels.
A lthough bacterem ia is s ign ifican tly  associated w ith  increased CRP levels (P =0.003), 
in a model w ith  c itru llin e  and bacterem ia as independent variables and outcom e 
log CRP the  co n trib u tio n  o f bacterem ia becomes ins ign ifican t (P =0.939). This 
im plies th a t given the  value o f c itru lline , the  presence or absence o f bacterem ia 
does no t in fluence the  value o f CRP, bu t given the  status o f bacterem ia, c itru llin e  
values are s till s ign ifican tly  negatively corre la ted  w ith  CRP.
Discussion
In our study, pa tien ts receiving an autologous HSCT, w ho were free  o f c lin ica lly  or 
m icrob io log ica lly  de fined in fections 6, s till e laborated a s ign ifican t in flam m ato ry  
response as evidenced by marked elevations o f CRP and an incidence o f feve r of 
69%. All pa tien ts suffered from  s ign ificant m ucositis o f the  oral cavity and gu t th a t 
coincided w ith  the  occurrence o f the  in flam m ato ry  response (Figure 1). Five 
patien ts w ith o u t fever never required em pirica l an ti-m icrob ia l the rapy and th e ir 
clinical course was uneventfu l despite the  presence o f p ro found neutropen ia. 
These data the re fo re  suggest th a t the  in flam m ato ry  response o f these patients 
developed a fte r cond ition ing  fo r  a HSCT in response to  chem otherapy-induced 
mucositis. This was supported by statistical analysis showing a significant corre lation
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between mucositis measured through citrulline, but not neutropenia, and inflammation 
de term ined by CRP.
In the  patien ts w ith  bacterem ia due to  gram -pos itive  bacteria, the  course o f events 
were very  s im ilar to  th a t o f the  pa tien ts w ith o u t in fections suggesting they  also 
p rim arily  suffered from  in flam m ation  re lated to  m ucositis, bu t th a t a superim posed 
in fec tion  aggravated the  response w ith  higher maximal CRP levels and an increased 
incidence o f feve r (Figure 1). An im p o rta n t observation was th a t the  in flam m ato ry  
response already preceded the bacterem ia by 2 days. This has been previously 
observed in the  se tting  o f allogeneic HSCT 19. It is consistent w ith  a study on rats 
exposed to  chem otherapy in which the  release o f p ro -in fla m m ato ry  cytokines was 
associated w ith  evolving mucositis and preceded microbial translocation 20. In addition, 
s ta tis tica l analysis revealed a stronger association over tim e  between c itru llin e  
levels and CRP than between bacterem ia and CRP, underlin ing  a p redom inant role 
fo r m ucositis in the  occurrence o f in flam m ation .
Interestingly, fo r patients developing bacteremia the c itru lline level was significantly 
low er than was th a t o f those w ith o u t in fection , suggesting th a t the  degree of 
m ucositis was a risk fa c to r fo r  bacterem ia. This is in line w ith  earlie r studies which 
have shown bacteria l trans loca tion  from  the mucosal surfaces to  be re lated to  the 
degree o f m ucositis 12. No d iffe rence  was seen in oral m ucositis score bu t th a t is 
probably expla ined by the  m ore sub jective na ture o f these m easurem ents. Future 
studies are required to  de te rm ine  m ore precisely the  re la tionsh ip  between 
m ucositis measured by c itru llin e  and the  occurrence o f bacterem ia. However, o ther 
fac to rs  such as d iffe rences in gastro in testina l bacteria l colon ization, innate 
im m un ity  and neutropen ia  may also play a ro le in the  occurrence o f bacterem ia 21, 
a lthough in our study no d iffe rence  in neutropen ia  was found between the  tw o  
pa tien t groups.
C urrently  the  neu troph il count is used to  p red ic t the  risk period fo r pa tien ts 
receiving a HSCT. Our data suggest th a t m on ito ring  c itru llin e  levels provides 
add itiona l in fo rm a tio n  to  p red ic t m ore precisely the  onset o f the  in flam m ato ry  
response and when bacterem ia is like ly to  occur. A lthough m ost patien ts had 
reached a c itru llin e  level o f 10 |amol/l be fore developing feve r and /o r bacterem ia, 
a de fin ite  cut o ff value could no t be established, an issue th a t should be addressed 
in fu tu re  studies.
In m ost patien ts baseline c itru llin e  levels were be low  the norm al value 18. Probably 
the  p rio r use o f chem otherapy and o th e r fac to rs  such as m a lnu tritio n  already 
resulted in some mucosal a trophy. If pa tien ts w ith  a low  base line c itru llin e  level 
are m ore at risk fo r  severe m ucositis is an im p o rta n t question, w h ich remains to  be 
answered.
Data from  o th e r studies ind ica te th a t m ucositis is an im p o rta n t cause o f feve r and 
in fections in HSCT, supporting  our find ings. Fact remains tha t despite use o f
4 7
CHAPTER 2
em pirica l an tib io tics  the re  remains a large group o f pa tien ts w ith  fever w ith o u t 
docum ented in fection  2. E ffo rts  to  reduce the occurrence o f feve r w ith  p re -em ptive  
an tib io tics  and G-CSF have yie lded largely unsa tis fac to ry  results 22;23. One study 
even showed th a t the  highest p re d ic to r fo r  in fec tion  was grade II-IV m ucositis, 
concluding tha t on ly reducing o f neutropen ia w ith  G-CSF is in su ffic ie n t to  prevent 
fever and in fections 23. In add ition , o th e r studies have shown tha t am e lio ra ting  
m ucositis, w ith  the  use o f recom binan t ke ra tinocyte  g row th  fa c to r (Paliferm in® ) 
or using reduced in tens ity  cond ition ing  regim en, also resu lted in a decreased 
incidence o f fever, despite unchanged neutropen ia  24;25.
Our study is lim ited  by being retrospective , a lthough the  data had been collected 
prospectively. Nevertheless, the  data show a clear pa tte rn  o f an in flam m ato ry  
response, irrespective o f the  presence o r absence o f in fection , and th a t this 
coincides w ith  the  occurrence o f m ucositis. Hence, at least fo r  some HSCT recip ients, 
the  in flam m ato ry  response and feve r are the  d irec t consequence o f m ucositis 
alone, and neutropen ia  plays a m inor ro le or none at all. The m agnitude o f the 
in flam m ato ry  response can however be aggravated by in te rcu rre n t in fections 
arising from  the loss o f the  mucosal ba rrie r and s im ultaneous neutropen ia. 
Consequently, the  te rm  "fe b rile  neu tropen ia " m ight be b e tte r replaced by the  te rm  
"fe b rile  m ucositis". Future research should the re fo re  focus on strateg ies d irected 
at the  preven tion  and tre a tm e n t o f m ucositis.
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Stem cell transp lan ta tion  (SCT) is s till com plica ted by the  occurrence o f feve r and 
in flam m ato ry  com plica tions a ttr ib u te d  to  neutropen ia  and subsequent in fectious 
com plica tions. The ro le o f mucosal ba rrie r in ju ry  (MBI) o f the  in testina l tra c t the re in  
has received lit t le  a tten tion .
Methods
We pe rfo rm ed a re trospective  analysis in 163 SCT recip ients o f which data had 
been co llected prospective ly  on in testina l damage (c itru lline), in flam m ation 
(C-reactive pro te in ), and neu troph il count. Six d iffe re n t cond ition ing  regimens 
were stud ied; 5 m yeloabla tive (MA) and 1 non-m ye loab la tive  (NMA). Linear mixed 
model m u ltiva ria te  and AUC analyses w ere  used to  de fine the  ro le o f in testina l 
damage in post-SCT in flam m ation . We also studied the  re la tionsh ip  between the 
degree o f in testina l damage and the occurrence o f early post-SCT com plications. 
Results
In the  5 M A regim en the re  was a strik ing  pa tte rn  o f in flam m ato ry  response tha t 
coincided w ith  the  occurrence o f severe in testina l damage. This contrasted w ith  a 
m odest in flam m ato ry  response seen in the  NMA regim en in which in testina l 
damage was lim ited . W ith  linear mixed m odel analysis the  degree o f in testina l 
damage was shown the m ost im p o rta n t de te rm inan t o f the  in flam m ato ry  response, 
and both neutropen ia and bacterem ia had on ly a m inor im pact. AUC analysis 
revealed a strong corre la tion  betw een c itru llin e  and CRP (Pearson corre la tion  r = 
0.96). In testina l damage was associated w ith  the  occurrence o f bacterem ia and 
acute lung in jury, and in fluenced the  kinetics o f acute gra ft-ve rsus-host disease.
Conclusion
The degree o f in testina l damage a fte r m yeloabla tive cond ition ing  appeared to  be 
the  m ost im p o rta n t de term ined o f the  in flam m ato ry  response fo llow ing  SCT, and 
was associated w ith  in flam m ato ry  com plica tions. Studies should explore ways to 
am e lio ra te  cy to tox ic  the rapy-induced in testina l damage in o rder to  reduce 
com plica tions associated w ith  m yeloabla tive cond ition ing  therapy.
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Introduction
Treating patien ts w ith  hem atological malignancies by use o f a hem atopo ie tic  stem 
cell transp lan ta tion  (SCT) is s till com plica ted by the  occurrence o f in fections and 
in flam m ato ry  com plica tions includ ing sepsis, acute lung in jury, and graft-versus- 
host disease (GvHD). H isto rica lly  the  focus was on neutropen ia  and fever ("feb rile  
neu tropen ia ") and its re la tion  to  in fections 1. However, a substantia l num ber o f SCT 
recip ients develop feve r unrelated to  in fec tion  ("unexpla ined feve r") 2, resu lting 
from  other causes including cytotoxic therapy-induced mucosal barrier in jury (MBI) 3;4. 
Many studies have shown associations betw een the  m agnitude o f the  C-reactive 
p ro te in  (CRP) response and cy tok ine release and post-SCT com plica tions 5-9, and 
these com plica tions m ight the re fo re  best be regarded as m anifesta tions o f a 
system ic in flam m ato ry  response syndrom e (SIRS) 8. O ther studies have shown tha t 
in fections may con tribu te  to  non-in fectious com plica tions includ ing acute GvHD 
10;11. However, few  if any o f these studies addressed the ro le o f MBI per se as an 
isolated cause o f in flam m ation  and risk fa c to r fo r  in fections, nor its ro le in the 
pathogenesis o f in flam m ato ry  com plica tions. Anim al m odels have enhanced our 
understand ing o f the  in flam m ato ry  processes th a t take place in the  in testine  
fo llow ing  chem otherapy 12-14, and in the  clinical se tting  o f SCT the re la tionship 
between in testina l damage and the  in flam m ato ry  response has become be tte r 
appreciated 4;15. Mucosal damage and deregulated host-m icrob ia l in te ractions have 
also been shown to  con tribu te  to  SIRS and post-SCT com plica tions such as acute 
GvHD 16;17. There fore, we hypothesized th a t in testina l damage could be the  most 
im p o rta n t de te rm inan t o f early SIRS fo llow ing  cond ition ing  w ith  chem otherapy 
and rad io therapy and th a t the  degree o f damage corre la tes w ith  the  occurrence o f 
post-SCT com plica tions.
Studying damage to  the gastro-in testina l tra c t during SCT remains d ifficu lt, since it 
remains hidden and h ith e rto  on ly ind irect and non-specific tests were available 18;19. 
Measuring serum or plasma c itru lline  levels provides a m ore d irect and specific way 
o f de term in ing intestinal damage o f certain conditions tha t are accompanied by gut 
fa ilure 20. Recently, c itru lline-based assessment o f in testinal damage has also shown 
to  be objective, reproducib le, specific, and reliable in the  setting o f SCT 21;22.
To tes t our hypothesis we stud ied the  re la tionsh ip  betw een the  m agnitude o f the 
in flam m ato ry  response and the degree o f in testina l damage as measured by 
c itru lline , the  du ra tion  o f neutropen ia, and the  occurrence o f bacterem ia. To 
achieve th is we selected rec ip ien ts o f a SCT fo r w h ich 5  cohorts  o f pa tien ts had 
been given d iffe re n t m yeloabla tive (MA) cond ition ing  regimens, and a single cohort 
had received a non-m ye loab la tive  (NMA) cond ition ing  regim en. We also investigated 
w he the r we could de te rm ine  a re la tionsh ip  betw een the  degree o f in testina l 
damage and the  occurrence o f early post-SCT com plications.
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Materials and methods
Study population
This was a re trospective  analysis o f 163 patien ts w ho had received an autologous 
or allogeneic SCT in our hospita l from  M ay 2004 to  Decem ber 2007. Plasma had 
been co llected prospective ly  and stored fo r la te r analysis o f c itru llin e , bu t o ther 
data includ ing CRP, tem pera tu re , and clinical and m icrob io log ica l in fections had 
been prospective ly  ga thered from  the day o f s ta rting  chem otherapy. Patients had 
given th e ir  in fo rm ed consent to  the  prospective co llec tion  o f data and plasma 
samples fo r  investigational use. The local eth ics com m ittee  (CMO Regio A rnhem ­
Nijmegen) judged th a t no fo rm al approval fo r th is  study was necessary regarding 
the  fac t tha t data were used anonym ously and the  analysis w ou ld  no t reveal results 
harm ing con tribu ting  patients.
Conditioning regimens and stem cell transplantation
The M A and NMA regimens are depicted in Table 1. All pa tien ts received a stem cell 
g ra ft on the  day scheduled. Auto logous SCT g ra fts  contained at least 2.0 x 106 
CD34+ cells per kg, and allogeneic SCT pa rtia lly  T ce ll-dep le ted g ra fts  contained on 
average 3.0 x 106 CD34+ cells per kg and 0.5 x 106 CD3+ cells per kg.
Treatment protocol
All pa tien ts w ere trea ted  according to  the  same pro toco l, which has been described 
earlie r 23. GvHD prophylaxis consisted o f cyclosporine only. A n ti-m icrob ia l 
prophylaxis consisted o f c ip ro floxacin  and valacyclovir. Fever was defined by a 
single ax illa ry  tem pe ra tu re  > 38.5oC. A t the  onset o f fever 40 mL o f periphera l 
blood was ob ta ined fo r cu ltu re  tog e the r w ith  10 mL from  each lum en o f the 
catheter, pa tien ts were exam ined fo r  any sign o f local in fec tion , and em pirica l 
the rapy w ith  ceftaz id im e was s ta rted  24.
Neutropenia was de fined as an ANC < 0.5 x109/L  , and the  du ra tion  and depth was 
recorded. CRP levels (mg/L) were de term ined every day and the  maxim um  CRP 
(CRPmax) recorded. Plasma c itru llin e  was de term ined to  estim ate in testina l damage 
before the  s ta rt o f cond ition ing  and 3 tim es weekly th e re a fte r un til discharge. 
C itru lline  concen tra tions (|amol/L) were measured by a standard procedure fo r 
de te rm in ing  am ino acids using h igh-perform ance liqu id  chrom atography 21. 
C itru lline  levels be low  10 ^m o l/L  were deem ed to  ind ica te hypoc itru llinem ia , and 
w ere regarded as re flec ting  severe in testina l damage 20.
Definition of stem cell transplantation complications
Clinical and m icrob io log ica lly  defined in fections w ere de fined according to  the 
Consensus de fin itions  o f Im m unocom prom ised Host Society 2. A blood cu ltu re  was
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Table 1 Conditioning regimens.
Regimen Doses Frequency Days Type of conditioning Type of SCT, day
HDM MA Autologous, day 4
Melphalan 100 mg/m2 Od 1,2
BEAM MA Autologous, day 7
Carmustine (BCNU) 300 mg/m2 Od 1
Etoposide. 100 mg/m2 Bd 2-5
Cytarabine 100 mg/m2 Bd 2-5
Melphalan 140 mg/m2 Od 6
Ida-Cyclo-TBI: MA Allogeneic
Idarubicine 42 mg/m2 Infusion over 48 h 1 Matched related donor,
Cyclophosphamide 60 mg/kg Od 7,8 day 13
TBI 4.5 Gy Od 11, 12
Cyclo-ATG-TBI MA Allogeneic
Cyclophosphamide 60 mg/kg Od 1,2 Matched unrelated do­
Thymoglobuline 2 mg/kg Od 3-6 nor, day 9
TBI 4.5 Gy Od 7,8
Cyclo-TBI: MA Allogeneic
Cyclophosphamide 60 mg/kg Od 1,2 Matched related donor,
TBI 4.5 Gy Od 5,6 day 7
Cyclo-Flu: NMA Allogeneic
Cyclophosphamide 1200 mg/m2 Od 1-4 Matched related donor,
Fludarabine 30 mg/m2 Od 1-4 day 7


































considered to  represent bacterem ia if one or m ore bo ttles  yie lded a m icroorganism , 
except in the  case o f coagulase-negative staphylococci (CoNS), w h ich required 
recovery o f the  same stra in from  tw o  separate positive blood cultu res 24. The 
incidence o f bacterem ia th a t occurred on the  day o f feve r was docum ented and 
com pared among the regimens. Invasive fungal diseases were scored according to  
the  EORTC/MSG consensus guidelines 25. Acute lung in ju ry  (ALI) was defined 
according to  cu rren t gu idelines 26. Acute GvHD, GvHD occurring the  f irs t  100 days 
a fte r SCT, was graded according to  the  crite ria  o f Przepiorka et al. 27. Early m o rta lity  
re lated to  SCT com plica tions was de fined as any death occurring w ith in  30 days 
fo llow ing  SCT (day +30), bu t unre la ted to  the  underly ing disease.
Data analysis
We em ployed descrip tive statis tics fo r  fever, neu troph il count, CRP levels, and 
c itru llin e  levels which were expressed as mean values tog e the r w ith  the  95% 
confidence in te rva l (Table 2). As c itru llin e  was measured th ree  tim es weekly, the 
real nadir m ight have been a tta ined betw een tw o  m easurem ents and hence was 
likely missed. To com pensate fo r  th is  and study the  tru e  length o f tim e  in which 
c itru llin e  levels were be low  10 |amol/L we m odeled the  course o f c itru llin e  as a 
fun c tion  o f tim e  during the  f irs t 30 days by developing a linear mixed model using 
firs t, second, th ird  and fo u rth  power o f tim e  as fixed fac to rs  to  p red ic t the  c itru llin e  
levels a fte r taking in to  account the  w ith in -p e rso n  corre la tions by incorpora ting  a 
random  pa tien t in te rcep t. To describe the  re la tionsh ip  o f CRP to  the  neu troph il 
count, in testina l damage (c itru llin e  concen tra tion ) and bacterem ia we used several 
linear mixed m odels fo r  the  f irs t  30 days w ith  random  pa tien t e ffe c t and the 
loga rithm ic  transfo rm ed CRP (log CRP) as the  ou tcom e variable.
To assess the  im pact o f cond ition ing  on in testina l damage and CRP we perfo rm ed 
an area under the  curve (AUC) analyses. Per pa tien t, the  CRPauc was defined as the  
sum o f the  30 estim ated CRP values, resu lting from  a piecewise linear m ixed model 
w hich uses a linear tim e  com ponent fo r  day 1-10 and a cubic tim e  com ponent fo r 
day 11-30. The cond ition ing  regim en and the  in te ractions betw een the pa rticu lar 
regim en and tim e  were also pa rt o f th is  model th a t also accounted fo r  w ith in  
person corre la tions by v ir tu e  o f a random  in te rcep t. Likewise, the  c itru llin e AUC per 
pa tien t was defined as the  sum o f the  30 estim ated 1 0 /c itru lline  values. We used 
the  c itru llin e  levels estim ated by the  linear mixed m odel described above and 
transfo rm ed these values in to  10 tim es the inverse o f the  estim ated value. 
Comparisons betw een the im pact o f the  d iffe re n t cond ition ing  regimens on 
neutropen ia, CRPauc and c itru llin e AUC were stud ied using the  Kruskal-W allis test. The 
corre la tion  betw een the  degree o f neutropen ia  and CRPauc versus c itru llin e AUC and 
CRPauc was stud ied by Pearson corre la tion  over the  d iffe re n t regimens
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Comparison o f the  mean onset o f acute GvHD betw een the  d iffe re n t regimens was 
done using one-w ay ANOVA. Comparison o f the  incidence o f ALI in re la tion  to  OVS 
between the  d iffe re n t regimens was done using the  x2-test.
Analyses were pe rfo rm ed using SAS 8.2 and a P-value o f <0.05 was considered to 
indica te s ta tis tica l significance.
Results
Study population and patient characteristics
Seventy-seven (77) patients received an autologous and 86 an allogeneic SCT (Table 2). 
All bu t 14 patien ts received M A cond ition ing . Auto logous SCT was pe rfo rm ed fo r 
pa tien ts w ith  m u ltip le  myelom a and non-H odgkin lym phom a, bu t allogeneic SCT 
was em ployed fo r a greater va rie ty  o f diagnoses includ ing acute and chronic 
lym phatic  and m yeloid leukemia and m yelodysplastic syndrom e. NMA cond ition ing 
was em ployed to  prepare patien ts w ho had received an autologous SCT 4-6 m onths 
earlie r fo r  M M .
Intestinal damage
MA cond ition ing  was associated w ith  severe and pro longed in testina l damage 
shown by a rapid decline in c itru llin e  to  < 10 ^m o l/L , a mean o f 10 days a fte r 
s ta rting  chem otherapy. The mean nadir o f c itru llin e  was 4.5-7.0 ^m o l/L , and hypo- 
c itru llinem ia  lasted fo r  m ore than one week in m ost pa tien ts (Figure 1A-E, 2A, 
Table 2). H ypoc itru llinem ia  was m ost pronounced in pa tien ts receiving idarubic in  in 
th e ir cond ition ing , lasting approxim ate ly  18 days. In con trast, an early and short 
drop o f c itru llin e  level was noticed fo r NMA cond ition ing , bu t hypoc itru llinem ia  
was no t ev ident fo r m ost pa tien ts (Figure 1F, 2A, Table 2).
Inflammatory response measured by C-reactive protein and fever
The course o f CRP during SCT o f the  d iffe re n t cond ition ing  regim ens is illus tra ted  in 
Figure 1 and 2B. W ith in  each type  o f M A cond ition ing , pa tien ts showed sim ilar 
pa tte rns o f in flam m ato ry  response, a lthough the re  was some varia tion  in the 
precise onset, peak and reso lu tion  o f CRP levels. Those w ith o u t bacterem ia did not 
have a d iffe re n t course when com pared to  those w ith ; a lthough in general CRP 
levels were low er (data no t shown). As fo r  in testina l damage, the  CRP response was 
highest in patien ts receiving idarubic in . Resolution o f in flam m ation  occurred w ith  
eng ra ftm en t and res to ra tion  o f the  in testina l damage defined by rising c itru llin e  
levels. In Cyclo-ATG-TBI cond ition ing  the  f irs t  peak o f CRP was re lated to  ATG 
induced lym phocyte  dep le tion  and cy tok ine release, bu t the  second peak resembled 
tha t seen fo r  the  o th e r M A regimens. Also some pa tien ts trea ted  w ith  Cyclo-TBI
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Age, mean (range), years 56 (33-65) 47 (18-65)
Gender: M/F 35/21 17/4
Diagnoses:
-MM 56 (100%) -





Type of conditioning MA MA
Type of SCT Autologous Autologous
Fever (axillary temperature > 38.50C) 88.0% 90.5%
Fever, day from start conditioning, mean (95%CI) 11.8 (11.4-12.2) 13.0 (12.2-13.9)
Neutrophils < 0.5 x109/L, days (95%CI) 8.4 (8.0-8.7) 9.5 (8.5-10.5)
Citrulline < 10 ^mol/L, number of patients, (%) 51 (91%) 21 (100%)
Measurements with citrulline <10 ^mol/L, mean 3.5 (3.2-3.9) 4.7 (4.0-5.3)
(95%CI)*#
Observed citrulline nadir ^mol/L, mean (95%CI)* 6.0 (5.4-6.6) 4.3(3.5-5.1)
Citrulline <10 ^mol/L, days, mean (95%CI)&# 7.9 (7.1-8.7) 11.2 (9.6-12.9)
Citrulline nadir ^mol/L, mean (95%CI)& 6.5 (5.7-7.2) 4.9 (3.7-6.0)
CRPmax (mg/L), mean (95%CI) 163 (136-189) 202 (160-246)
Characteristics o f patients, stem cell transplantation and general outcome measures of intestinal 
damage (citrulline), inflam m ation (CRP and fever), and neutropenia (neutrophil count < 0.5 x109/L) for 
each conditioning regimen. *C itru lline was measured 3 times weekly. # Only those patients included 
w ith  c itru lline levels below 10 ^m ol/L . & Based on estimated values. MA = myeloablative, NMA = non- 
myeloablative, CRP = C-reactive protein, M M  = m ultip le  myeloma, NHL = non-Hodgkin lymphoma, CLL = 
chronic lymphatic leukemia, AML/ALL = acute myeloid and lymphatic leukemia, MDS = myelodysplastic 
syndrome, CML/MPD = chronic myeloid leukem ia/m yeloproliferative disease.
6 0









46 (18-64) 43 (20-58) 50 (38-59) 54 (39-65)






















100% Early: 73.5% 
Late: 100%
100% Early: 28.6% 
Late: 78.6%
12.9 (12.2-13.6) 4.1 (3.7-4.5)
14.1 (13.0-15.1)
13.4 (12.0-14.8) 3.0 (1.7-4.3)
16.0 (14.4-17.5)
15.8 (14.6-17.0) 15.5 (14.6-16.4) 11.1 (9.8-12.4) 12.4 (10.8-14.1)
26 (93%) 30 (88%) 10 (100%) 4 (29%)
6.2 (4.6-7.8) 4.8 (4.0-5.7) 3.5 (2.4-4.6) 3.0 (1.1-4.9)
4.6 (3.9-5.3) 5.6 (4.9-6.3) 5.6 (4.2-7.0) 10.8 (8.9-12.6)
17.7 (15.6-19.8) 14.6 (13.3-15.9) 11.0 (7.9-14.1) 7.5 (5.4-9.6)
4.5 (3.5-5.7) 7.0 (6.1-7.9) 6.6 (5.1-8.1) 12.4 (10.2-14.6)
257 (222-291) 188 (162-213) 211 (154-269) 66 (38-95)
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Figure 1 Course o f c itru lline  and CRP in tim e after s ta rt o f conditioning.
Five MA and one NMA cond ition ing  regimens are shown; A = HDM, B = BEAM, C = Ida-Cyclo-TBI, 
D = Cyclo-ATG-TBI, E = Cyclo-TBI, F = Cyclo-Flu. Observed values (•), mean values (• ).
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Figure 1 Continued.
and BEAM had an early peak in CRP during cond ition ing , which was probably related 
to  chem otherapy-induced cytok ine release.
Only a m odera te in flam m ato ry  response occurred a fte r NMA (Figure 1F and 2B). 
Also, the  tim ing  was d iffe re n t when com pared to  MA regimens w ith  a peak occurring 
early during cond ition ing  and a second peak much later. The la tte r occurred during 
engra ftm en t and the reby resem bled to  some exten t the  in flam m ato ry  com plica tion 
designated eng ra ftm en t syndrom e 28.
V irtu a lly  every pa tien t w ho had received MA developed fever as did 80% o f those 
given NMA cond ition ing . Some pa tien ts receiving Cyclo-ATG-TBI and Cyclo-Flu also 
experienced an early episode w ith  feve r during cond ition ing  (25 and 4 patients, 
respectively). In MA regimens feve r occurred on days 12-14, 2-3 days a fte r CRP had 
become elevated (Figure 1, Table 2). By con trast, fever occurred late during 
engra ftm en t at a mean o f day 16 a fte r s ta rting  NM A cond ition ing .
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Day 1 is the day o f s ta rt o f conditioning. To co rrect fo r unobserved c itru lline  and CRP values we 
modeled the course o f c itru lline  and CRP as described in methods. 1 = HDM, 2 = BEAM, 3 = Ida-Cyclo-TBI, 
4 = Cyclo-ATG-TBI, 5 = Cyclo-TBI, 6 = Cyclo-Flu. Mean CRP in mg/L, mean c itru llline  in ^m ol/L .
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Relation intestinal damage to inflammation
In MA cond ition ing  CRP levels s ta rted  to  increase from  10-11 fo llow ing  the  s ta rt of 
cond ition ing  which coincided w ith  the  deve lopm ent o f hypoc itru llinem ia  (Figure 
1A-E and 2). The peak o f the  in flam m ato ry  response coincided w ith  the  nadir of 
c itru llin e  levels. A lthough in te rind iv idua l d iffe rences existed the  occurrence of 
in flam m ation  was re lated to  the  deve lopm ent o f in testina l damage in a lm ost every 
pa tien t.
A dd itiona l AUC analysis was used to  grade the  im pact o f cond ition ing  on in testina l 
damage and CRP. There were s ign ificant d iffe rences in both CRPauc and c itru llin e AUC 
between the various conditioning regimens (Kruskal-Wallis P <0.001), except between 
BEAM, Cyclo-TBI, and Cyclo-ATG-TBI. Interestingly, a very strong corre lation between 
the degree o f in testina l damage and the  in flam m ato ry  response was seen fo r the 
d iffe re n t regim ens (Pearson corre la tion  0.96, Figure 3). By contrast, the re  was only 
a weak corre la tion  betw een the  du ra tion  o f neutropen ia and in flam m ation  (Pearson 
corre la tion  0.48, Figure 3).
Figure 3 Pearson corre lation between the mean degrees of neutropenia (NP in 
days) and inflam m ation (CRPauc) versus intestinal damage (C itrullineAUC) 
and inflam m ation (CRPauc) over the d iffe rent regimens.
1 = HDM, 2 = BEAM, 3 = Ida-Cyclo-TBI, 4 = Cyclo-ATG-TBI, 5 = Cyclo-TBI, 6 = Cyclo-Flu.
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Bacteremia on day of fever 29 10
-OVS 22 (39.3%) 6 (28.5%)
-CoNS 12 (21.4%) 7 (33.3%)
-Other 2 -
Concomitant OVS/CoNS 7 3
Candidemia 1 0
Clinically defined infection: 5 5
-Phlebitis superficial vein. - -
-Tunnel infection/infected thrombosis 1 3
-Pneumonia. 4 2
-Probable/Proven IA. - -
ALI 4/56 (7.1%) 2/21 (9.5%)
ALI following OVS bacteremia 3/22 (13.6%) 1/6 (16.7%)
Early mortality (day +30 post SCT) 0 1
-ALI. - 1
-Acute GvHD - -




Onset from day SCT, mean (95%CI) NA NA
OVS = oral viridians streptococci, CoNS = coagulase-negative staphylococci, IA = invasive Aspergillosis, 
ALI = acute lung injury, acute GvHD = acute graft-versus-host disease. Grading of acute GvHD was done 
according to  the criteria  o f Przepiorka et al. 27 and probable/proven IA was defined according to  EORTC/ 
MSG consensus defin itions 25.
In un ivaria te  linear mixed model analysis, 10 /c itru lline , the  type  o f cond ition ing 
regim en, neutropen ia  and bacterem ia were s ign ifican tly  associated w ith  log CRP. In 
m u ltiva riab le  analyses on ly c itru llin e  and type  o f cond ition ing  regim en rem ained 
im p ortan t.
Stem cell transplantation complications
Bacteremia
There was a s ign ificant d iffe rence  between MA and NMA regarding bacterem ia on 
the  day o f feve r (Table 3) w ith  up to  85% o f pa tien ts experiencing bacterem ia 
predom inan tly  due to  oral viridans strep tococci (OVS) and CoNS a fte r MA 
cond ition ing , com pared w ith  none o f those receiving NMA (P <0.001). OVS was
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26 (16-36) 46 (29-63) 23 (19-27) 40 (19-61)
recovered w ith  CoNS in 20 /55 (36%) o f cases. A m in o rity  o f pa tien ts experiencing a 
bacterem ia w ith  CoNS on the  day o f fever had any clinical o r rad io log ical signs o f a 
CVC related tunne l in fec tion  or th rom b op h le b itis  at the  same tim e  (5/55 (9%)).
Acute lung injury
The overall incidence o f ALI was 18/163 (11%), w ith  14/18 (78%), being associated 
w ith  OVS bacterem ia. Conversely, ALI a ffec ted  14/53 (26.4%) pa tien ts w ith  OVS 
bacterem ia. However, th is  incidence varied s ign ifican tly  between cond ition ing 
regimens and was re lated to  the  severity  o f in testina l damage as ALI occurred in 
3/22 (13.6%), 4 /13 (30.8%) and 4 /7  (57.1%) in pa tien ts receiving HDM, Cyclo-ATG-TBI, 




No diffe rences w ere seen in the  to ta l incidence o f acute GvHD, a lthough the re  were 
no cases o f acute GvHD III-IV in the  group w ith  NMA; w ith  on ly skin acute GvHD 
being encountered. However, the re  was a s ign ificant d iffe rence  in the  onset of 
acute GvHD. In Ida-Cyclo-TBI and Cyclo-TBI, despite receiving a pa rtia lly  T-cell- 
depleted g ra ft, acute GvHD occurred early w ith  a mean onset on day +25 post SCT. 
In bo th Cyclo-ATG-TBI and Cyclo-Flu the  onset was delayed, w ith  a mean onset on 
day +46 and +40 post SCT, respective ly (P =0.02).
Early m orta lity
Overall, early m o rta lity  was low  6/163 (3.7%), and re lated to  ALI and acute GvHD, 
and all but one death occurred fo llow ing  MA cond ition ing  fo r an allogeneic SCT.
Discussion
In th is study w e show the course and exten t o f in testina l damage and in flam m ato ry  
responses fo llow ing  various cond ition ing  regim ens used to  prepare fo r a 
hem atopo ie tic  SCT. There was a s trik ing  pa tte rn  o f in flam m ato ry  response 
coincid ing w ith  the  occurrence o f severe in testina l damage fo r pa tien ts receiving 
MA cond ition ing , de fined by hypoc itru llinem ia  20. M oreover, the  degree o f in testina l 
damage seemed the  m ost im p o rta n t de te rm inan t o f in flam m ation  and was highly 
corre la ted w ith  the  m agnitude o f the  in flam m ato ry  response measured by CRP. 
N e ither neutropen ia  nor bacterem ia had a m ajor im pact on th is. The close 
re la tionsh ip  between in testina l damage and in flam m ation  was fu rth e r underscored 
by the  fac t th a t NM A resulted in on ly a m odest in flam m ato ry  response, w ith  a 
com ple te ly  d iffe re n t tim e  course, and the  v irtu a l absence o f severe in testina l 
damage. Consequently, in testina l damage appears the  prim ary  de te rm inan t of 
in flam m ation  fo llow ing  m yeloabla tive cond ition ing  w ith  chem o- and rad io therapy 
in the  se tting  o f autologous and allogeneic SCT.
W hile  the re  are lim ita tion s  associated w ith  re trospective  analysis and the potentia l 
fo r bias resu lting from  selection, the  re la tionsh ip  o f in testina l damage to  SCT 
com plica tions was rem arkable. As expected, the re  was a s ign ifican t d iffe rence  in 
occurrence o f bacterem ia betw een those receiving MA and NMA cond ition ing  29. 
The s im ilar du ra tion  o f neutropen ia  and the  marked d iffe rence  in in testina l damage, 
suggest th a t the  gu t may have been the  orig in  o f bacterem ia 30. M oreover, most 
pathogens recovered from  blood cu ltu res are known residents o f the  gut 31;32. 
Notably, a considerable p ro po rtion  of pa tien ts had bacterem ia w ith  both CoNS and 
OVS, which was probably due to  s im ultaneous in testina l trans loca tion  31.
A strong re la tionsh ip  has been found betw een the  occurrence o f OVS bacterem ia
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and septic shock and ALI in neutropen ic patien ts, which was expla ined by v iru lence 
fac to rs  and pu lm onary c y to to x ic ity  o f chem otherapy 33-35. In teresting ly, we saw 
tha t in pa tien ts w ith  OVS bacterem ia the  incidence o f ALI was re lated to  the  degree 
o f in testina l damage. It is known tha t ba rrie r dysfunction  fac ilita tes  bacteria l 
trans loca tion , bu t in testina l damage also seems to  de te rm ine  the  resu lting 
in flam m ato ry  response. This was con firm ed in our linear m ixed m odel, which 
showed c itru llin e  bu t no t bacterem ia re lated to  the  CRP response. A lthough ALI 
seems d irec tly  associated w ith  OVS bacterem ia th is  m ight be on ly coinc iden ta l, as 
both com plica tions are consequences o f severe in testina l damage. So in testina l 
damage 'p rim es' the  im m une system w ith  subsequent aggravated cy tok ine release 
fo llow ing  activa tion  o f pa tte rn  recogn ition  receptors from  trans loca ting  m icrobia l 
m otifs  12.
This 'p rim ing ' o f the  im m une system also applies to  the  occurrence acute GvHD in 
which the  ro le o f in testina l damage has been acknow ledged 16. A lthough we found 
no apparent d iffe rences in the  c itru llin e  and CRP levels between patien ts w ith  and 
w ith o u t acute GvHD w ith in  any given regim en, betw een regimens the re  was a clear 
d iffe rence  in the  k inetics o f acute GvHD. In add ition  severe acute GvHD did not 
develop a fte r NMA, as opposed to  6-10% a fte r MA, and GvHD o f liver or gu t did not 
occur. The early onset o f acute GvHD a fte r Ida-Cyclo-TBI and Cyclo-TBI suggests 
tha t the  tissue in flam m ation , resu lting from  the pro found in testina l damage, 
con tribu tes to  the  accelerated a llo -reactive  T-cell response 36, even in the  se tting  of 
partia l T ce ll-dep le tion . The delay in onset o f acute GvHD in patien ts cond itioned 
w ith  ATG results from  add itiona l in vivo T ce ll-dep le tion  creating a 'tim e -w in d o w ' 
between the  in testina l dam age-induced in flam m ation  and T cell recovery. A fte r 
NMA we also saw a delay in the  onset o f acute GvHD, which is in accordance w ith  
previous data from  studies in mice 37 and humans 38. This a lte red kinetics o f acute 
GvHD was, at least in part, re la ted to  the  absence o f s ign ificant in testina l damage 
and tissue in flam m ation . D ifferences in the  k inetics o f acute GvHD in NMA have 
been largely a ttr ib u te d  to  a lte ra tions in antigen presenting cell chim erism , T cell 
chim erism  and regu la to ry  T cell activa tion  37, bu t our data underscore the  ro le con­
d ition ing -induced  in testina l damage plays in the  com plex pathogenesis o f acute 
GvHD.
Several studies have shown corre la tions between CRP and the  occurrence o f SCT 
com plica tions bu t they  all used d iffe re n t c u t-o ff values 5;7. CRP is not a specific 
m arker since chem otherapy and ATG, and the  process o f en g ra ftm en t itself, e lic it 
in flam m ato ry  responses. Hence it is not possible to  id e n tify  w ho is at risk o r when 
tha t risk m ight occur. C itru lline  could provide an a lte rna tive , because it is a specific 
m arker o f en te rocy te  mass, w h ich decreases on ly when the re  is in testina l damage. 
Furtherm ore, c itru llin e  levels correspond w ith  the  in flam m ato ry  responses 
fo llow ing  MA cond ition ing , and m ore im p o rta n tly  w ith  SCT com plica tions. Clearly
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it  is necessary to  con firm  the  pred ic tive  value o f c itru llin e  fo r  ind iv idual patients 
and to  de fine  c u t-o ff values m ore precisely. Classifying o ther cond ition ing  regimens, 
by means o f measuring c itru lline can already help determ ine the need fo r antim icrobial 
prophylaxis, hospital care, and the use o f an ti-in flam m atory  trea tm ent.
Given the ro le o f in testina l MBI in com plica tions a fte r SCT studies should explore 
ways to  am e lio ra te  cy to tox ic  therapy-induced in testina l damage in o rder to  reduce 
in flam m ato ry  com plica tions associated w ith  m yeloabla tive cond ition ing  therapy.
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Single nucleo tide  po lym orphism s (SNPs) in the  NOD2 gene have s ign ifican t im pact 
on bo th  trea tm e n t-re la te d  m o rta lity  (TRM) and acute gra ft-ve rsus-host disease 
(aGvHD) in hem atopo ie tic  stem cell transp lan ta tion  (HSCT). The e ffec t o f these 
po lym orphism s when using T -ce ll-dep le ted g ra fts  has been poorly  stud ied. We re t­
rospective ly  analyzed NOD2 polym orphism s in a coh o rt o f 85 patien ts and donors 
th a t received a HLA identica l sib ling pa rtia lly  T -ce ll-dep le ted HSCT (0.5 x 106 CD3+ 
T-cells/kg) fo llow ing  idarub ic in -con ta in ing  cond ition ing  regimens. NOD2 
polym orphism s were present in 14 o f 85 (16.5%) o f pa tien ts and 18 o f 85 (21%) o f 
donors. The risk o f severe aGvHD (grade III-IV) and the  1-year TRM was sign ificantly  
higher in the  presence o f NOD2 polym orphism s (hazard ra tio  (HR) 6.0, P =0.02 fo r 
severe aGvHD and HR 3.3, P =0.02 fo r  TRM, respective ly) and was m ost prom inen t 
in cases w here pa tien t and donor both had a po lym orphism  (HR 10.5, P=0.002 and 
HR 3.9, P =0.002). There was also a trend  tow ards increased risk o f bacterem ia due 
to  coagulase-negative staphylococci in pa tien ts w ith  a NOD2 po lym orphism . We 
conclude tha t NOD2 po lym orphism  screening should be used to  op tim ize donor 
selection and an tim icrob ia l prophylaxis in o rder to  reduce the  occurrence o f aGvHD 
and TRM fo llow ing  allogeneic HSCT.
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Introduction
Acute gra ft-ve rsus-host disease (aGvHD), in fections and o th e r in flam m ato ry  
com plica tions fo llow ing  cond ition ing  the rapy s till have considerable im pact on 
m o rb id ity  and m o rta lity  in hem atopo ie tic  stem cell transp lan ta tion  (HSCT). An 
uncon tro lled  in flam m ato ry  response as a resu lt o f the  mucosal ba rrie r in ju ry  (MBI) 
induced by cy tos ta tic  chem otherapy and subsequent m icrob ia l trans loca tion , are 
tho ugh t to  play an im p o rta n t ro le in the  in itia tio n  o f aGvHD 1-3. Polym orphism s of 
innate im m une genes (non-HLA genes) can a ffec t the  in flam m ato ry  responses and 
the re fo re  the  incidence o f aGvHD 4;5. Any po lym orphism  th a t pred ic ts  com plications 
should the re fo re  be screened fo r  to  select the  m ost suitab le stem cell donor.
A robust association between single nucleotide polym orphism s (SNPs) in NOD2/ 
CARD15 and the  outcom e o f allogeneic HSCT has been reported by Holler et al. 6. 
NOD2 is as an in tracytosolic  pattern recognition receptor tha t senses muramyl 
d ipeptide (MDP) o f bacterial cell walls, and is expressed in Paneth cells, dendritic  
cells, neutrophils, and m onocytes 7. A ltered function  due to  NOD2 polym orphism s 
can result in uncontro lled in flam m ation o f the  gut mucosa and can result in Crohn's 
disease 8. The pathogenesis is not fu lly  understood bu t the re  are several hypotheses 
involving the  loss o f an ti-m icrob ia l ac tiv ity  and a deregulated im m une response. 
Reduced antim icrob ia l ac tiv ity  results from  decreased production o f antim icrob ia l 
peptides 9;10, decreased autocrine cytokine release 11 and increased gut perm eability  
12, leading to  bacterial translocation th a t e lic its an im m une response through to ll-like  
receptor (TLR) signaling. This response is deregulated w ith  increased production of 
Th1, and probably Th17 cytokines, due to  reduced inh ib ition  o f TLR-mediated cytokine 
release ("loss o f to le rance") 13-16 o r decreased production o f IL-10 17.
Several reports , bu t no t all, have shown th a t NOD2 polym orphism s in fluence the 
evo lu tion  o f aGvHD, the  occurrence o f trea tm e n t-re la te d  m o rta lity  (TRM) 6, the 
incidence o f disease relapse 18, and the  deve lopm ent o f b ronch io litis  ob lite rans 19. 
This underlines the  im portance  o f the  specific cond itions surrounding HSCT. For 
instance, T -ce ll-dep le ted HSCT w ith  delayed T-cell recovery could reduce the 
im pact o f NOD2 polym orphism s on aGvHD. There fore, we unde rtook  a re trospective  
analysis on the  im pact of NOD2 polym orphism s in a hom ogenous coh o rt o f Dutch 
recip ients o f a pa rtia lly  T -ce ll-dep le ted HSCT at our hospita l.
Patients, materials and methods
Patients and donors
One hundred and sixteen (n=116) Dutch pa tien ts and th e ir  donors were in itia lly  
included in the  study. All had pa rtic ipa ted  in supportive  care studies and been
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adm itted  to  our transp lan t un it be tw een May 1996 and Novem ber 2005 fo r  an 
HLA-identical sibling, T -ce ll-dep le ted allogeneic HSCT. To ob ta in  the  most 
hom ogenous coh o rt possible, we selected 85 patien ts w ho had been given 
idarubic in in th e ir cond ition ing  regim en. The characteristics o f pa tien ts, donors, 
and HSCT procedures are depicted in Table 1.









Age at transplantation, year (range) 46.9 (20-62) 43.7 (16-60) 0.274
Sex no female/no male 26/37 6/16 0.243
Disease:
- Acute leukemia, no (%) 33 (52) 13 (59.5) 0.894
- CML/MPS, no (%) 13 (21) 3(13.5)
- Lymphoma, no (%) 7 (11) 3 (13.5)
- MDS, no (%) 10 (16) 3(13.5)
Donor characteristics
Age at donation, year (range) 47.1 (21-69) 43 (20-60) 0.188
Sex no. female/no. male 29/34 11/11 0.748
Stem cell transplantation
Gender combination: male/female, no (%) 16 (25%) 8 (36%) 0.325
Disease status at HSCT: advanced, no (%) 12 (19%) 3 (14%) 0.567
Stem cell source:
- Peripheral blood, no (%) 23 (37) 13 (59) 0.065
- Bone marrow, no (%) 40 (63) 9 (41)
Conditioning regimen:
- Ida-Cyclo-TBI, no (%) 53 (84) 20 (91) 0.432
- Ida-Bus-Cyclo, no (%) 10 (16) 2 (9)
T-cell-depletion:
- CD34 selection, no (%) 32 (51) 13 (59) 0.146
- Counterflow elutriation, no (%) 22 (35) 8 (36)
- CD3/CD19 selection, no (%) 9 (14) 1 (5)
The study group consisted o f 85 HSCT recipients and the ir donors. All received a HLA matched sibling 
T-cell-depleted HSCT fo llow ing conditioning w ith  an idarubicin-contain ing regimen. GvHD prophylaxis 
consisted o f cyclosporine only. C haracteristics are expressed in absolute num bers and percentage. 
Age is expressed as mean value w ith  the to ta l range. D ifferences between the study groups were 
compared using the Pearson's x2-test o r Fisher's exact test and w ith  the use of the independent t-test.
8 0
N 0 D 2  POLYMORPHiS MS iNFLUENCE SCT OUTCOME
Treatment protocol
All pa tien ts had been trea ted  according to  the  same pro toco l and received a centra l 
venous ca the te r (CVC). The cond ition ing  regim en consisted o f idarubic in  (42 m g/m 2 
in 48 hours), cyclophospham ide (60 m g/kg fo r 2 days) and e ith e r to ta l body 
irrad ia tion  (TBI 4.5 Gy fo r 2 days) or busulfan (4 m g/kg fo r 4 days). Idarubic in was 
used in th is  cond ition ing  regim en to  reduce the  risk o f relapse in the  se tting  o f 
T -ce ll-dep le ted HSCT 20. Partia l T -ce ll-dep le tion  was achieved by coun te r-flow  
e lu tr ia tion , CD34 selection or CD3/CD19 dep le tion . On day 0, all pa tien ts were 
given a g ra ft con ta in ing 3.0 x 106 CD34+ ce lls/kg (range 0.8-11.4; BM or PBSC) and 
0.5 x 106 CD3+ ce lls/kg (range 0.3-0.7) achieved by dosed T-cell ad back. GvHD 
prophylaxis consisted o f cyclosporine A (CsA) only.
GvHD was diagnosed by clin ical signs, o r patho log ica l exam ination o f biopsies of 
skin, gut or liver. GvHD was graded according to  the  crite ria  o f G lucksberg et al. 21. 
The score was decreased by one stage when the re  were o th e r causes, such as drug 
reactions and in fections, th a t m ight con tribu te  to  the  clin ical signs o f skin, gu t or
liver 22.
A n tim icrob ia l prophylaxis consisted o f 500 mg c ip ro floxacin  given tw ice  da ily and 
500 mg va lac ic lov ir given th ree  tim es daily. Fluconazole was on ly given at a dose 
200 mg per day o ra lly  to  those w ho were considered colonized by Candida albicans. 
Patients received trim ethoprim -su lpham e thoxazo le  480 mg per day ora lly  at 
discharge, as prophylaxis against in fections due to  Pneumocystis jirovecii.
Twice w eekly blood was drawn fo r  aerobic cu ltu re  from  each lum en o f the  CVC. A 
blood cu ltu re  was considered positive if a m icroorganism  was recovered from  one 
or m ore bo ttles , w ith  the  exception o f coagulase-negative staphylococci (CoNS), 
fo r which tw o  separate positive b lood cu ltu res w ith  the  same stra in  were required 
23. A t the  onset o f fever, de fined as an axilla ry tem pe ra tu re  > 38.5oC, em pirica l 
the rapy was sta rted  w ith  2000 mg ceftaz id im e given th ree  tim es da ily in travenously 
a fte r blood cultu res were ob ta ined from  each ca the te r lum en as w e ll as from  
periphera l b lood. T w en ty -fou r pa tien ts (n=24) had received m eropenem  
pre -em p tive ly  s ta rting  the  day o f HSCT.
Genotyping for NOD2 polymorphisms
DNA from  pa tien ts and donors was extracted by standard procedures (QIAamp 
DNA blood m in i kit, Qiagen) from  periphera l blood cells co llected be fore HSCT. 
Patients and th e ir  donors had given th e ir  in fo rm ed consent to  the  prospective 
co llec tion  of DNA samples fo r  investigational use. W e assayed SNP8 (Arg702Trp), 
12 (Gly908Arg) and 13 (Leu1007fsinsC) using a rea l-tim e TaqMan PCR. Control 
samples tha t had been con firm ed by sequencing were k indly supplied by Dr. E. 
Holler and J. Brenm oehl (U n iversity Hospital of Regensburg). Probes and prim ers 
were synthesized by App lied Biosystems (Lingley House, W arring ton , UK), w ith
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re p o rte r dye 6-FAM or VIC linked at the  5' end and the  quencher dye TAMRA at the 
3' end. The fina l reaction m ix tu re  o f 50 ^ l consisted o f M aster M ix (MgCl2 5 m M , 10 
x TaqMan bu ffe r 5 |al, dNTP 250 ^M , AmpliTaq Gold 1.25 mU), 300 nM o f each 
fo rw a rd  and reverse prim er, 200 nM o f each fluo rescen t probe and 50 ng o f DNA. 
PCR am p lifica tion  and fluorescence de tec tion  were achieved using an ABI Prism 
7700 (Applied Biosystems).
Statistical analysis
We used descrip tive  sta tis tics fo r  the  study group characteristics regarding the 
HSCT w ith  values expressed in absolute num bers and percentage. D ifferences 
between p a tie n t/d o n o r pairs w ith  and w ith o u t NOD2 polym orphism s were 
com pared using the  Pearson's x2-tes t o r Fisher's exact tes t fo r  p ro po rtions  and w ith  
the  independent t-te s t fo r num erica l data (SPSS version 14.0).
The ou tcom e variables aGvHD, TRM at 1 year, and the  occurrence o f bacterem ia 
were analyzed in re la tion  to  NOD2 polym orphism s.
The tim e  to  clinical event (1-year TRM, aGvHD) was de term ined from  the  date of 
HSCT. The tim e  span fo r aGvHD extended to  day 100, and th a t fo r  1-year TRM to 
day 365 a fte r HSCT. The incidence o f bacterem ia was de term ined from  s ta rt of 
chem otherapy (day -12) un til 14 days a fte r transp lan ta tion .
The cum ula tive incidence was estim ated to  re fle c t the  com peting risks o f death 
w ith in  100 days from  o th e r tox ic ities  o r relapse fo r aGvHD, death from  relapse fo r 
TRM, and tre a tm e n t re lated death w ith in  14 days w ith o u t bacterem ia fo r 
bacterem ia. Groups were fo rm ed  according to  occurrence o f any po lym orphism  vs. 
w ild -typ e  and polym orphism s in bo th pa tien t and donor vs. w ild -typ e  to  a llow  
analysis o f po lym orphism s in re la tion  to  aGvHD and TRM. In the  analysis of 
bacterem ia on ly rec ip ien t status was considered o f im portance and patien ts w ith  a 
po lym orphism  w ere com pared w ith  w ild -types.
The Gray tes t was used to  evaluate the  diffe rences betw een cum ula tive  incidence 
curves in these groups. These diffe rences were also quan tified  by calcu la ting the 
hazard ratios (HR) th a t resu lted from  the  Fine and Gray m odels th a t take in to  
account com peting risks. These m odels w ere  also used to  ad just these HRs fo r  age 
o f the  pa tien t and donor, gender com bination , the  underly ing hem atological 
disease and status at HSCT, the  T -ce ll-dep le tion  technique, and the  stem cell source. 
Because the study group was small we had to  lim it the  num ber o f variables included 
in the  m u ltiva riab le  analysis to  the  risk fac to rs  m ost associated w ith  aGvHD and 
TRM.
The com peting risks analyses were pe rfo rm ed using the  cmprsk package o f open 
source language R version 2.6.2. (w w w .r-p ro je c t.o rg ). P-value <0.05 was considered 
to  ind ica te sta tis tica l significance.
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Results
NOD2 polymorphism frequency
The frequency o f any po lym orphism  among patien ts was 16.5, and 21% among 
donors (Table 2). A lle le frequencies were 6.2, 0.6 and 3.2% fo r SNP8, 12 and 13 
respectively, s im ilar to  the  general Dutch popu la tion  (5.9, 0.7 and 1.9) 24. There 
were fo u r pairs (4.7%) in which on ly the  pa tien t, 8 pairs (9.4%) in wh ich on ly the 
donor and 10 pairs (11.8%) in which both had a SNP. There w ere  no sign ificant 
d iffe rences in the  characteristics o f p a tie n t/d o n o r pairs w ith  and w ith o u t a 
po lym orphism  (Table 1).
Table 2 Frequency o f SNPs in patients and donors.
NOD2 status Study group (n=85)
Patient no (%) Donor no (%)
W t/w t 71 (83.5) 67 (79)
SNP8/wt 9 (10.5) 12 (14)
SNP12/wt 0 (0) 1 (1)
SNP13/wt 3(3.5) 5 (6)
SNP13/SNP13 1 (1) 0
SNP12/SNP13 1 (1) 0
NOD2 polymorphisms and outcome
Acute Graft-versus-Host disease
In the  analysis o f aGvHD, fo u r patien ts, one w ith  a po lym orphism , w ere excluded 
because o f death be fore eng ra ftm en t. The overall incidence o f aGVHD grade II-IV 
and grade III-IV was 32.1% and 7.4%, respectively.
We f irs t  com pared the  incidence o f aGvHD in pairs w ith  any po lym orphism  present 
w ith  the  outcom e o f w ild -typ e  p a tie n t/d o n o r pairs and found no sign ificant 
d iffe rence  in grade II-IV aGvHD (cum ulative incidence 43 vs. 30%, HR 1.5 95%CI: 
0.7-4.6, P =0.30). However, an e ffec t o f NOD2 po lym orphism s was seen fo r  severe 
aGvHD w ith  a cum ula tive incidence o f 19% in pairs w ith  any po lym orphism  
com pared to  3% fo r pairs w ith  w ild  type  status (HR 6.0, 95%CI: 1.1-100, Gray tes t P 
=0.02). The m agnitude o f th is  d iffe rence  was accounted fo r  by the  higher incidence 
o f severe aGvHD in the  subgroup o f pairs in which both had a po lym orphism , w ith  
an incidence o f 33% (HR 10.5, 95%CI: 1.8-100, Gray tes t P =0.002, Figure 1). 
Furtherm ore, m u ltiva riab le  analysis, includ ing pa tien t and donor age, gender
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Figure 1 Cumulative incidence o f severe acute graft-versus-host disease 
(aGvHD grade III-IV) in re lation to  NOD2 polym orphism s.
Cum ulative incidence severe aGvHD (%)
P= 0.002
R + D polymorphism
Wild type
0 20 40 60 80 100
Days post HSCT
R + D polym orphism  indicates recip ient and donor both having a NOD2 polym orphism , w ild type; both 
recip ien t and donor w ith o u t polym orphism . Comparison of R + D vs. w ild type showed a sta tistica lly 
s ign ificant increased risk o f severe aGvHD associated w ith  NOD2 polym orphism s. P-value Gray test.
com bination , stem cell source, and T -ce ll-dep le tion  technique, showed tha t 
po lym orphism s in NOD2 were the  on ly s ign ificant p re d ic to r o f the  occurrence of 
severe aGvHD (P <0.001).
Treatment related m orta lity  and relapse
The overall 1-year TRM was 16.5%. The presence o f a po lym orphism  was a sign ificant 
fa c to r w ith  a cum ula tive  incidence o f 32% com pared to  11% fo r w ild -typ e  status 
(HR 3.3, 95%CI: 1.2-9.1, Gray tes t P =0.02). Again th is  was m ostly  accounted fo r by 
p a tie n t/d o n o r pairs both bearing a po lym orphism  w ith  an incidence o f 50% (HR 5.9, 
95%CI: 1.9-18.0, Gray tes t P =0.002, Figure 2). M o rta lity  was p redom inantly  
a ttr ib u te d  to  aGvHD and in fections, especially fungal in fections. In pairs w ith  any 
po lym orphism  m o rta lity  was in 42.9% related d irec tly  to  aGvHD com pared to  0% 
fo r the  w ild -types.
In m u ltiva riab le  analysis, includ ing pa tien t age and gender, underly ing disease and 
disease status at HSCT, th is  im pact rem ained w ith  a HR o f 3.8 fo r  all po lym orphism s 
and a HR o f 7.8 fo r  pairs both having a po lym orphism .
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Figure 2 One year trea tm ent-re la ted  m orta lity  (1-year TRM).
R + D p o ly m o rp h is m  in d ica te s  re c ip ie n t and d o n o r  b o th  hav ing  a NOD2 p o ly m o rp h is m ; w ild  ty p e , b o th  
re c ip ie n t and d o n o r  w ith o u t  p o ly m o rp h is m . C o m pa rison  o f R + D vs. w ild  ty p e  show ed  a s ta tis tic a lly  
s ig n if ic a n t increased 1-year TRM associa ted  w ith  NOD2 p o lym o rp h ism s . P -va lue G ray tes t.
No diffe rences in the  occurrence o f disease relapse at 1- and 3-year fo llo w -u p  were 
found in e ith e r un ivariab le  o r m u ltiva riab le  analysis (data no t shown).
Bacteremia
Bacterem ia occurred in 68% o f pa tien ts, w ith  an incidence o f bacterem ia due to 
coagulase-negative staphylococci (CoNS) o f 45.9% and th a t due to  oral viridans 
strep tococci (OVS) o f 25.9%. Analysis o f the  OVS bacterem ia was no t possible as 24 
patien ts had received m eropenem . There was a cum ula tive incidence o f CoNS 
bacterem ia un til day 14 o f 64.3 vs. 36.6% (HR 1.85; 95%CI 0.95-3.60, P =0.07) among 
patien ts w ith  a po lym orphism  com pared to  w ild -types.
Discussion
We show th a t the re  was a s ign ificant im pact o f NOD2 po lym orphism s on trea tm e n t 
outcom e, in pa rticu la r severe aGvHD and TRM, among recip ients o f T-ce ll-dep le ted 
HSCT. The im pact was m ost pronounced when both the  pa tien t and donor had a
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NOD2 po lym orphism , suggesting th a t a "con tinuous" NOD2 dysfunction  in both 
ep ithe lia  and im m une cells w ith  subsequent de fective  an tim icrob ia l a c tiv ity  and 
im m une deregu la tion  results in a worse clin ical outcom e. This find ing  was sim ilar 
to  the  results reported  by Ho lle r et al. 6. However, the  subgroups were too  small to 
de te rm ine  the  im pact when only a pa tien t or donor had a po lym orphism . Our data 
suggest th a t screening fo r NOD2 po lym orphism s in th is  pa tien t popu la tion  could 
aid in im proving the  ou tcom e a fte r HSCT. This especially applies to  the  se tting  of 
HLA-identical sib ling HSCT, because o f a considerable chance o f bo th pa tien t and 
donor bearing a po lym orphism , w ith  s ign ificant consequences. Selecting a w ild -type  
NOD2 sib ling is pre fe rred , bu t th is  m ight prove d iff ic u lt  because o f the  lack of 
m atched siblings. There fore, o th e r approaches m ight be to  select a vo lun ta ry  
unrelated donor w ith o u t NOD2 polym orphism s or to  adapt an tim icrob ia l 
prophylaxis.
Our results con trast w ith  those o f Granell et al. w ho found no im pact o f NOD2 
polym orphism s on aGvHD and associated TRM in T -ce ll-dep le ted HSCT 25. There are 
several exp lanations fo r  these d iffe re n t results. The m ost im p o rta n t is the  higher 
overall incidence o f aGvHD (grade II-IV 32.1 vs 10%) w h ich probably relates to  the 
use o f ida rub ic in -con ta in ing  regim en, as th is  induces m ore MBI and aGvHD 20. 
Furtherm ore, the  use o f pa rtia lly  T -ce ll-dep le ted gra fts , w ith  a mean o f 0.5 x 106 
CD3+ T-cells/kg, con tribu tes to  the  higher incidence o f aGvHD in our patients. 
There was also a higher alle le frequency o f NOD2 polym orphism s in our coh o rt (9.7 
vs. 5.1%). This results from  tru e  genetic he te rogene ity  between the  Dutch and 
Spanish popu la tions 26, bu t could also be in fluenced by chance. Consistent w ith  the 
increased incidence o f severe aGvHD, in patien ts w ith  NOD2 polym orphism s, TRM 
was re lated to  aGvHD and in fectious com plica tions resu lting from  im m unosuppres­
sive therapy, especially fungal in fections. No specific  increase in m o rta lity  re lated 
to  pneum onia was found con tra ry  to  the  study of Granell et al..
In the  se tting  o f HSCT using unre la ted donors discrepancies in the  im pact o f NOD2 
polym orphism s on TRM and relapse have been a ttr ib u te d  to  the  use o f T-cell- 
dep le tion  w ith  alem tuzum ab (MabCampath®) o r not 27. This underlines the  necessity 
to  take " th e  c o n te x t" o f studies in to  account, especially w ith  respect to  the  level of 
T -ce ll-dep le tion  and the  overall incidence o f aGvHD. As always, local data are 
required be fore adop ting general conclusions and screening proposals.
We saw m ore bacterem ia due to  CoNS in patien ts w ith  a NOD2 po lym orphism  than 
was found among w ild -types, a lthough the d iffe rence  did no t reach sta tistica l 
significance. We were unable to  de te rm ine  the  im pact on bacterem ia due to  OVS, 
because 24 patien ts had received m eropenem  and a fte r co rrec tion  the  study group 
was to o  small to  draw  firm  conclusions. NOD2 senses the  cell wall con s tituen t MDP 
which is present in the  gram -negative and gram -positive  bacteria th a t colonize 
body surfaces or cause in fection . NOD2 is im p o rta n t in the  an tibacte ria l defenses
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especially by regulating the production of defensins at the epithelial barriers of gut 
and lung 9;28;29. Defensins possess anti-staphylococcal and anti-streptococcal 
activity 30 and, in the gut, are e laborated predominantly by Paneth cells. Their  
production has been shown decreased when there  are NOD2 polymorphisms 9;10. 
The increased incidence of CoNS bacteremia found in patients w ith  a NOD2  
polymorphism suggests that lower num ber or activity of the  peptides influence  
infectious complications in HSCT. This might explain how the  gut may be an 
im portant origin of staphylococcal and streptococcal bacteremias 31;32. Consequently, 
polymorphisms in NOD2 predispose to infections with gram-positive bacteria when  
patients are given prophylaxis with f luoroquinolones while suffering from MBI and 
lung epithelial damage.
Importantly, sensing bacteria or derived MDP by NOD2 has an impact on the 
incidence of aGvHD, since the impact of NOD2 polymorphisms on aGvHD disappears 
with the use of comprehensive prophylaxis 33. MBI is induced by myeloablative  
conditioning therapy 1, and is an inflam m atory condition of the gut associated with  
the occurrence of aGvHD 2;3. Inflammation is exacerbated by the translocation of 
bacteria and microbial products which elaborate  cytokine release through the 
stimulation of TLRs. In case of NOD2 polymorphism reduced defensin production  
could contribute to increased bacterial translocation. Additionally "loss of 
tolerance" increases TLR activity and cytokine release 13-16. Consequently, reducing 
the microbial burden of the  gut using antimicrobial prophylaxis that provides better  
gram-positive and anaerobic coverage could prove of benefit  for patients bearing 
a NOD2 polymorphism to reduce the risk of severe aGvHD and therewith  TRM.  
This would especially apply to those patients in whom  no wild-type donor can be 
selected.
The role of donor polymorphisms is less easy to explain, especially in the setting of 
T-cell-depletion. However, donor immune cells can indirectly lower the production  
of defensins 34 and also suffer from the "loss of tolerance", so they could influence  
incidence and severity of aGvHD.
Our study is limited by being of a retrospective nature and the fact that  the study 
group was small. Nevertheless, in this very homogenous cohort of Dutch patients 
we w ere  able to detect a significant impact of NOD2 polymorphisms in T-cell- 
depleted HSCT with regard to severe aGvHD and TRM and showed a higher incidence 
of gram-positive bacteremia. We conclude that in our population NOD2 polymorphism 
screening should be used to optimize donor selection and antimicrobial prophylaxis 
to reduce the occurrence of aGvHD and TRM following allogeneic HSCT.
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CHAPTER 5
Abstract
Background: Intensive tre a tm e n t o f hem atological malignancies w ith  hem atopo ie tic  
stem cell transp lan ta tion  (HSCT) is accom panied by a high incidence o f o p po rtu n is tic  
invasive fungal in fections, bu t ind iv idual risk varies sign ificantly. Dectin-1, a C-type 
lectin  which recognizes 1,3-p-glucans from  fungal pathogens, includ ing Candida 
species, is involved in the  in itia tio n  o f the  im m une response against fungi. 
Methods: Screening fo r the  DECTIN-1 Y238X po lym orphism  w ith in  a group o f 142 
patien ts rece iving HSCT was corre la ted w ith  Candida co lon ization and candidem ia. 
Furtherm ore, func tiona l studies were pe rfo rm ed on the  consequences o f the 
po lym orphism .
Results: Patients bearing the  Y238X po lym orphism  in the  DECTIN-1 gene were m ore 
likely to  be colonized w ith  Candida species com pared w ith  pa tien ts bearing w ild ­
type  DECTIN-1, necessitating m ore frequ en t use o f fluconazole in the  prevention 
o f system ic Candida in fec tion . Functional assays dem onstra ted a loss-o f-function  
phenotype o f the  po lym orphism , as shown by the  decreased cy tok ine p roduction  
by im m une cells bearing th is  po lym orphism .
Conclusions: The Y238X po lym orphism  is associated w ith  increased oral and 
gastro in testina l co lon ization w ith  Candida species. This suggests a crucial role 
played by dectin-1 in the  mucosal an tifungal mechanisms in im m unocom prom ised 
hosts. The find in g  th a t DECTIN-1 po lym orphism s rendered HSCT recip ien ts at 
increased risk fo r  fungal com plica tions may con tribu te  to  the  selection o f h igh-risk 
patien ts w ho should be considered fo r an tifungal prophylaxis to  prevent system ic 
candidiasis.
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Introduction
The trea tm en t  of patients w ith  hematological malignancies with a hematopoietic  
stem cell transplantation (HSCT) following myeloablative conditioning is 
accompanied by complications that  include mucosal barrier injury, prolonged  
neutropenia and graft-versus-host disease (GvHD), all of which contribute to fungal 
and other opportunistic infections 1;2. Traditional risk factors are predictive for  
the incidence of invasive fungal disease in general, but the individual risk is more  
difficult to determ ine, although this is needed for a more guided use of antifungal 
prophylaxis and therapy.
Dectin-1 is a m em ber of the C-type lectin receptor family that  recognizes the p-1,3-  
glucan motif  of the cell wall of pathogenic fungi 3. Dectin-1 is mainly expressed by 
immune cells of the myeloid lineage (neutrophils, macrophages and dendritic cells). 
Several studies have shown that dectin-1 belongs to the arm am entar ium  of immune  
cells against fungal pathogens, including Candida species and Aspergillus species 
4;5. Furthermore, dectin-1 synergizes with  TLR2 and TLR4 signals and promotes Th1 
and Th17 responses to activate antifungal host defense 6-8.
Recently, we have dem onstrated that  a polymorphism in DECTIN-1 (Y238X,  
rs16910526) is responsible for recurrent mucocutaneous fungal infections in a 
Dutch family 9. This polymorphism resulted in an early stop codon which leads to 
the loss of the last 10 amino acids of the extracellular domain, and in a diminished 
capacity to bind p-glucans.
To test the hypothesis that DECTIN-1 variants influence the  susceptibility to 
fungal infections in general and Candida infections in particular of patients 
receiving HSCT, w e  first assessed the frequency of DECTIN-1 polymorphisms in 
a healthy Dutch population. W e  identified the Y238X mutation as an important  
polymorphism, and the only one with significant functional consequences for the  
recognition of Candida species. Subsequently, w e  have investigated the  impact of 
this DECTIN-1 polymorphism on the incidence of mucosal Candida colonization and 
the  occurrence of candidemia and other invasive fungal infections in 142 patients 
receiving a sibling T-cell-depleted allogeneic HSCT.
Patients, materials and methods
Genetic screening for DECTIN-1 polymorphisms
DNA tem plate  of the DECTIN-1 gene (also named CLEC7A) was taken from GenBank, 
chromosome position 12p13, NC _000012 .10 . Sequencing of the exonic and 
nearby intronic regions of the DECTIN-1 gene in the 138 healthy volunteers was 
perform ed by applying the primers and conditions depicted in table 1. Genotyping
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Table 1 Primers and PCR conditions applied to  am p lify  every exon and proximal 
in tron ic regions o f the  DECTIN-1 gene, to  u ltim ate ly  perform  sequence 
analysis.
Exon Primer Sequence (5'- 3') [MgCl2] (mM) Annealing
temperature
1 Forward TTTCACCACGTTAGCCAAGCT 2.5 52°C
Reverse CT GAAATAGTTTGCATCGGTT
2 Forward CCCTTTATAAGTGAAATGGGC 1.75 60°C
Reverse ACCGTGCAAGGCCAGATTTT
3 Forward 1 GCCAGT GATAAAT CAGTTACT 3.5 56°C
Reverse 1 TTCTTCTTCTCCACCTTCTT







5 Forward GCTGCTCGACAGAGGTTTTC 1.75 62°C
Reverse GGATGGTCTCGATCTCCTGA
6 Forward AATCACAGCCTCTCCCTTCA 2.5 60°C
Reverse GATTTAAGCCTCCTTTTCCAA
For all am p licons sequence analyses was ca rried  o u t w ith  th e  fo rw a rd  and th e  reverse p rim e r. For the  
sequences o f exon 3 techn ica l d iff ic u lt ie s  w e re  enco u n te re d . T h e re fo re  w e a m p lifie d  exon 3 w ith  tw o  
d iffe re n t  p r im e r pa irs  and a ligned b o th  fo rw a rd  assays a f te r  sequence analysis.
fo r the  presence o f the  Y238X po lym orphism  in the  pa tien t and donor groups was 
pe rfo rm ed by applying the  TaqMan s ing le -nucleo tide  po lym orphism  (SNP) assay 
C_33748481_10 on the  7300 ABI Real-Time PCR system (Applied Biosystems). 
Patients, donors, and healthy vo lun teers had given in fo rm ed consent to  prospective 
co llec tion  o f DNA samples fo r investigational use.
Flow cytom etry
For sta in ing o f m em brane-bound dectin-1, m onocytes were incubated w ith  5 ^ g /  
mL m urine an ti-dectin -1  d irected tow ards the  stalk region (BD6) conjugated w ith  
b io tin , or mouse IgG2b iso type con tro l, fo llow ed  by s trep tav id in -a llophycocyan in  
conjugated goat an ti-m ouse an tibody (Pharmingen). Dectin-1 expression was 
de term ined by f lo w  cy to m e try  (FACScalibur; BD Biosciences).
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Confocal microscopy
Confocal laser scanning m icroscopy was pe rfo rm ed as described by M eyer-W entrup 
et al. 10. Cells were stained w ith  10 |ag/mL mouse an ti-dectin -1  (clone 259931; R&D 
systems) or mouse IgG2b iso type con tro l, fo llow ed by goat anti-m ouse-A lexa647- 
conjugated secondary an tibody (M olecu lar Probes). Samples w ere  m ounted in 
m ow io l and analyzed by confocal laser scanning m icroscopy (O lympus FV1000).
Cytokine stim ulation assays
Isola tion o f m ononuclear cells was pe rfo rm ed as described previously 8. Cells were 
incubated at 37°C fo r the  indicated du ra tion  (4 h or 48 h) w ith  e ithe r cu ltu re  medium 
or the  various s tim uli: 105 heat-k illed Candida albicans (heat-k illed by incubation at 
56°C fo r 30 min), the  TLR2 agonist Pam3Cys (10 ug/m L) and p-glucan (10 ug/m L) 
or a com bination  o f Pam3Cys and p-glucan. In a pa rt o f the  experim ents, a fte r 
periphera l b lood m ononuclear cells (PBMC) iso la tion, m onocytes were pu rified  
by CD14+ MACS M icroBeads (M ilteny i Biotec) and stim u la ted as described above. 
Cytokine p roduc tion  was measured by ELISA (R&D Systems).
Patients and donors
We pe rfo rm ed a re trospective  analysis in 142 Dutch patien ts undergoing HSCT due 
to  hem atological malignancies. The pa tien ts and th e ir  donors w ere  consecutively 
adm itted  at our transp lan t un it between May 1996 and Septem ber 2007 fo r  a 
human leukocyte an tigen-iden tica l sibling, pa rtia lly  T -ce ll-dep le ted allogeneic 
HSCT. The characteristics o f patients, donors and HSCT procedures are depicted 
in tab le  2.
Treatm ent protocol
The tre a tm e n t p ro toco l has been previously described in de ta il 11. C ond ition ing 
regim en consisted o f cyclophospham ide (60 m g/kg fo r 2 days) in com bination  w ith  
e ithe r to ta l body irra d ia tion  (4.5 Gy fo r  2 days) o r busulfan (4 m g/kg fo r 4 days). 
Idarubic in (42 m g /m 2 in 48 h) was o ften  added in these cond ition ing  regim en to 
reduce the risk o f relapse in the  se tting  o f T -ce ll-dep le ted HSCT 12. On day 0, all 
pa tien ts w ere  given an allogeneic HSCT con ta in ing 3.2 x 106 CD34+ ce lls/kg (range 
0.6-11.6) and 0.5 x 106 CD3+ ce lls/kg (range 0.1-0.8).
A n tim icrob ia l prophylaxis consisted o f 500 mg c ip ro floxacin  given tw ice  da ily and 
500 mg va lac ic lov ir given 3 tim es daily. Surveillance cu ltu res fo r  Candida were 
co llected tw ice  w eekly from  hospita l admission un til hospita l discharge, w ith  
the  f irs t  cultures taken on the  day o f admission before the  s ta rt o f cond ition ing . 
Fluconazole (200 mg daily) was only prescribed to  those w ho were colonized w ith  
Candida albicans, C. tropicalis o r C. parapsilosis (not C. krusei o r C. glabrata) when 
the yeast was present in both fecal cultu res and m outh washes ob ta ined on the
95
c h a p t e r  5
Table 2 Clinical characteristics o f the  study group.












Recipients 65% 60% 0.78
Donors 56% 64% 0.64
Age, mean (range)
Recipient 47.5 (18.5-64.4) 42.8 (19.2-59.8) 0.11
Donor 47.4 (14-75.6) 43.3 (23.8-67.6) 0.24
Diagnosis:
-AML/ALL no (%) 60 (47.6) 8 (53.3) 0.79
-CML/MPS, no (%) 26 (20.6) 3 (20)
-MDS, no (%) 23 (18.3) -
-Lymphoma/CLL, no (%) 17 (13.5) 4 (26.7)
Conditioning regimen:
-Ida-Cyclo-TBI, no (%) 79 (62.7) 10 (66.7)
-Ida-Cyclo-Bus, no (%) 15 (11.9) 1 (6.7)
-Cyclo-TBI, no (%) 27 (21.4) 1 (6.7)
-Cyclo-Bus, no (%) 5 (4.0) 3 (20)
TBI, no (%) 106 (84.1) 11 (73.3) 0.25
Stem cell source:
-Peripheral blood, no (%) 72 (57.1) 9 (60.0) 1.0
-Bone marrow, no (%) 54 (42.9) 6 (40.0)
T-cell-depletion:
-CD34 selection, no (%) 61 (48.5) 9 (60.0)
-Counterflow elutriation, no (%) 41 (32.5) 4 (26.7)
-CD3/CD19 selection, no (%) 24 (19.0) 2(13.3) 0.43
Duration of neutropenia 11.9 (6-20) 11.0 (6-15) 0.23
< 0.1 x 109/ l  in days(range)
Acute GvHD:
-Grade 0-I, no (%) 81 (64.3) 11 (73.3) 0.77
-Grade II-IV, no (%) 39 (31.0) 4 (26.7)
-Grade III-IV, no (%) 10 (7.9) 1 (6.7)
-NA 6 (4.7) -
All p a tie n ts  rece ived an HLA m atched s ib ling  p a rt ia lly  T -ce ll-d e p le te d  HSCT. GvHD p rophy lax is  consisted 
o f  o n ly  cyc lo spo rine  in all pa tie n ts . C h ara c te ris tics  are expressed in abso lu te  num bers  and percentages. 
Age and n e u tro p e n ia  are expressed as m ean va lue w ith  th e  to ta l range. D iffe rences be tw e e n  th e  s tudy  
groups w e re  com pared  using th e  Pearson's x2 te s t o r Fisher's exact te s t and w ith  th e  use o f the  
in d e p e n d e n t t-test w h e re  a p p ro p ria te . No s ig n ifica n t d iffe re n ce s  w e re  ob ta in e d . A b b re v ia tio n s : A M L / 
ALL = acute  m ye lo id  and lym p h a tic  leukem ia , C M L/M P S = ch ron ic  m ye lo id  le u k e m ia /m y e lo p ro life ra tiv e  
syndrom e, MDS = m ye lod ysp las tic  syndrom e, CLL = ch ro n ic  lym p h a tic  leukem ia , Ida = id a ru b ic in , Cyclo = 
cyc lo phospha m ide , Bus = busu lphan , TBI = to ta l bod y  ir ra d ia tio n , GvHD = g ra ft-ve rsus-h os t-d isease , NA 
= n o t app licab le .
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same day, o r when ob ta ined from  the same site on tw o  consecutive occasions 13. 
Invasive fungal in fections were defined according to  the European Organization fo r 
the Treatm ent o f Cancer/Mycoses Study Group consensus guidelines, designating 
invasive fungal disease as possible, probable o r proven 14. Oral mucositis was graded 
daily according to  the validated Nijmegen Nursing Mucositis Scoring System (NNMSS) 
15. Acute GvHD was diagnosed by clinical signs or pathological exam ination o f biopsies 
of skin, gut or liver and graded according to  the criteria  o f Glucksberg et al. 16.
Statistical analysis
In m u ltiva riab le  log istic regression analyses, we investigated the  association of 
DECTIN-1 status o f the  pa tien t w ith  Candida co lon ization, con tro lling  fo r  underlying 
hem atological disease, age and gender o f the  pa tien t. In the  analysis on the  im pact 
o f early candidem ia the  DECTIN-1 status o f on ly patients, bu t no t o f the  donors, 
was considered o f im portance. Early candidem ia was de fined as occurring on day 
21 o r earlier. In m yeloabla tive stem cell transp lan ta tion , m onocyte recovery usually 
occurs on ly 3-4 weeks a fte r HSCT 17, and the re fo re  the  genetic m ake-up o f the 
donor is considered as no t re levant fo r  the  suscep tib ility  to  early candidem ia. The 
association betw een DECTIN-1 status o f the  pa tien t and the  occurrence o f early 
candidem ia was stud ied using log istic regression m odels accounting fo r  confounding 
by includ ing age o f pa tien t, the  underly ing disease, the  du ra tion  o f neutropen ia, 
presence o f co lon ization on adm ission and the presence o f GvHD. In con trast, in 
the  analysis on the  im pact o f proven and probable invasive m ould in fections up to 
day 100, DECTIN-1 status o f bo th pa tien ts and donors was included.
To com pare percentages betw een tw o  independent groups we used the x2 test, or 
the  Fisher's exact tes t when appropria te . D ifferences in the  cy tok ine production  
capacity were tested by the  Student's t  test. P < 0.05 was considered to  represent 
a s ta tis tica lly  s ign ifican t d iffe rence.
Results
DECTIN-1 polymorphism screening in healthy individuals
Genetic va ria tion  in the  DECTIN-1 gene was investigated in 138 Dutch healthy 
vo lunteers, which revealed the  po lym orphism s depicted in figu re  1. A small num ber 
o f po lym orphism s were id en tified  w ith  the  Y238X (rs16910526) in exon 6 being the 
on ly exonic po lym orphism . This po lym orphism  was present in 19 (13.8%) ou t of 
138 individuals, all o f whom  were heterozygous, resu lting in an alle le frequency of 
6.9%. This po lym orphism  was id en tified  ea rlie r in a fam ily  previously analyzed fo r 
m ucocutaneous Candida in fections 9; 3 m em bers o f th is  fam ily  were homozygous 
fo r the  Y238X po lym orphism .
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Figure 1 Schematic draw ing o f the  DECTIN-1 gene (also known as CLEC7A),
consisting o f an N -term inal cytoplasm atic ta il (Cyto), encoded by exon 
1, a transm em brane region (TM, exon 2), a stalk region (exon 3) and 
the carbohydrate recognition domain (CRD, exon 4-6). Intronic 
polym orphism s were detected in 5'UTR, in tron  2, in tron  3, exon 6 and 
3'UTR. All variations are depicted together w ith  the ir corresponding 
chrom osom e location and rs number, if  available.
Dectin-1 protein expression
We investigated the  consequence o f the  po lym orphism  on dectin-1 expression and 
localization at the  pro te in  level. M onocytes iso lated from  indiv iduals homozygous 
fo r the  w ild -typ e  DECTIN-1 a lle le and from  indiv iduals heterozygous or homozygous 
fo r the  Y238X po lym orphism  were analyzed fo r dectin-1 expression by flo w  
cy to m e try  and confocal m icroscopy. M onocytes from  the  ind iv iduals homozygous 
fo r the  Y238X po lym orphism  exh ib ited no dectin-1 expression on the  cell surface, 
whereas cells from  indiv iduals heterozygous fo r  the  Y238X po lym orphism  had 
in te rm ed ia te  cell surface expression com pared to  cells from  indiv iduals w ith  
the  w ild -typ e  alle le (figure 2A). In line w ith  this, no cell surface expression o f 
dectin-1 could be de tected on m onocytes isolated from  indiv iduals homozygous 
fo r the  Y238X po lym orphism  in con trast to  w ild -typ e  cells, when m onocytes were 
analyzed by confocal m icroscopy (figure 2B). However, dectin-1 mRNA expression 
was dem onstra ted to  be equal between the  genotypes (data no t shown). Thus, 
these find ings dem onstra te  th a t dectin-1 pro te in  expression is absent from  the  cell 
m em brane o f m onocytes from  the  ind iv iduals homozygous and in te rm ed ia te  on 
m onocytes from  indiv iduals heterozygous fo r the  Y238X polym orphism .
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Figure 2 (A) Flow cy tom etry  graphs o f extrace llu la r dectin-1 staining, and 
(B) fluorescent confocal staining o f dectin-1 (right panel) and light 
m icroscopic image (le ft panel) on unstim ulated m onocytes derived 
from  individuals homozygous fo r the w ild -type  DECTIN-1 allele (WT) 
and heterozygous (HET) or homozygous fo r the DECTIN-1 Y238X 
polym orphism  (HOM).
5
Cytokine production
Functional consequences o f the Y238X polym orphism  were investigated in monocytes 
and PBMCs isolated from  indiv iduals bearing on ly the w ild -type  DECTIN-1 allele 
and indiv iduals being heterozygous o r homozygous fo r  the Y238X po lym orphism . 
In terleuk in  (IL)-13 induction  by C. albicans was low er in cells from  individuals 
bearing the  Y238X po lym orphism  (figure 3A, P <0.05). Dectin-1 has been previously 
dem onstra ted to  am p lify  TLR2 signaling 8; th is  e ffe c t was absent in cells isolated 
from  indiv iduals homozygous fo r the Y238X allele (figure 36). In con trast, IL-18 
and in te rfe ron  (IFN)-y p roduction  was not de fective  in cells isolated from  these 
indiv iduals (figure 3C, P = not significant). A lthough a tendency tow ards a low er 
IL-18 p roduc tion  capacity has been observed in cells from  indiv iduals heterozygous
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fo r Y238X com pared w ith  cells bearing on ly the  w ild -ty p e  DECTIN-1 allele, th is  did 
not reach sta tis tica l significance. IL-18 p roduction  in cells o f indiv iduals homozygous 
fo r the  Y238X m uta tion  was s im ilar to  p roduc tion  in cells from  indiv iduals w ith  
the  w ild -typ e  allele. Furtherm ore, IFN-y p roduc tion  capacity is p ractica lly  equal 
between the  genotypes.
DECTIN-1 Y238X polymorphism in patients and donors
The DECTIN-1 genetic status could be de term ined in 141 pa tien ts and 138 donors. 
Insu ffic ien t am ounts o f DNA precluded the  de te rm ina tion  in 1 pa tien t and 4 donors. 
F ifteen (10.6%) o f 141 pa tien ts and 22 (15.9%) o f 138 donors had the DECTIN-1 Y238X 
po lym orphism ; all indiv iduals were heterozygous. In 9 pa tien t-donor pairs, both 
indiv iduals were heterozygous fo r  the  po lym orphism . There were no s ta tis tica lly  
s ign ificant d iffe rences between the clinical characteristics o f pa tien ts w ith  and 
w ith o u t the  DECTIN-1 Y238X po lym orphism  (table 2). No d iffe rence  was detected 
in the  severity  o f m ucositis be tw een patien ts w ith  o r w ith o u t the  DECTIN-1 Y238X 
po lym orphism , w ith  a mean NNMSS score o f 3.8 vs. 3.9 on day 0 and 7.2 vs. 7.6 on 
day 7 (P = no t significant).
Candida species colonization
Seven patien ts w ho received secondary antifunga l prophylaxis at hospita l admission 
were excluded from  the  study, as w ere  11 patien ts w ith  missing co lon iza tion  data, 
leaving 124 patien ts e lig ib le  fo r analysis o f Candida co lon ization. A t hospital 
admission, 46 (37.1%) o f 124 pa tien ts were colonized w ith  Candida species. 
Patients w ho were heterozygous fo r the  Y238X po lym orphism  were s ta tis tica lly  
s ign ifican tly  m ore o ften  colonized than were patien ts w ith  DECTIN-1 w ild -typ e  
alleles (11 (84.6%) o f 13 vs. 35 (31.5%) o f 111; P <0.001) (odds ra tio  (OR), 11.9; 95% 
confidence in te rva l (CI), 2 .5 -56 .8 ). A fte r ad justing fo r  diagnosis, the  OR was 12.2 
(95% CI, 2 .5 -59.7); a fte r ad justing fo r  pa tien t age and sex, the  OR was 12.0 (95% 
CI, 2.5-57.1). On the day o f HSCT (day 0), th is  d iffe rence  persisted: 12 (92.3%) of
13 patien ts vs. 50 (45.1%) o f 111 patien ts (P =0.001). The unadjusted OR was 14.6 
(95% CI, 1 .8-116.5) and the  OR adjusted fo r  diagnosis, pa tien t age, and sex was 15.5 
(95% CI, 1.9-125.6).
Patients w ith  a DECTIN-1 po lym orphism  w ere m ore like ly than o th e r pa tien ts to 
receive fluconazole (9 (69.2%) o f 13 vs. 42 (37.8%) o f 111; P =0.03) (table 3). Among 
those pa tien ts w ho received fluconazole, erad ica tion  was achieved in 1 (11.1%) of 
9 pa tien ts w ho were heterozygous fo r  the  Y238X po lym orphism , com pared w ith
14 (33.3%) o f 42 pa tien ts w ho bore on ly the  w ild -typ e  DECTIN-1 a lle le (P =0.25). 
Colonizing species were C. albicans (87% o f patients), C. glabrata  (8.1%), and 
sporadically, C. krusei, Candida kefyr, Candida parapsilosis, and Candida dubliniesis 
(1.6% each). No d iffe rence  in the  frequency o f co lon ization w ith  pa rticu la r Candida
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Figure 3 Cytokine production capacity o f IL-1 p, IL-18 and IFN-y a fte r stim ulation 
o f m onocytes during 4 hours (panel A) or PBMCs during 48 hours w ith  
heat-killed C. albicans (panel C) or w ith  p-glucan, Pam3Cys or p-glucan 
/Pam3Cys (panel B). Cells were obtained from  individuals being 
w ild -type  (WT, n=5), heterozygous (HET, n=4) and homozygous (HOM, 
n=3) fo r the  DECTIN-1 Y238X polym orphism . Data are percentages 




Table 3 Observed Candida colonization and invasive fungal disease in HSCT 
patients. For details see m aterial and methods.











Candida colonization on 
admission
31.5% (35/111) 84.6% (11/13) <0.001 11.9
Candida colonization day of HSCT 
(day 0)
45.1% (50/111) 92.3% (12/13) 0.001 14.6
Surveillance-culture guided 
fluconazole therapy
37.8% (42/111) 69.2% (9/13) 0.03 3.7
Early candidemia, < day 21 8.0% (9/112) 18.2% (2/11) 0.26 2.5
Invasive mould disease < day 100 3.0% (3/100)* 5.0% (1/20)* 0.52 1.7
*T he  gene tic  DECTIN-1 s ta tus  o f  th e  p a tie n t-d o n o r coup les (e ith e r p a tie n t, d o n o r o r b o th  he te rozygous 
fo r  th e  Y238X p o lym o rp h ism ) was inc luded  in th is  analysis o f th e  im p a c t o f th e  p o lym o rp h ism  on the  
occurrence  o f  invasive m ou ld  disease < day 100.
species was observed between patien ts w ho w ere  heterozygous fo r Y238X and 
patien ts w ho bore on ly the  w ild -typ e  DECTIN-1 allele.
Invasive fungal disease
Patients w ho received early an tifungal prophylaxis w ith  e ithe r itraconazole, 
voriconazole, o r posaconazole, s ta rting  from  day 0 o r ea rlie r and un til day 21, 
were excluded (18 patients, 7 o f whom  had received secondary prophylaxis and 
11 o f whom  had pa rtic ipa ted  in an tim icrob ia l studies). The overall incidence of 
candidem ia un til day 21 was 8.9% (11 o f 123 patients). There was no s ta tis tica lly  
s ign ificant d iffe rence  in the  incidence o f early candidem ia betw een patien ts w ith  
and patien ts w ith o u t the  DECTIN-1 Y238X po lym orphism  (2 (18.2%) o f 11 vs. 9 
(8.0%) o f 112; P =0.26) (table 3); the  OR was 2.5 (95% CI, 0 .5 -13.6). However, this 
study was no t designed to  de tect d iffe rences in the  risk o f developing invasive 
candidiasis, because patien ts w ho were colonized were prescribed fluconazole 
to  prevent system ic Candida in fec tion , and the  study was underpow ered to  find  
a d iffe rence . Candidemia was caused by C. albicans in 7 o f 11 cases, w ith  the 
rem ainder o f the  cases being due to  C. glabrata  (1 case), C. parapsilosis (2), and 
C. dubliniesis (1). Eight (15.7%) o f 51 patien ts w ho were colonized and received 
fluconazole experienced candidem ia. Two (3.6%) o f 55 pa tien ts w ho were not 
colonized, and w ho the re fo re  received no fluconazole developed candidem ia.
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The incidence of proven and probable invasive mold infection up to day 100 was 
3.3% (4 of 120 patients), with 4 probable and no proven mold infections. Three  
probable cases w ere  due to Aspergillus species, and 1 probable case was due to 
Rhizomucor species. There was no statistically significant difference between  pairs 
with and w ithou t  a DECTIN-1 Y238X polymorphism; 1 (5.0%) of 20 patients with the 
Y238X polymorphism had a probable case, compared with 3 (3.0%) of 100 patients  
with the  DECTIN-1 w ild-type allele (P =0.52) (table 3). However, the study was 
underpowered to detect a difference, especially because of the very low incidence 
of mold infection.
Discussion
In this study, we  dem onstrate  that  a newly characterized polymorphism in DECTIN-1 
is associated with  increased susceptibility to fungal colonization among HSCT 
recipients. As a consequence, among patients who w ere  immunocompromised as 
a result of HSCT, the  need to prescribe fluconazole to prevent systemic Candida 
infection was, in part,  defined by the presence of this polymorphism.
Dectin-1 is one of the most im portant  pattern recognition receptors for fungal 
pathogens in general, and Candida species in particular. Polymorphisms in pattern  
recognition receptors are known to be associated with  an increased susceptibility 
to fungal infections 18;19. W e  hypothesized that genetic variants of DECTIN-1 could 
influence susceptibility to Candida colonization and infection in HSCT recipients.  
Screening of all 6 exons of the DECTIN-1 gene in a healthy Dutch population  
revealed 1 exonic polymorphism and several intronic SNPs. Since the  intronic SNPs 
are not likely to affect dectin-1 function, we considered the  Y238X polymorphism  
as the only polymorphism that could alter dectin-1 function and could influence  
susceptibility to fungal infections.
To characterize the  functional consequences of the Y238X polymorphism in more  
detail, f low  cytom etry  and confocal microscopy w ere  perform ed. Expression 
of dectin-1 was absent on the cell m em brane of cells isolated from individuals 
homozygous for the Y238X allele, wich suggested a defective transport of the  
mutated form of dectin-1 to the cell m em brane. Accordingly, dectin-1 expression 
was interm ediate  on cells from individuals heterozygous for the  polymorphism.  
After stimulation with heat-killed C. albicans or p-glucan, IL-ip secretion was 
in term ediate  in cells isolated from individuals heterozygous for the Y238X poly­
morphism and low in cells from individuals homozygous for this polymorphism,  
compared with individuals who w here  homozygous for the w ild -type allele. 
Moreover,  the previously described synergism between TLR2 and dectin-1 signals 
8 was completely absent in individuals homozygous for the Y238X polymorphism.
103
c h a p t e r  5
These data dem onstrate  the loss-of-function e ffect of the  Y238X polymorphism for 
dectin-1 activity. However, no difference in production of IL-18 and IFN-y could be 
observed betw een  the d ifferent DECTIN-1 genotypes. This could well be due to a 
certain redundancy of dectin-1 signaling in production of these cytokines, and this 
is accompanied by a normal Candida killing activity by neutrophils from individuals 
bearing the Y238X polymorphism (data not shown), resulting in an adequate host 
defense in systemic infections.
In the follow-up of these genetic and immunological studies, we dem onstrate  that  
this polymorphism has a significant impact on oral and gastrointestinal mucosal 
colonization with Candida species in HSCT recipients, which defined the need for 
the use of fluconazole in our approach. This is in line with the finding of recurrent  
mucocutaneous candidiasis in a family with  individuals w ho where  homozygous for 
the DECTIN-1 polymorphism 9. The overall rate of fungal colonization at admission 
was comparable to that  in earl ier studies, with colonization rates of 28-57%  20;21. 
These data strongly support a role of dectin-1 mediated mechanisms for mucosal 
anti-Candida defense.
The mechanisms of the increased susceptibility to mucosal colonization with  
Candida in individuals bearing the DECTIN-1 polymorphism cannot be definitively  
pinpointed, although the defective cytokine responses are probably involved. 
Although monocytes are im portan t  for mucosal defenses, epithelial cells may also 
contribute to these effects. Interestingly, the expression of dectin-1 on epithelial  
cells has been recently dem onstrated  and the interaction of these cells with  fungal 
pathogens leads to chemokine release 22. One has to consider however, that  in the  
setting of HSCT, both monocytes and epithelial cells of the mucosa are damaged for 
a prolonged period, although largely intact on admission and during the first days 
of conditioning. On the other hand, the residential macrophages of the mucosa are 
less affected, and it is most likely that  the  impact of the DECTIN-1 polymorphism is 
exerted at their level.
The presence of the DECTIN-1 polymorphism did not result in a significantly 
higher incidence of candidemia, although that might have been expected since 
mucosal colonization is associated with  systemic candidiasis in HSCT recipients 
who experience mucosal barrier injury 23;24. Importantly, in this cohort patients  
w ere prescribed oral f luconazole when colonized, which is known to reduce the  
incidence of candidemia 21;25. Therefore, fluconazole was most likely a confounding  
factor, precluding a definit ive conclusion regarding the role of the DECTIN-1 Y238X 
polymorphism for susceptibility to early candidemia, although our data may suggest 
an increased risk (OR 2.5, 95%CI 0.5-13.6).  In addition, our study was underpowered  
to study the impact of the  polymorphism on the occurrence of invasive mould  
infections because of the low incidence of these infections.
In our culture-guided approach fluconazole could safely be w ithheld for those  
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individuals w ho were no t colonized w ith  Candida species, p reventing ove rtre a tm en t 
and accom panied side e ffec ts  and costs. However, those indiv iduals w ho were 
colonized rem ained at s ign ifican t risk fo r  candidem ia, necessitating b e tte r ways 
to  predict, de te rm ine  and tre a t co lon ization at an early stage. D ete rm in ing the 
DECTIN-1 status before HSCT m ight be a fa c to r con tribu ting  to  a m ore risk adapted 
p rophylactic  approach. Because Candida co lon ization is associated w ith  invasive 
disease in HSCT, we propose th a t pa tien ts bearing the  po lym orphism  should be 
considered fo r  an tifungal prophylaxis to  prevent system ic candidiasis. Nevertheless, 
fu tu re  studies in prospective tria ls  are necessary to  fu r th e r con firm  the im pact of 
th is new ly characterized DECTIN-1 po lym orphism  and to  de fine  its ro le in selecting 
adequate prophylaxis o r early tre a tm e n t fo r  HSCT recipients.
5
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CHAPTER 6
Abstract
Dectin-1 plays an im p o rta n t ro le in an tifungal im m unity . The dectin-1 Y238X 
po lym orphism , w h ich results in decreased Th17 responses, is associated w ith  
increased Candida co lon ization o f stem cell transp lan ta tion  (SCT) recip ients. In this 
study we found no im pact o f the  po lym orphism  on the  incidence o f graft-versus- 
host disease (GvHD), o r on disease-free and overall survival in these SCT recipients. 
However, pa tien ts from  pa tien t-d on o r pairs bearing the  w ild -typ e  alle le w ho where 
colonized w ith  Candida had a s ign ificant increased incidence o f acute GvHD 
com pared to  non-co lon ized patien ts (OR=2.6, P=0.04). The fac t th a t was no t the 
case in pa tien ts from  pairs w ith  the  Y238X po lym orphism  (OR=1.2, ns) suggests tha t 
despite increased co lon ization de fective  dectin-1 signaling m ight have prevented 
an im pact o f Candida co lon ization on the  incidence o f acute GvHD to  occur. These 
are the  f irs t  human data showing a ro le fo r  Candida in the  pathogenesis o f acute 
GvHD. The mechanism could involve C-type lectin  receptor m ediated Th17 
responses.
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Introduction
We have recently  established a ro le o f the  pa tte rn  recogn ition  recep to r (PRR) 
dectin-1 fo r  the  mucosal im m u n ity  against Candidaspp in SCT recip ients by showing 
increased Candida co lon ization among patien ts bearing the  dectin-1 Y238X 
po lym orphism  1. This early s top-codon po lym orphism  results in the  loss o f the  last 
ten am ino-acids and an a lte red th ree -d im ensiona l s truc tu re  o f the  extrace llu la r 
dom ain o f dectin-1, resu lting in the  reduced a b ility  to  bind its ligand p-glucan and 
im paired induction  o f p ro -in fla m m ato ry  cytokines 1.
Besides its ro le in an tifungal im m unity , dectin-1 exh ib its  a broader fun c tion  in 
im m unity . S tim ula tion  o f dectin-1 w ith  e ith e r curdlan o r p-glucan a ffects antigen 
presen ta tion  2, m odulates T -lym phocytic  (CD4+, both Th1 and Th17, and CD8+) and 
B-lym phocytic  responses 3;4, and induces cy tok ine p roduc tion  includ ing in te rleukin  
(IL) 10, IL-12 and IL-23. These specific T-cell responses and cytokines are o f pa rticu la r 
in te rest in SCT because they are involved in gra ft-versus-leukem ia (GvL) effects, as 
well as in the  pathogenesis o f gra ft-ve rsus-host disease (GvHD), a lthough the  role 
o f the  IL-23/Th17 response has on ly recently  been explored in animal m odels 5-7 and 
in human studies 8. M oreover, ac tiva tion  o f PRRs by m icrobia l com ponents can 
m od ify  a llo -reactive  im m une responses w ith  im p lica tions fo r  the  ou tcom e o f SCT 9. 
In add ition , w ith  respect to  T-cell responses, p-glucan shows prom ising in v itro  and 
in vivo a c tiv ity  as an im m une ad juvant in the  tre a tm e n t o f solid and hem atological 
m alignancies. The a n ti-tu m o r a c tiv ity  is d irec tly  re lated to  signaling through 
dectin-1 4;10, suggesting th a t the  ce llu la r im m un ity  e lic ited  by p-glucan could be of 
the rapeu tic  value, possibly by e lic iting  GvL reactions in SCT.
There fore, our hypothesis was th a t changes in dectin-1 activa tion  e ith e r by a "loss- 
o f- fu n c tio n " resu lting from  the Y238X po lym orphism  or by Candida colon ization 
could have an im pact on the  im m unolog ical responses fo llow ing  SCT and the 
outcom e. We pe rfo rm ed a re trospective  study on the  im pact o f the  Y238X 
po lym orphism  and Candida co lon iza tion  in the  se tting  o f m atched re lated, pa rtia lly  
T ce ll-dep le ted SCT, w ith  the  focus on GvHD and relapse (GvL).
Patients and methods
Patients
We perfo rm ed a re trospective  analysis among 140 patien ts w ho had been 
consecutively ad m itted  fo r  a m atched re lated, pa rtia lly  T ce ll-dep le ted , allogeneic 
SCT. The characteristics o f patients, donors and SCT procedures are depicted in 
Table 1.
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Table 1 Clinical characteristics o f the  study groups.
Recipient, donor and SCT Dectin-1 wt pairs Dectin-1 Y238X P-value




Gender (no, % male)
Patients 70 (62.5%) 18 (64.3%) ns
Donors 63 (56.3%) 17 (60.7%) ns
Age, mean (range)
Patients 47.6 (18.5-64.4) 43.8 (19.1-59.8) P=0.09
Donors 47.7 (14.0-75.6) 43.7 (21.7-68.3) ns
Diagnosis
-AML, no (%) 40 (35.7%) 13 (46.4%) ns
-ALL, no (%) 12 (10.7%) 4 (14.3%)
-CML/MPS, no (%) 23 (20.5%) 4 (14.3%)
-MDS, no (%) 17 (15.1%) 2 (7.1%)
-NHL/CLL, no (%) 20 (17.9%) 5 (17.9%)
Conditioning regimen
-Ida-Cyclo-TBI, no (%) 75 (67.0%) 15 (53.6%)
-Ida-Cyclo-Bus, no (%) 11 (9.8%) 5 (17.9%)
-Cyclo-TBI, no (%) 21 (18.8%) 5 (17.9%)
-Cyclo-Bus, no (%) 5 (4.5%) 3 (10.7%)
TBI 96 (85.7%) 20 (71.4%) P=0.09
Stem cell source
-PB, no (%) 58 (51.8%) 17 (60.7%) ns
T cell-depletion
-CD34 selection, no (%) 50 (44.6%) 17 (60.7%) ns
-Counterflow elutriation, no (%) 38 (33.9%) 7 (25.0%)
-CD3/CD19 depletion, no (%) 24 (21.4%) 4 (14.3%)
Male patient/female donor, no (%) 31 (27.6%) 6 (21.4%) ns
Prophylactic DLI, no (%) 31 (27.7%) 12 (42.9%) ns
All pa tie n ts  received an HLA m atched  s ib ling  p a rtia lly  T c e ll-d e p le te d  SCT. C h ara c te ris tics  are expressed 
in abso lu te  num bers  and percentages. Age is expressed as m ean va lue w ith  th e  to ta l range. D iffe rences 
b e tw e e n  the  s tu d y  groups w e re  com pared  using ch i-squared  te s t o r  F isher's exac t te s t and w ith  th e  use 
o f  th e  in d e p e n d e n t i- te s t w h e re  a p p ro p ria te . No s ig n ifica n t d iffe re n ce s  w e re  fo u n d ; P-values < 0.10 are 
show n. A b b re v ia tio n s : AM L/ALL = acute  m ye lo id  and lym p h a tic  leukem ia , C M L/M P S = ch ron ic  m yelo id  
le u k e m ia / m y e lo p ro life ra tiv e  syndrom e, MDS = m ye lod ysp las tic  syndrom e, CLL = ch ron ic  lym pha tic  
leukem ia , Ida = id a ru b ic in , Cyclo = cyc lo phospha m ide , Bus = busu lphan , TBI = to ta l bod y  irra d ia tio n , DLI 
= d o n o r lym p h o cy te  in fus ion .
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Transplantation procedure
All patients had been treated  according to the same protocol as previously has 
been described 1;11. The myeloablative conditioning regimen consisted mainly of 
idarubicin and cyclophosphamide in combination with  e ither total body irradiation  
(TBI) or busulphan. GvHD prophylaxis consisted of three  months of cyclosporine 
only. Patients who had remained free of GvHD three  months afte r  stopping 
cyclosporine w ere  eligible for prophylactic donor lymphocyte infusion (DLI). 
Surveillance cultures for Candida w ere  collected tw ice weekly  from admission until 
discharge, with the  first cultures taken on the day of admission before the  start of 
conditioning. Fluconazole (200 mg daily) was only prescribed to those w ho were  
colonized with Candida albicans, C. tropicalis or C. parapsilosis (not C. krusei or C. 
glabrata) when the yeast was present in both fecal cultures and mouth washes 
obtained on the same day, or when obtained from the  same site on tw o  consecutive 
occasions.
Genetic screening fo r  Dectin-1 polym orphism
Genotyping for the presence of the Y238X polymorphism was performed by applying 
TaqMan SNP assay C_33748481_10, as previously described 1. Patients and donors had 
given informed consent to collecting DNA samples for investigational use.
Definitions and grading o f outcome m easures
Acute and chronic GvHD w ere  classified respectively according to the criteria of 
Glucksberg et al. 12 and to Shulman et al. 13. Disease-free survival (DFS), relapse- 
related m orta l i ty  (RRM), overall survival (OS), and non-relapse morta l i ty  (NRM)  
w ere defined according to standard criteria.
Statistical analysis
The end-points GvHD, DFS, RRM, NRM and OS w ere  analyzed in relation to dectin-1  
genetic status. Study groups w ere  formed according to presence of polymorphism  
Y238X, comparing patient-donor pairs w ith  at least one bearing the  polymorphism  
with pairs comprising the wild-type. The time-to-clinical event was determined  
from the  date of SCT. Because the study groups w ere  small, w e  limited the number  
of variables included in the multivariable logistic and Cox regression analysis to 
known risk factors and those variables having P-values <0 .20  in univariable analysis. 
Hence, the  conditioning regimen, NOD2 status and gender combination were  
included in the analysis of acute and chronic GvHD. Disease-status, diagnosis, 
conditioning regimen, and use of prophylactic DLI w ere  included in the analysis of 
DFS and RRM, disease status, diagnosis, conditioning regimen and acute GvHD in 
the analysis of NRM and OS.
113
c h a p t e r  6
In add ition , acute GvHD was analyzed in re la tion  to  Candida co lon ization on the  day 
o f SCT. P atien t-donor pairs bearing on ly the  w ild -ty p e  dectin-1 alle le and pairs w ith  
at least one dectin-1 po lym orphism  w ere analyzed separately. Cond ition ing 
regim en, NOD2 status and gender-com bination  were included in m ultivariab le  
logistic regression analysis.
The chi-squared tes t o r the  Fisher's exact tes t was em ployed to  com pare p roportions 
between tw o  independent groups, depending upon which was m ore appropria te . 
P <0.05 was considered to  represent a s ta tis tica lly  s ign ifican t d iffe rence.
Results and discussion
Among the  140 p a tien t-donor pairs, the  alle le frequency o f the  Y238X polym orphism  
was 6.6%, w ith  10.7% o f pa tien ts and 15.7% o f donors bearing the  Y238X 
po lym orphism . All w ere  heterozygous and at least one po lym orphism  was present 
in 28 o f 140 (20%) pa tien t-donor pairs.
The mean du ra tion  o f fo llo w -u p  a fte r SCT was 37.5 m onths (range 0.1-132.0). DFS, 
RRM, NRM and OS at 5-years were 37.8%, 25.6%, 20.7% and 53.6%, respectively. 
Acute GvHD grades II-IV a ffected 30.7% o f pa tien ts and 7.9% had severe acute 
GvHD (grades III-IV). Chronic GvHD occurred in 28.6% o f pa tien ts, being lim ited  in 
10.7% and extensive in 17.9%. No s ign ificant d iffe rences were seen in DFS, RRM, 
NRM and OS betw een pairs w ith  or w ith o u t the  Y238X po lym orphism  both in 
un ivariab le and m u ltiva riab le  analysis (Table 2). Also the  occurrence o f acute GvHD 
and chronic GvHD did no t d iffe r  between couples w ith  o r w ith o u t the  po lym orphism  
(Table 2).
In teresting ly, Candida co lon ization during aplasia was associated w ith  an increased 
risk o f acute GvHD. This however seemed to  depend on the  dectin-1 status. Data on 
Candida co lon ization had been co llected in 124 pa tien ts (97 w ild  type  pairs and 27 
pairs w ith  at least one Y238X polym orphism ). On the day o f SCT, 63% o f the  patients 
from  pa tien t-donor pairs w ith  a dectin-1 po lym orphism  were colonized vs. 44.5% 
among w ild  type  pairs. This d iffe rence  was p redom inan tly  due to  the  s ign ificantly  
increased co lon iza tion  in pa tien ts bearing the  Y238X po lym orphism  1. Colonized 
patien ts received fluconazole, a lthough ra the r late in the  second and th ird  week of 
SCT, and fu ll eradication of Candida was rarely achieved. Fluconazole use was similar 
(= 80%) in colonized patients w ith  and w ith o u t the  po lym orphism . The incidence of 
acute GvHD was increased among pa tien ts from  w ild -typ e  dectin-1 pairs who 
w here colonized w ith  Candida spp com pared to  non-co lon ized patien ts (41.9% vs. 
20.4%, OR=2.6, 95%CI: 1.02-6.58, P=0.04, m u ltiva riab le  analysis, Fig. 1). This e ffec t 
on acute GvHD was however no t seen in patien ts from  pairs bearing at least one 
Y238X po lym orphism  (23.5% colonized vs. 20% not colonized, OR=1.2, ns, Fig. 1).
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Table 2 Outcome of SCT in dectin-1 wild type (wt) vs. dectin-1 Y238X  
patient-donor pairs.






or Odds ratio 
(95%CI)
P-value
Overall survival, 5 year 56.2% 42.8% 1.5 (0.8-2.8)* P=0.18
Disease free survival, 5 year 36.7% 40.6% 0.9 (0.5-1.6)* P=0.75
Non-relapse mortality, 5 year 20.5% 21.4% 1.1 (0.5-2.7)* P=0.82
Relapse-related mortality, 5 year 23.3% 35.8% 2.1 (0.9-4.7)* P=0.09
Acute GvHD 33.3% 25.9% 0.9 (0.3-3.0)** P=0.89
Chronic GvHD 28.5% 29.2% 1 .0 (0.3-3.0)** P=0.98
These are  th e  resu lts  o f  th e  m u lt iv a r ia b le  Cox reg ress ion  ana lysis (HR)* and m u lt iv a r ia b le  lo g is tic  
regress ion analysis (O R )**.
Figure 1 The impact of Candida colonization and dectin-1 status on the  
incidence of acute GvHD grade II, III and IV.
W t = w ild  ty p e  d e c tin -1 , SNP = Y238X p o ly m o rp h is m , ns = n o t s ig n if ic a n t.
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Looking only at the patients colonized with  Candida, the presence of the Y238X 
polymorphism reduced the  impact of colonization on the incidence of acute GvHD 
(41.9% w ild -type vs. 23.5% Y238X, P=0.18).
A role for micro-organisms residing at mucosal surfaces has long been implicated 
in the pathogenesis of acute GvHD 9. Use of antimicrobial agents in order to achieve 
gut decontamination has already proved to decrease the incidence and severity of  
acute GvHD 14. Although the focus so far has been on gut bacteria, our data 
underscore the importance of fungi as well. Moreover, in a study by M arr et al. a 
decreased incidence of gut acute GvHD was observed when using early fluconazole  
prophylaxis 15, supporting the  association between Candida colonization and acute 
GvHD.
Th17 responses have been shown to play an im portant role both mucosal and 
systemic anti-Candida host defenses in mice 16;17 and humans 18;19. These responses 
are induced through the activation of d ifferent PRRs, most im portantly  dectin-1, 
dectin-2, mannose receptor, and TLR-2. At the  same time, recent studies have 
directed at a previous unrecognized role for Th17/IL-23 in the  pathogenesis of 
GvHD, especially acute GvHD 6-8. Therefore  the link between  Candida colonization  
and acute GvHD might prove to be the induction of Th17/IL-23 responses by the  
fungus. Previously, we have shown that the Y238X polymorphism results in a 
decreased Th17 response 20, explaining the mechanism of increased Candida 
colonization in patients bearing the polymorphism. The fact that colonization in 
patient-donor pairs w ith  the polymorphism did not result in increased acute GvHD 
but did in w ild-type pairs, suggests that  despite increased colonization defective  
dectin-1 signaling prevented an increase in Th17-mediated acute GvHD (Fig. 2). 
However, the  limited sample size of this study precludes firm statements regarding  
the role of dectin-1, especially since other PRRs are also im portant for anti-Candida 
immunity. Therefore, additional studies are necessary to confirm our results and 
these studies should incorporate measurements of cytokines and Th-subsets. 
Nevertheless, our study presents the  first human in vivo data showing a clear link 
between Candida colonization and acute GvHD. In addition, our data support that  
the mechanism could involve C-type lectin mediated Th17 responses, which have 
recently been implicated in the pathogenesis of acute GvHD.
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Figure 2 Sim plified hypothesis on the  role o f Candida colonization in the 
pathogenesis o f acute GvHD.
G vHD = g ra ft-v e rs u s -h o s t d isease, TLR = T o ll- lik e  re c e p to r , M AM Ps = m ic ro b e -a s s o c ia te d  m o le c u la r  
p a tte rn s .
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Human la c to fe rrin  is a natural defense p ro te in  belonging to  the  innate im m une 
system present in several body flu ids  and secretions as w e ll as in the  secondary 
granules o f po lym orphonuclear neu troph ils . Lac to fe rrin  and its deriva tives have 
p le io trop ic  func tions  includ ing broad-spectrum  an ti-m icrob ia l a c tiv ity , an ti-tu m or 
a c tiv ity , regu la tion  o f cell g ro w th  and d iffe re n tia tio n , and m odu la tion  of 
in flam m ato ry  as well as hum oral and ce llu la r im m une responses. This is the  reason 
why much research has addressed the po ten tia l the ra pe u tic  a c tiv ity  o f these 
molecules in d iffe re n t clinical settings, especially regarding in fectious diseases and 
uncon tro lled  in flam m ato ry  conditions. In pa tien ts w ith  hem atological malignancies 
trea ted  w ith  a hem atopo ie tic  stem cell transp lan ta tion  (HSCT) m o rb id ity  and 
m o rta lity  due to  in fections and uncon tro lled  in flam m ation  remains high, despite 
many advances in supportive  care. These life  th rea ten ing  com plica tions are a resu lt 
o f the  damage caused by the  cond ition ing  regimens to  the  mucosal barrier, and the 
innate and adaptive, hum oral and ce llu lar im m une defenses. These com plica tions 
necessitate the  continued exp lo ra tion  o f new tre a tm e n t m odalities. Systemic and 
probably local levels o f la c to fe rrin  are decreased fo llow ing  HSCT. There fore, the 
use o f lac to fe rrin , o r sho rt peptide deriva tives th a t re ta in  the  ca tion ic N -te rm ina l 
m o ie ty  th a t is essential fo r  the  an ti-m icrob ia l and an ti- in flam m ato ry  activ ity , may 
prove to  be a prom ising versa tile  class o f agents fo r managing the  com plica tions 
th a t arise from  HSCT.
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Introduction
Because mammalian neonates of primates depend on milk for their nutritional needs 
as well as for their immune protection much research has addressed the beneficial 
components of milk. One of these components, lactoferrin, was first identified in 
1939, isolated in human milk in 1969 1 and later detected in the granules of human 
polymorphonuclear neutrophils (PMNs) 2. Since then this protein has been extensively 
studied. In 1978 Broxmeyer identified lactoferrin as a regulator of myelopoiesis 
inhibiting the production of granulocyte-macrophage colony stimulating factor by 
monocytes and macrophages. Because PMNs in chronic myeloid leukemia were  
shown deficient of lactoferrin, a role in the pathogenesis of leukemia through  
defective growth inhibition was suggested, implying a potential therapeutic effect of 
lactoferrin 3. This provided an impulse for further investigations, reviewed in 1984, 
on the biological significance of lactoferrin in hematology 4. However, many conflicting 
data existed which resulted in an extensive discussion regarding the potential role of 
lactoferrin in myelopoiesis, designated "the lactoferrin controversy"5. This discussion 
was not resolved and interest in lactoferrin from a hematological point of view  
appeared to subside. In that same period, a promising report suggested that  
lactoferrin given orally as anti-bacterial prophylaxis in neutropenic patients deserved 
further study 6. But measurement of the plasma level of lactoferrin as an early means 
of monitoring hematopoietic regeneration following bone marrow transplantation  
seemed to be the only application 7.
However, interest in the hematological value of lactoferrin re-emerged in a report  
of children with  refractory graft-versus-host disease (GVHD) following hematopoietic  
stem cell transplantation (HSCT) w here  there  was dramatic im provem ent seen in 
four of the seven cases following oral t rea tm ent  with lactoferrin 8.
Research has mainly focused on the anti-microbial activity of lactoferrin, recognizing 
it as a powerful anti- infective protein in synergy with  o ther anti-microbial peptides 
and proteins released from PMNs and Paneth cells such as defensins, lysozyme and 
bactericidal/permeability-increasing protein 9. Recently, an extensive review was 
published on lactoferrin emphasizing its im portant role in host defenses and 
immune responses suggesting a potential therapeutic  benefit , especially in treating  
infectious diseases 10-15. Therefore, it seems appropriate to reassess the biological 





M olecular structure and production
Lactoferrin belongs to the family of transferrins, glycoprotein's that binds ferric 
ions. It is a protein weighing 80 kDa consisting of a single polypeptide chain 
comprising 692 amino acid residues. This chain forms two homologous domains, 
the so-called N- and C-lobe each binding a ferric ion, which are connected by a 
a-helix (Fig. 1) 10.
Figure 1 Molecular structure of lactoferrin.
L a c to fe rr in  co n ta in s  tw o  h igh a f f in it y  b in d in g  s ites fo r  iro n  and th e re fo re  seem s im p o r ta n t  in iro n  
h om eostas is . The N -te rm in a l m o ie ty  o f  la c to fe r r in ,  espe c ia lly  th e  f i r s t  f iv e  a m in o  acids (1G ly -A rg -A rg - 
A rg -A rg 5), d e n o te d  w ith  N, has a h igh ca tio n ic  charge  a llo w in g  b in d in g  to  n e g a tive ly  charged  m o lecu les  
in c lu d in g  lysozym e, D N A and b a c te r ia l p ro d u c ts . This m o ie ty  is o f  p a r t ic u la r  in te re s t fo r  th e  
a n ti-m ic ro b ia l and im m u n e -m o d u la tin g  a c tio n s  o f  la c to fe rr in .
Besides being present in human milk, lactoferrin has been found in tears, saliva and 
secretions of the nasal, urogenital, respiratory and biliary tract 11. The production 
and secretion seems to be located in the glands of mucosal surfaces where it 
contributes to the barrier defenses. Limited evidence exists that lactoferrin is 
produced by the intestinal epithelium, especially Paneth cells, but lactoferrin mRNA 
expression has been shown to occur in small intestinal cells 16.
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The PMNs are another major source of lactoferrin 2, which is stored in secondary  
granules and released on neutrophil activation. Serum lactoferrin mirrors the  
release from neutrophils, normally being low with  concentrations ranging from  
0,1-1,0 |ag/mL, but increasing enormously during active inflammation, to up to 20  
|ig /mL 17.
Functional properties o f lactoferrin
The most striking physiochemical feature of lactoferrin is its high affin ity for iron. 
Its role in iron homeostasis is emphasized by a study on iron deficiency anemia in 
pregnant wom en in which lactoferrin increased hemoglobin and total serum iron 18. 
However, lactoferrin possesses pleiotropic functions independent of its iron binding 
capacity that have been attr ibuted to several factors. Specific 'classical' receptors  
(LfRs) have been determ ined on many cell types including intestinal epithelial cells 
(lECs), respiratory epithelial cells, lymphocytes, monocytes and macrophages, 
throm bocytes and hepatocytes 13. Current knowledge about the  intracellular 
effects following receptor binding is modest, although lactoferrin is shown to  
activate d ifferent intracellular signaling pathways 19.
M o re  important, most functional properties of lactoferrin result from interaction  
of its N-terminal moiety with both soluble and membrane bound molecules (Fig. 1). 
This N-terminal moiety, in particular the first five amino acids 1-5 (1Gly-Arg-Arg-  
Arg-Arg5), has a high cationic charge allowing binding to negatively charged 
molecules including heparin, DNA and bacterial products such as lipopolysaccha-  
rides (LPS, also known as endotoxin) and CpG motifs of bacterial DNA (CpG-DNA)  
20;21. Furthermore the N-terminal m oiety  of lactoferrin facilitates the interaction  
with sulphated proteoglycans. These proteoglycans function as co-receptors of 
LfRs or as aspecific receptors themselves, mediating the internalization and 
transport of lactoferrin into the  nucleus, leading to the N-terminal m oiety  being 
christened the 'nuclear localization signal' of lactoferrin 22. In the  nucleus lactoferrin  
modulates transcription of genes, e.g. related to cytokine production 23;24. Therefore,  
short peptides such as human lactoferrin 1-11 (hLF1-11) and lactoferricin (Lfcin) 
containing this N-terminal moiety have been developed and are currently under  
investigation 25;26.
The list of lactoferrin's properties (Table 1) now includes anti-microbial activity  
12;14, regulation of cell growth and differentiation 27 and modulation of inflammatory,  
humoral and cellular immune responses 11;28. Furthermore, induction of apoptosis 
has been shown in solid tum or and leukemia cell lines 12.
The timing and its abundant release from PMNs during inflammation suggest 
lactoferrins function might be predominantly one of negative feedback regulation  
to prevent uncontrolled inflammation. Indeed, several studies have supported this 
by showing lactoferrin to possess anti- in f lam m atory  activity 23;24;29-33 and exhibit
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Table 1 Functional properties of lactoferrin and lactoferrin derivatives.
Functional properties
Anti-microbial activity 
Modulation of inflammatory reactions 
Modulation of humoral immune responses 
Modulation of cellular immune responses 
Immune reconstitution fo llow ing chemotherapy 
Anti-cancer activity: solid tumors, leukemia 
Intestinal epithelial regeneration 
Iron homeostasis
inhibition of the  effector-phase of adaptive cellular imm une reactions 8;28;33-35. 
Therefore lactoferrin seems to be part of the innate defenses attenuating inflammation  
and adaptive cellular immune responses, thereby promoting resolution and repair. 
Paradoxically, lactoferrin can also act as an imm une stimulant though this 
predominantly occurs in the context of inactive immune systems 36-38 underlining  
the importance of the immune status upon the eventual outcome.
Lactoferrin production in hem atopoietic stem cell transplantation
The systemic production and secretion of lactoferrin decreases in parallel to the  
declining PMN count following myeloablative therapy from normal concentrations  
of 0,5 |ag/mL to 0 ,05 |J.g/mL 7 as a result of the absence of functional neutrophils  
during neutropenia. Much less is known about local levels of lactoferrin. Following 
cytotoxic chem otherapy and radiotherapy changes in saliva composition occur, at 
first with elevated salivary lysozyme and lactoferrin secretion, probably mirroring  
acinary cell damage, followed by reduced secretion 39. Furthermore GVHD of the  
gut is associated with  salivary dysfunction 40 probably altering lactoferrin production  
and secretion, although no proof exists w h e ther the  local levels are indeed  
diminished.
Inflammatory complications of hematopoietic stem cell 
transplantation
HSCT is still accompanied by many complications resulting in an overall survival rate 
of 60% after 5 years 41. Most of these complications are caused by the conditioning 
regimens necessary to prepare for HSCT impairing barrier defenses and innate and
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acquired im m une systems both local and system ic favoring  in fections and causing 
uncon tro lled  in flam m ation.
Infections
Bacterial pathogens account fo r  m ost o f the  in fections occurring sho rtly  a fte r 
transp lan ta tion  during neutropen ia, when mucosal ba rrie r in ju ry  (MBI) is most 
pronounced. W hile  pa tien ts are likely receiving an ti-bacte ria l prophylaxis w ith  
fluo roqu ino lones, the  m a jo rity  o f in fections are caused by g ram -positive  bacteria 
(65-75%), m ainly viridans group strep tococci and coagulase-negative staphylococci, 
and a m in o rity  by gram -negative pathogens, m ostly Enterobacteriaecae. The 
incidence o f fungal in fections also remains re la tive ly  high a ffec ting  up to  15% in 
allogeneic HSCT, w ith  Candida species and Aspergillus fum igatus  predom ina ting . 
Finally in fections w ith  herpesvirus, when patien ts are no t receiving prophylaxis 
w ith  acyclovir, or o th e r m em bers o f th is  class, and resp ira to ry  viruses also 
con tribu te  to  the  in fectious com plica tions in HSCT recip ients.
Mucosal Barrier Injury
U ncontro lled  activa tion  o f in flam m ation  o f the  mucosal m em branes o f the 
a lim en ta ry  tra c t is tho ugh t to  be the  d irec t results o f the  MBI induced by cy to tox ic  
chem otherapy. The pathogenesis o f MBI is regarded a m ultiphase process w ith  
successive events eventua lly  resu lting in an uncon tro lled  in flam m ato ry  reaction 42. 
A ctiva tion  o f nuclear fa c to r kappa B (NF-k B), d irec tly  by cy to tox ic  chem otherapy 
and rad io therapy and in d ire c tly  th rough reactive oxygen species (ROS), up-regulates 
the  p roduc tion  o f p ro -in fla m m ato ry  cytokines (in te rleukin -1  (IL-1), IL-6, tu m o r 
necrosis fa c to r alpha (TNFa)) and chem okines (IL-8) by IECs, endo the lia l cells and 
macrophages 43;44. S im ultaneously apoptosis in c ryp t ep ithe lia l stem cells is induced 
resu lting in hypoplasia and villous a trophy w ith  increased mucosal pe rm eab ility  45. 
T ranslocation o f bacteria and th e ir  wall com ponents, such as LPS, occurs 46, 
s tim u la ting  the  cy tok ine p roduc tion  o f previously prim ed macrophages, augm enting 
the  in flam m ato ry  response ('cy tok ine  s to rm ') w ith  possibly de trim en ta l system ic 
e ffec ts  includ ing high fever, acute resp ira to ry  distress syndrom e, th ro m b o tic  m i­
croangiopathy, veno-occlusive disease, m u lti-o rgan  fa ilu re  and centra l nervous 
system d isorders 47;48.
Acute Graft-versus-Host Disease
A no ther type  o f uncon tro lled  in flam m ation  is GVHD, which s till causes sign ificant 
m o rb id ity  and m o rta lity  in allogeneic HSCT recip ients. A pprox im ate ly  30% w ill 
develop grade 2 or worse acute GVHD involving the skin and gastro intestinal tra c t 49. 
The pathogenesis o f GVHD is generally described in 3 phases, the  f irs t  2 designated 
the  a ffe re n t and the  th ird  the  e ffe c to r phase 49;50. The f irs t  phase is dom inated by
129
CHAPTER 7
the  release o f p ro -in fla m m ato ry  cytokines fo llow ing  cy to tox ic  chem otherapy and 
rad io therapy inducing NF-k B, aggravated by the  trans loca tion  o f bacteria and th e ir 
products such as LPS 43;44;50;51. These cytokines increase expression o f co -s tim u la to ry  
m olecules, adhesion m olecules and m ajor h is to com p a tib ility  com plex type  II 
(M HC-II) antigens critica l fo r the  induction  o f the  adaptive ce llu la r im m une 
response. The exten t o f mucosal damage and in flam m ation  is re lated to  the 
in tens ity  o f the  cond ition ing  regim ens and has been corre la ted  w ith  the  occurrence 
and severity  o f GVHD 43;44. In the  second phase activa tion  o f antigen presenting 
cells occurs which present host antigens to  T-lym phocytes. Subsequent activa tion  
and p ro life ra tio n  o f T-lym phocytes, p redom inan tly  Th1-lym phocytes, ensues, 
crucial to  the  pathogenesis o f GVHD. Finally, the  th ird  phase concerns the  occurrence 
o f damage to  host cells as a resu lt o f the  cy to tox ic  e ffec ts  o f activa ted T-lym phocytes 
and natural k ille r cells as w e ll as increased release o f Th1 type  cytokines. 
Subsequently, gu t mucosal damage leads to  am p lifica tion  o f in flam m ation , th rough 
trans loca tion  o f bacteria l products such as LPS, again increasing cy tok ine  release 
and s tim u la ting  Th1 responses 52.
Lactoferrin and management of infectious complications
Anti-m icrobial activ ity
In 1982 the im portance o f lacto ferrin  in host defense was acknowledged in a report of 
a patient w ith  lacto ferrin  deficiency who suffered from  recurrent bacterial infections 
53. Neutropenic patients, fo llow ing chemotherapy, showed a lower incidence of 
predom inantly gram -negative bacteremia if treated ora lly w ith  lacto ferrin  6. 
Lacto ferrin  has both bacte rios ta tic  and bacteric ida l ac tiv ities  as w ell as an tifungal 
p roperties  (Fig. 2) 12. Bacteriostasis is a ttr ib u te d  to  the  che la ting p ro pe rty  o f 
la c to fe rrin  which deprives bacteria from  iron the reby  in h ib itin g  th e ir m etabolic  
activ ities. The bacteric ida l e ffec ts  are considered also very im p o rtan t, because the 
cation ic charge o f the  N -term inal m o ie ty  o f la c to fe rrin  fac ilita tes  the  bind ing to  
an ionic m icrob ia l wall com ponents such as LPS and lipo te icho ic  acid (LTA) 54;55 
resu lting in m em brane d isrup tion  and subsequently osm otic  shock. Lactoferrin  
binds to  the  ou te r m em brane o f gram -negative bacteria resu lting in rapid release 
o f LPS, exposing the  underly ing peptidoglycan (PGN) to  the  digestive action of 
lysozyme 55. S im ilarly, th rough  bind ing to  LTA la c to fe rrin  d isrupts the  m em brane o f 
gram -positive  bacteria 54.
Other antibacterial activities described comprise induction o f au to ly tic  cell wall 
enzymes, proteolysis o f virulence factors (serine protease activity), inhib ition of biofilm  
form ation, altering bacterial m etabolic activ ity  and m itochondria l ROS generation and 
gene transcription. By contrast bacteria o f the gut commensal flora Bifidobacterium
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Figure 2 Anti-m icrob ia l activ ities o f lacto ferrin .
Several b a c te r io s ta t ic  and b a c te r ic id a l p ro p e rtie s  have been desc rib ed  fo r  la c to fe r r in  as w e ll as th e  
p o te n t ia l to  decrease th e  p ro d u c t io n  o f  severa l v iru le n c e  fa c to rs  and b a c te r ia l de fense  m e chan ism s . 
F u r th e rm o re , la c to fe r r in  enhances im m u n e  responses d ire c te d  aga ins t m ic ro b e s  fo r  in s tan ce  th ro u g h  
increased p ha gocy to s is  and s tim u la te d  c e llu la r  im m une  response s. L a c to fe rr in  cou ld  a lso  p re v e n t 
in fe c tio n s  b y  m a in ta in in g  an in ta c t m ucosa l b a rr ie r  and a c c e le ra tin g  im m u n e  re c o n s t itu tio n  fo llo w in g  
t re a tm e n t w ith  c h e m o - and ra d io th e ra p y .
bifidum  and Lactobacillus acidophilus are resistant against lacto ferrin favoring the ir 
survival resulting in enhanced colonization resistance 56. Direct anti-fungal activ ity of 
lactoferrin and derivatives result from  comparable mechanisms 57-59.
Im m unom odulatory effects
Lacto ferrin  accelerates the  im m une reco ns titu tio n  fo llow ing  intensive trea tm ents  
w ith  cy to tox ic  chem otherapy and rad io therapy and shortens the  neutropen ic 
phase in animal models. In m ice given cyclophospham ide and m etho th rexa te  
im m une recovery was accelerated resu lting in enhanced clearance o f Escherichia 
coli and Staphylococcus aureus 60.
Furtherm ore, la c to fe rrin  prom otes phagocytosis th rough  d irec t opson in-like 
a c tiv ity  61 and increased com plem ent deposition , and enhances in trace llu la r k illing 
a c tiv ity  o f phagocytes e.g. th rough increased superoxide genera tion  37.
131
CHAPTER 7
Increased adaptive ce llu la r im m une responses by increased IL-12, IL-18 and IFNy 
p roduction , ac tiva ting  Th1 responses d irected against yeasts, viruses and bacteria, 
w ith  ora lly  adm in is tered la c to fe rrin  have been repo rted  14;36-38. These e ffec ts  were 
probably m ediated th rough a lte red cy tok ine p roduc tion  by IECs 38.
Lactoferrin and Mucosal Barrier Injury
As described earlier, MBI is an in flam m ato ry  cond ition  in itia ted  by chem o- and 
rad io therapy and aggravated by the  trans loca tion  by bacteria l com ponents. 
There fore it is im p o rtan t, regarding a po ten tia l ro le fo r la c to fe rrin  in a ttenua ting  
MBI, th a t m ost studies on the  an ti-in fla m m a to ry  e ffe c t o f la c to fe rrin  have examined 
the  in h ib itio n  o f in flam m ato ry  responses m ediated by bacteria l com ponents 
especially LPS, bu t also CpG-DNA and LTA.
In v itro  investigations in mice and humans show reduced LPS-induced release o f 
p ro -in fla m m ato ry  cytokines IL-1, IL-6, IL-8, and TNFa by m onocytes and macrophages 
23;24;29, IL-6 and IL-8 by IECs 29;30 and IL-8 by the  endo the lium  62. O ther studies showed 
in h ib itio n  o f LPS-mediated expression o f the  endo the lia l adhesion m olecules 
E-selectin and ICAM-1 63 and reduced LPS-mediated reactive oxygen p roduction  by 
leukocytes 64. These e ffec ts  involved in h ib itio n  o f NF-kB ac tiva tion  and as a 
consequence a lte red mRNA expression and the  p roduc tion  o f several p ro- and 
a n ti- in flam m ato ry  cytokines.
There is un ce rta in ty  abou t the  precise mechanism th rough  w hich lac to fe rrin  
fac ilita tes  th is  in h ib itio n . Elass-Rochard et al. have suggested th a t d irec t b inding 
o f la c to fe rrin  to  LPS, the  so-called LPS-scavenging (or endo toxin  antagonism), 
prevents the  in te rac tion  o f LPS w ith  m em brane bound CD14, the  co -recep to r o f 
to ll- lik e  receptor 4 (TLR-4), the reby  in h ib itin g  the  associated in trace llu la r signaling 
pathways 65 (Fig. 3). The same investiga tor also showed reduced IL-8 expression on 
endo the lia l cells as a resu lt o f la c to fe rrin  preventing in te rac tion  between LPS and 
soluble CD14 62. Sim ilarly, CpG-DNA induced im m une responses via TLR-9 are 
inh ib ited  by the  scavenging p rope rties  o f la c to fe rrin  66.
However, o thers suggested th a t la c to fe rrin  inh ib its  cy tok ine  p roduc tion  regardless 
o f its LPS scavenging p rope rties  23;24. They dem onstra ted th a t la c to fe rrin  was taken 
up by human m onocytes and transported  in to  the  nucleus w ith  subsequent 
decreased bind ing o f NF-k B to  the  TNF a  p ro m o te r resu lting in decreased expression 
and p roduc tion  o f p ro -in fla m m ato ry  cytokines (Fig. 3). Since in te rna liza tion  and 
nuclear localization o f la c to fe rrin  is docum ented in IECs th is  mechanism o f NF-k B 
in h ib itio n  m ight in fluence th e ir  cy tok ine release 13. There fore, la c to fe rrin  could 
reduce in flam m ation  in 's te rile ' in flam m ation , as is the  case in the  early phases of 
MBI before the  mucosal ba rrie r is in jured and m icrobes translocate .
132
LAcroFERRIN AND DERivATivEs iN sTEM cELL TRANspLANTATioN
Figure 3 Anti-inflammatory properties of lactoferrin.
Severa l a n t i- in f la m m a to ry  m echan ism s o f  la c to fe r r in  are desc rib ed , a lth o u g h  n o t all are c o m p le te ly  
u n d e rs to o d . T h roug h  iro n  scaveng ing la c to fe r r in  decreases th e  p ro d u c t io n  o f  re a c tive  oxygen species, 
th u s  p ro te c tin g  tissues fro m  o x id a tiv e  dam age re s u lt in g  fro m  fo r  in s tan ce  ch e m o - and ra d io th e ra p y . 
The scaveng ing o f  m ic ro b ia l co m p o n e n ts , such as LPS and CpG-DNA, p re ve n ts  g e n e ra tio n  o f  p ro - in ­
fla m m a to ry  cy to k in e s  n o rm a lly  re s u lt in g  f ro m  th e  a c tiv a tio n  o f  p a tte rn  re c o g n itio n  re ce p to rs  
in c lu d in g  TLR-4. F u rth e rm o re , in tra c e llu la r  in h ib it io n  o f  NF-k B decreases p ro - in f la m m a to ry  responses. 
O th e r a n t i- in fla m m a to ry  a c tio n s  in vo lv in g  th e  co m p le m e n t system  and ch e m o ta x is  have been 
describ ed .
Other anti- in f lam m atory  mechanisms of lactoferrin involve direct anti-oxidative  
effects, inhibitory effect on the com plem ent system and competition with  
chemokines (Fig. 3). Ferric (Fe3+) ions are at the centre of ROS generation through  
their ability to catalyze the Haber-Weiss reaction. Lactoferrin binds Fe3+ with high 
affinity thereby functioning as an iron scavenger decreasing inflammation through  
reduced ROS production. High levels of non-transferr in-bound iron resulting in
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increased ROS production are often present in recipients of HSCT and are associated 
with transplantation-re lated complications. Lactoferrin might therefore  a ttenuate  
oxidative stress and subsequent inflammation in these patients.
Conflicting data exist on the modulation of the com plem ent system by lactoferrin, 
although most data support a down-regulatory e ffect on the  classical com plem ent  
pathway, with reduced C3 and C5 deposition, through decreased C3-convertase  
formation 67.
Lactoferrin inhibits IL-8-mediated chemotaxis through competition for binding sites 
on heparan sulphate proteoglycans involved in IL-8 expression on endothelial cells 62. 
The broad array of anti- in f lam m atory  actions associated with lactoferrin might  
have a protective e ffect for patients who develop MBI following cytotoxic  
chemotherapy. In fact, the protective activity of orally administered lactoferrin on 
the gut mucosa was shown in animals with various inflam m atory conditions such as 
NSAID-related enteropathy 68, LPS induced mucositis 31, dextran sulfate-induced  
colitis 33 and acute gut GVHD 8. Furthermore, recently human lactoferrin has been  
shown to protect IECs from oxidative damage induced by hydrogen peroxide 32. In 
addition, lactoferrin might also a ttenuate  MBI through the stimulation of mucosal 
regeneration, similar to keratinocyte growth factor 27.
Lactoferrin and acute Graft-versus-Host Disease
Attenuating the uncontrolled inflammation following myeloablative conditioning  
for HSCT makes lactoferrin a potentially attractive agent for the  prevention of 
acute GVHD, when administered during the initial phase (see the role of lactoferrin  
in MBI).
In the  e ffector phase lactoferrin could also a ttenuate  the inf lamm atory response 
through several direct and indirect mechanisms. The role of endotoxin translocation  
promoting local and systemic cytokine release amplifying GVHD is accepted, 
suggesting that LPS antagonists such as lactoferrin might be useful for trea tm ent  52. 
Lactoferrin also directly down-regulates LPS- and CpG-DNA-m ediated Th1 
responses. Decreased expression of MHCII and co-signaling molecules (CD40, 
CD86), necessary for Th1 responses, was shown in dendritic cell cultures stimulated  
with LPS following trea tm ent  with  lactoferrin. Further studies have shown that  
lactoferrin can shift adaptive cellular immune responses from Th1 towards Th2, 
e.g. by increasing IL-10 and decreasing IL-12 and IL-18 secretion, which would be 
beneficial during the e ffector phase of GVHD 28;33;34.
However, in the second phase, lactoferrin might pose a risk by promoting acute 
GVHD. For instance, lactoferrin was shown to stimulate Th1-lymphocytes and 
induce delayed type hypersensitivity responses in mice 69. Lactoferrin increased
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the  release o f IL-12 and IL-18 in animal m odels o f in fections and cancer 37;38, both 
cytokines known to  p rom ote  Th1 im m une responses in GVHD. Furtherm ore, 
lac to fe rrin  prom otes lym phopoiesis, lym phocyte  d iffe re n tia tio n  and res to ra tion  o f 
adaptive ce llu la r im m une responses 19;60.
Inoue et al. showed a tten ua tio n  o f gu t GVHD in 4 o f 7 children a fte r HSCT suffering 
from  gu t GVHD re fra c to ry  to  conventional im m unosuppressive therapy, suggesting 
tha t lac to fe rrin  m ight con tribu te  to  the  preven tion  and tre a tm e n t o f GVHD in 
humans 8. Ind irec t evidence from  studies in patien ts con tact de rm a titis  suggest 
tha t la c to fe rrin  could also a ttenua te  skin GVHD since the  pathogenesis o f skin 
GVHD and con tact de rm a titis  are regarded as being sim ilar 35. Taken tog e the r these 
data suggest lac to fe rrin  m ight prove a logical and po ten t ad junctive  the rapeu tic  
agent fo r  managing GVHD, a lthough tim in g  seems o f crucial im portance.
Future directions
Lacto ferrin  holds prom ise fo r the  fu tu re  as a the ra pe u tic  agent fo r trea ting  
com plica tions arising during the  d iffe re n t phases o f HSCT (Fig. 4). Its p le io trop ic  
properties, especially the  an ti-m icrob ia l and an ti-in fla m m a to ry  activ ities, are o f 
in te rest because in fections and uncon tro lled  in flam m ation  pose the  greatest 
th rea ts  to  HSCT recip ients. Correcting la c to fe rrin  de fic iency seems a logical and 
sim ple tre a tm e n t op tion . C urrently  on ly 2 small studies have shown prom ising 
results 6;8; the re fo re  fu r th e r  studies are necessary.
Several la c to fe rrin  deriva tives have been developed as pow erfu l an ti-m icrob ia l 
peptides such as Lfcin and hLF1-11 12;25;26, all con ta in ing the  essential cationic 
N -term inal m o ie ty  o f la c to fe rrin . These deriva tives have physical and func tiona l 
prope rties  com parable to  th a t o f the  sho rt ca tion ic  peptides present in v ir tu a lly  
every life  fo rm , such as defensins, pro tegrins and cathelic id ins, which fun c tion  as 
'na tu re 's  an tib io tics ' bu t also as im m une m odulators 70. The use o f these derivatives 
is pre fe rred  because o f superio r an ti-m icrob ia l a c tiv ity  as has been shown fo r 
hLF1-11 57. Furtherm ore, these deriva tives exh ib it as broad an an ti-m icrob ia l 
spectrum  o f a c tiv ity  as natural la c to fe rrin  25;57;71;72, a very  desirable qua lity  in the 
ligh t o f g row ing a n tib io tic  and an ti-funga l resistance. Finally, the  an ti- in flam m ato ry  
and a n ti-tu m o r ac tiv ities  are also re ta ined 12;24;73. This is not to  say th a t derivatives 
posses all the  activ ities  present in the  in tac t lac to fe rrin  molecule.
A lthough m ost data on la c to fe rrin  derive from  studies w ith  la c to fe rrin  given ora lly  
the  in travenous rou te  seems the  m ost logical and practical fo r HSCT recip ients 
because oral adm in is tra tion  m ight no t prove feasible ow ing to  reduced oral intake, 
dysphagia and mucosal absorp tion  associated w ith  extensive m ucositis. Systemic 
ava ilab ility , the re fo re , can be b e tte r achieved th rough  in travenous use. Pharma-
135
C H AP TER  7
Figure 4 The potentia l role fo r lacto ferrin  in the  trea tm en t o f HSCT recipients.
HSCT com prises  th re e  phases. The f ir s t  phase is th e  p e rio d  o f  n e u tro p e n ia  fo llo w in g  c o n d it io n in g  w ith  
ch e m o - and ra d io th e ra p y  w ith  increased risk o f in fe c tio u s  co m p lic a tio n s . S im u ltaneous ly , M BI occurs 
re su lt in g  in an in fla m m a to ry  response  and d is ru p tio n  o f th e  n o rm a l a n a to m ica l b a rr ie rs  fu r th e r  
in crea s ing  th e  risk  o f in fe c t io n . The second phase is th e  phase o f  m ucosa l re g e n e ra tio n  and im m u n e  
re c o n s t itu tio n  a ccom pan ied  by c lin ica l recove ry . In th e  th ird  phase p a tie n ts  re ce iv in g  a HSCT are at 
risk  o f  d e ve lo p in g  c o m p lic a tio n s  fro m  g ra ft-v e rs u s -h o s t d isease (GVHD). GVHD is an in a p p ro p r ia te  
ce llu la r im m u n e  response d ire c te d  a t th e  p a tie n ts  skin, live r and g a s tro - in te s tin a l t ra c t  re s u lt in g  in an 
in fla m m a to ry  response  and d is ru p tio n  o f th e  g u t b a rr ie r. In c o m b in a tio n  w ith  th e  n ece ss ity  fo r  im - 
m u n e -supp ress ive  th e ra p y  and w ith  s till re co ve rin g  im m u n ity  r isk  o f in fe c tio n s  is increased . In phase 
one  and th re e  la c to fe r r in 's  a n t i-m ic ro b ia l and a n t i- in f la m m a to ry  p ro p e r t ie s  m ig h t p rove  b e n e fic ia l 
a tte n u a t in g  in fla m m a tio n  and p re v e n tin g  and decreas ing  m ucosa l b a rr ie r  in ju ry  as w e ll as in fe c tio u s  
co m p lic a tio n s . In th e  second phase acce le ra te d  im m u n e  re c o n s t itu tio n  m ig h t p rove  o f b e n e fit,  
a lth o u g h  th e o re tic a l ly  in it ia t io n  and a g g ra va tio n  o f GVHD m ig h t pose a th re a t  in th is  phase. Day 0 is 
th e  day o f  HSCT.
cokinetic data show clearance o f lac to fe rrin  and derivates th rough  the  liver w ith  
b ilia ry  secretion and en terohepatic  c ircu la tion  74-76. Consequently lac to fe rrin  
reaches the  sites where it  is needed, namely, the  gut where m icrob ia l transloca tion  
takes place and in flam m ation  originates.
Because lac to fe rrin  is a natural com ponent o f the  human innate im m u n ity  d irec t 
adverse events would not be expected from  in travenous adm in is tra tion , however 
the  safe ty and to le ra b ility  o f these deriva tives has to  be established in humans.
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These and th e ir clinical e fficacy can on ly be evaluated by fo rm a l tria ls  in the  clinical 
se tting  o f HSCT.
In summary, despite many advances in supportive  care, transp lan ta tion -re la ted  
m o rb id ity  and m o rta lity  due to  in fections and uncon tro lled  in flam m ation  remains 
high, necessitating the  continued exp lo ra tion  o f new tre a tm e n t m odalities. Against 
th is background and w ith  th e ir  an ti-m icrob ia l and an ti-in fla m m a to ry  effects, 
la c to fe rrin  deriva tives th a t re ta in  the  N -te rm ina l m o ie ty  o f the  parent m olecule 
may prove prom ising fo r  managing the  com plica tions th a t arise fo llow ing  HSCT.
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LACTOFERRIN AND DERIVATIVES IN STEM CELL TRANSPLANTATION
t ra n s p o r t o f la c to fe rr in  fro m  th e  in te s tin a l 
lum en in to  th e  b ile  via th e  b lo o d  in p ig le ts . 
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CHAPTER 8
Abstract
Background: The trea tm en t  of patients w ith  hematological malignancies by means 
of hem atopoietic  stem cell transplantation (HSCT) is o ften accompanied by life 
threatening infections. W ith  emerging antimicrobial resistance there  is an increased 
need for new agents, w ith  a beneficial safety profile. Therefore  w e  evaluated the  
safety of the promising new antimicrobial peptide human lactoferrrin 1-11 (hLF1-11) 
in healthy volunteers and patients.
Methods: W e undertook a sequential, randomized, double-blinded, p lacebo-con­
trolled study using ascending single (0.005, 0.05, 0.5, 5 mg) and multip le intravenous 
doses (0.5, 5 mg) in healthy volunteers, and open-label, single intravenous 5 mg 
dose in autologous hem atopoietic  stem cell transplant (HSCT) recipients.
Results: Single and multiple doses of hLF1-11 w ere  tolerable up to 5 mg intravenously 
in healthy volunteers, while 5 mg single dose was tolerable in patients. Elevations 
in transaminases possibly related to trea tm ent  w ere  reversible and not serious. 
Conclusions: The new antimicrobial hLF1-11 is well-to lerated  in healthy volunteers  
with repeated daily doses up to 5 mg. The side-effect profi le is very favorable for 
an antimicrobial, the only undesirable e ffect being a possible elevation of 
transaminases, which may be related to hLF1-11 although the  current data do not 
allow conclusive interpretation of trea tm en t  relationship. A lower dose is 
recomm ended for the forthcoming multiple dosing studies in HSCT patients.
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SAFETY AND TOLERABILITY OF HLF1-11 iN HUMANS
Background
The tre a tm e n t o f pa tien ts w ith  hem atological malignancies w ith  hem atopo ie tic  
stem cell transp lan ta tion  (HSCT) is o ften  accom panied by life  th rea ten ing 
com plica tions as a resu lt o f the  damage caused by the  cond ition ing  regim ens to  the 
mucosal barrier, and the  innate and adaptive, hum ora l and ce llu la r im m une 
defenses 1-3. Despite many advances in supportive  care, transp lan ta tion -re la ted  
m o rb id ity  and m o rta lity  due to  bacteria l and fungal in fections and uncon tro lled  
in flam m ation  remains high 4;5. A troub lesom e fac t is the  increasing resistance 
against several im p o rta n t an tim icrob ia l drugs includ ing quinolones, azoles and 
cephalosporins, making con tro l o f bacteria l and fungal in fections in HSCT a d iff ic u lt 
task 6-8. There fore, the  d iscovery o f a broad array o f na tu ra lly  occurring an tim icrob ia l 
peptides (AMPs) is in te resting , a lthough few  AMPs have been stud ied so fa r and 
even less have been stud ied in c lin ical settings 9-11.
Human la c to fe rrin  (hLF) is a natural defense p ro te in  present in body flu ids  and 
secretions as w e ll as neu troph ils  12;13, and has p le io trop ic  func tions  includ ing broad 
spectrum  an tim icrob ia l ac tiv ity , a n titu m o r activ ity , regu la tion  o f cell g ro w th  and 
d iffe re n tia tio n , and m odu la tion  o f in flam m ato ry , hum ora l and ce llu la r im m une 
responses 14-17. Levels o f la c to fe rrin  are decreased fo llow ing  HSCT 18, con tribu ting  to  
the  overall im m une deficiency. C orrecting th is  d e fic it m ight am e lio ra te  im m un ity  
in HSCT recip ien ts 19.
Human la c to fe rrin  1-11 (hLF1-11) is a la c to fe rrin  de riva tive  being developed fo r the 
tre a tm e n t o f bacteria l and fungal in fections in HSCT recip ients. It contains the 
N -term inal m oiety, consisting o f eleven am ino acids, o f hLF th a t is essential fo r  the 
an tim icrob ia l and an ti- in fla m m a to ry  a c tiv ity  15;17. Preclinical studies have shown 
prom ising an tim icrob ia l a c tiv ity  even in the  se tting  o f im m unodefic iency ju s tify ing  
fu r th e r investigation fo r  clinical app lica tion  20-24. Being a de riva tive  o f a 'n a tu ra l' 
human p ro te in  hLF1-11 m ight have the  advantage o f few e r side e ffec ts  and less 
fo rm a tio n  o f antibodies and an tim icrob ia l resistance, especially since an tim icrob ia l 
peptides are unlike ly to  induce resistance because o f the  evo lu tiona ry  d iff ic u lty  in 
changing bacteria l m em brane s truc tu re  11.
We re p o rt on the  f irs t  th ree  studies conducted in humans w ith  ascending doses of 
hLF1-11 in healthy vo lun teers and in pa tien ts receiving autologous HSCT fo llow ing  
cond ition ing  w ith  high-dose m elphalan (HDM) fo r m u ltip le  m yeloma or lym phop- 
lasm ocytic lym phom a.
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Methods
Study design
The 3 studies were conducted sequentia lly  and included a to ta l o f 56 subjects 
(placebo: 12; hLF1-11: 44) as fo llow s. Study 1: single in travenous (IV) adm in is tra tion  
o f ascending hLF1-11 doses (0.005, 0.05, 0.5, 5 mg) in healthy vo lun teers; study 2: 
m u ltip le  IV adm in is tra tion  o f 2 ascending hLF1-11 doses (0.5, 5 mg daily fo r 5 days) 
in healthy vo lun teers; study 3: single in travenous (IV) adm in is tra tion  o f a fixed 
hLF1-11 dose (5 mg) in pa tien ts undergoing an autologous HSCT (Table 1).
Blinding and subject selection
Studies 1 and 2 w ere  conducted in healthy vo lun teers, bo th were randomized, 
p lacebo-contro lled , enro lled  48 vo lun teers  in to ta l (placebo: 12; an tim icrob ia l 
peptide  (AP): 36) (Table 1) and were conducted at the  Phase-I Clinical Pharmacology 
Unit, Xendo Drug D evelopm ent BV, Groningen, The Netherlands, w ith  p rio r approval 
by the  appropria te  Ins titu tio na l Review Board (IRB). Entry crite ria  were s im ilar fo r 
studies 1 and 2, nam ely subjects considered healthy during m edical screening by a 
qua lified  physician, m edical h isto ry, physical exam ination , v ita l signs, b lood and 
urine evaluations, and 12-lead e lectrocard iogram  (ECG). Age and body mass index 
(BMI) en try  crite ria  were 18-45 years (study 1) and 1-65 years (study 2), w h ile  body 
mass index (BMI) was 18-30 kg /m 2 (study 1) and 18-28 kg /m 2 (study 2). A ll vo lun teers 
provided w ritte n  in fo rm ed consent and the  studies w ere conducted in com pliance 
w ith  cu rren t Guidelines on Good Clinical Practice 25. Enro lm ent too k  place between 
M arch-A pril 2005 (study 1) and August-Septem ber 2005 (study 2). The aims o f both 
studies were to  evaluate the  safety, to le ra b ility  and pharm acodynam ics of 
in travenous adm in is tra tion  o f hLF1-11. Safety param eters were adverse events, 
v ita l signs, changes in ECG, hem atology, clinical chem istry, urinalysis and 
im m unogenicity. Pharmacodynamics evaluations w ere  conducted during m u ltip le  
dosing (study 2) at baseline, days 1 and 5: cy tok ine release (Interleukin(IL)6, IL10, 
and tu m o r necrosis fa c to r (TNF) a) a fte r ex vivo s tim u la tion  w ith  lipopolysaccha- 
ride (LPS) in w ho le  blood.
Study 3 was conducted in autologous HSCT recip ients. The study was open, enrolled 
8 pa tien ts (Table 1) be tw een M arch -O ctober 2006 at the  D epartm ent o f Hematology, 
Radboud U nivers ity  Nijm egen M edical Centre, The Netherlands, w ith  p rio r approval 
by the  hospita l's  IRB. Study conduct was in com pliance w ith  cu rren t Guidelines on 
Good Clinical Practice 25. Entry crite ria  were m ales/fem ales aged 18 years or older 
who were ad m itted  to  hospita l fo r au tologous HSCT a fte r m yeloabla tive therapy 
w ith  high dose m elphalan HDM fo r m u ltip le  m yeloma or lym phoplasm ocytic  
lym phom a, BMI <30 kg /m 2, w ith o u t serious o the r pathologies, or h is to ry  o f hepa titis  
B or C, o r HIV in fec tion . The aims o f study 3 were to  evaluate the  safe ty and
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32(12) 183 (7) 78 (12) 23(3)
Study 3 HSCT patients 53 (8) 178 (7) 78(14) 24(3)
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to le ra b ility  hLF1-11 given as single IV adm in is tra tion  (5 mg) on the  day o f transp lan­
ta tio n . Safety param eters were adverse events, v ita l signs, changes in ECG, 
hem atology, clin ical chem istry, urinalysis, and im m unogen ic ity . Safety and 
to le ra b ility  were evaluated by adverse event reporting , v ita l signs, changes in ECG, 
hem atology, clinical chem istry, and urinalysis. Adverse events were graded 
according the  to  the  Common Term inology Criteria fo r  Adverse Events (CTCv3.0, 
National Cancer Ins titu te , Bethesda, MD, USA) 26.
B linding in studies 1 and 2 was assured by centra l a lloca tion  o f random ization codes 
in sealed envelopes, audited on com p le tion  o f each study and by supply o f study 
m edica tion in ind istingu ishable form .
For the pharmacodynamics evaluations, cytokine measurements were analyzed in 
study 2 using validated assays fo r each cytokine once prio r to  dosing and at six 
tim e-poin ts post-dosing (5 min, 30 min, 2 h, 4 h, 8 h, and 24 h) on days 1 and 5, while 
antibodies against hLF1-11 were measured in all three studies as specific IgG anti-HLF1-11 
and IgE anti-hLF1-11 once prio r to  dosing and at three tim e-poin ts post-dosing (days 2 
and 3, 5 to  8 and 14 and 15) by validated enzyme-linked im m unosorbent assay (ELISA), 
centrally by Xendo Biotech Centre, Groningen, The Netherlands.
Study m edication (active and placebo) was supplied by AM -Pharm a BV (Bunnik, the 
Netherlands) as lyophilized pow der fo r  so lu tion  in norm al saline (0.9% NaCl 
so lu tion) according to  dose.
Statistics, assignment and analysis
Treatm ent a lloca tion  was sequentia l in all studies, w ith  random ization lists issued 
as single blocks o f e ight (tw o placebo and six active) fo r  studies 1 and 2, w h ile  there  
was no random ization in study 3. The in te n tio n -to -tre a t (ITT) popu la tion  fo r safety 
evaluations was defined in all studies as all random ized subjects w ho received any 
m edication. Data fo r  studies 1 and 2 were analyzed by Xendo Drug Developm ent, 
Groningen, using SAS version 8.2 (SAS, Cary, NC, USA) and fo r study 3 by CRM 
B iom etrics GmBH (Bonn, Germany) w ho also checked the  databases fo r the  o ther 
tw o  studies. Means, standard devia tions, medians, ranges, upper and low er 
quartiles were calculated, and param eters were listed by subject, sum m arized and 
evaluated using descrip tive statistics.
Results
Subject characteristics and progress through studies
Demographic data fo r all three studies at entry are displayed in Table 1, w ith  pathological 
characteristics o f patients in study 3 presented in Table 2. One volunteer in study 2, 
o rig ina lly  a llocated to  the  placebo group (m u ltip le  dosing) received one dose of
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Table 2 Hematopoietic stem cell transplant patients' disease characteristics.
Patient
no.
Age (y) Gender Diagnosis, stage* Paraprotein type Bence Jones Prior treatment** Status*** Melphalan
dose
(mg/kg)
SC001 61 M Multiple myeloma, lll-A IgG kappa Not present VAD, CAD Partial response 3.92
SC002 62 F Multiple myeloma, lll-A IgG kappa Present VAD, CAD Progressive disease 5.61
SC003 50 M Multiple myeloma, lll-A Light chain kappa Present VAD, CAD Minimal response 5.19
SC004 55 M Multiple myeloma, lll-A IgG kappa, light chain 
kappa
Not present VAD, CAD Partial response 5.13
SC005 45 M Multiple myeloma, lll-A Light chain kappa Present PAD, CAD Partial response 6.25
SC006 39 M Multiple myeloma, lll-B IgG kappa Not present VAD, CAD Minimal response 4.37
SC007 54 M Multiple myeloma, ll-A IgG kappa Not present Thalidomide, 
dexamethasone, CAD
Stable disease 5.07
SC008 61 M Lymphoplasmocytic 
lymphoma, IV-A
IgG kappa, light chain 
kappa
Present VAD, CAD Minimal response 5.13
* :  S taging by Durie &  Sa lm on c r ite r ia 41
* * :  VAD: v in c ris tin e , a d ria m yc in , dexam ethasone , CAD: cyc lo phospha m ide , a d ria m yc in , dexa m e thason e , PAD: b o rte zo m ib , a d ria m yc in , dexam ethasone . 


















hLF1-11 (5 mg) on day 4 due to an administrative error, and his safety data were  
computed in the  active group. All o ther subjects in the studies received study 
medication as planned and yielded complete datasets for safety and other  
analyses.
Safety and tolerability results
The main adverse events from the safety evaluations are presented in Table 3 for 
studies 1 and 2 and, Table 4 for study 3. Overall, intravenous administration of 
hLF1-11 did not raise safety concerns in e ither volunteers or patients. During single 
dosing in volunteers, all events blindly rated as possibly-related to trea tm en t  were  
reported once and occurred on placebo and the lowest hLF1-11 dose (0.005 mg), 
none being reported on the tw o  higher doses. During multiple dosing, the  
commonest reported events on hLF1-11 w ere  elevations in liver enzymes (alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST)), which w ere  below  
tw ice the upper level of normal range (ULN: 40  U/l for ALT; 45 U/l for AST) in one 
volunteer on 0 .5  mg and in tw o  volunteers on 5 mg. The third event was below  
three  times ULN. Detailed analysis of daily measurements of liver enzymes,  
regardless of levels being reported as adverse events, recorded enzymes levels 
above ULN in 1 /2  placebo volunteers and in 3 /6  volunteers on 0 .5  mg dose, while  
levels above ULN w ere  recorded in 6 /7  volunteers on 5 mg. All but one of the daily 
measurements w ere  below twice ULN (one ALT measurement was 127 U/l on day 6; 
5 mg dose). All levels w ere  in the normal range within 7 days thereafter.
In HSCT recipients a fter conditioning with  HDM, as expected, several events were  
recorded, ranging from 5 to 35 events per patient (Table 4). Four serious events 
(SAEs) w ere  reported, none of which was considered to be related to hLF1-11, while  
four non-serious events w ere  reported  in one patient, considered possibly related 
to hLF1-11, none being reported for the remaining seven patients.
Other clinical laboratory (hematology, biochemistry, and urinalysis) did not suggest 
any trea tm ent-re la ted  abnormalit ies in any of the three  studies. No abnormalities  
in coagulation tests were seen. Hemodynamic (blood pressure, heart rate) and 
12-lead ECGs (including QT interval) did not yield any trea tm ent-re la ted  effects. 
None of the  HSCT recipients developed signs of hemolysis or unexpected cytopenias 
and no abnormalit ies regarding engra ftm ent w ere  seen.
Pharmacodynamics evaluations
There w ere  no changes in any of the pharmacodynamics evaluations in volunteers  
during single or multiple dosing or in patients a fte r  single dosing. Cytokine 
measurements in study 2 (healthy volunteers) showed high variability intra- and
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Subjects per Group 3* (100) 6 (100) 7* (100)
ALT increase - 2 (33.3) 3 (42.9)
AST increase - - 1 (1 4 .3 )
D ry skin 1 (33.3) 1 (1 6 .7 ) -
H yperhydros is - 1 (1 6 .7 ) -
In je c tio n  s ite  e ry th e m a 1 (33.3) - -
In je c tio n  s ite  pain 1 (33.3) - -
In je c tio n  s ite  re ac tion - 2 (3 3 .3 ) 1 (1 4 .3 )
M ala ise - 1 (1 6 .7 ) -
Nausea - 1 (1 6 .7 ) -
Study 1 Placebo, n hLFl-11 hLFl-11 hLFl-11 hLFl-11
(single dosing) (%) 0.005 mg, 0.05 mg, 0.5 mg, 5 mg,
n (%) n (%) n (%) n (%)
Subjects per Group 8 (100) 6 (100) 6 (100) 6 (100) 6 (100)
Diarrhea - 1(16.7) - - -
Dizziness - - - - 1 (16.7)
Epistaxis 1(12.5) - - - -
Feeling cold - 1(16.7) - - -
Flatulence - - - - 1 (16.7)
Headache 1(12.5) 1(16.7) - - 1 (16.7)
Increased appetite 1(12.5) - - - -
Phlebitis - - - - 1 (16.7)
Purpura - - - - 1(16.7)
Somnolence 1(12.5) - - - 1(16.7)
Obs: all lis te d  e ven ts  w e re  ra te d  b lin d ly  as p o ss ib ly -re la te d  to  tre a tm e n t.
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Table 4  Adverse events in HSCT patients (n=8).
All recorded events (n) 187
All events possibly treatment-related (n) 4
Events per patient (min-max) (n) 5-35









Serious Adverse Events (SAEs) (n)** 4
Heart failure/pulmonary edema 1
Pulmonary infiltrates 1
Hypoxemia/Respiratory insufficiency 2
Treatment-related SAEs (n) 0
* : All 4 even ts occurred  in one p a tie n t (no. 001)
* * :  The 4 SAEs o ccu rred  in 2 p a tie n ts  (no. 002 and no. 005) 
HSCT: h e m a to p o ie tic  s te m  cell t ra n sp la n t
in te rind iv idua lly . Levels o f IL10 were unde tectab le  in all samples. Release o f IL6 
and TNFa on LPS s tim u la tion  seemed a ttenua ted  w ith  0.5 and 5 mg; however this 
was ne ithe r c lin ica lly  nor s ta tis tica lly  sign ificant. No antibodies against hLF1-11 
were de tected (IgG anti-hLF1-11 o r IgE anti-hLF1-11) in vo lun teers or patients.
Discussion
Bacteria l pathogens account fo r  m ost in fections occurring sho rtly  a fte r 
transp lan ta tion  during neu tropen ia , when mucosal ba rrie r in ju ry  is m ost 
pronounced. W h ils t m ost patien ts receive standard an tibacte ria l prophylaxis w ith  
f luo roq u in o lone s , the  m a jo rity  o f in fections are caused by g ram -positive  bacteria 
(65-75%), m ainly viridans group streptococci and coagulase-negative staphylococci 
as observed in all our patien ts, and a m in o rity  by gram -negative pathogens, m ostly 
Enterobacteriaecae 27. The incidence o f fungal in fections also remains re la tive ly  
high a ffec ting  up to  15% in a llogeneic HSCT, w ith  Candida species and Aspergillus
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fum igatus  predominating 27. Lactoferrin or derivatives may prove to be a promising 
versatile class of agents for managing infectious complications that  arise from  
HSCT, because of their broad antimicrobial activity especially in the  context of 
emerging antimicrobial resistance to currently used antimicrobial agents. 
Additionally, immune modulating and anti- in f lam m atory  properties might a ttenuate  
mucosal barrier injury and graft-versus-host disease in HSCT, although for now this 
remains speculative 19.
The N-terminal m oiety  of hLF, in particular the first five amino acids (Gly-Arg-Arg- 
Arg-Arg), has a high cationic charge allowing binding to negatively charged 
molecules including microbial products such as lipopolysaccharide (LPS) and CpG 
motifs of bacterial DNA (CpG-DNA) 28;29. These interactions result in microbial cell 
wall disruption and direct microbial killing 30. Additionally, indirect antimicrobial 
activity is seen through the  interm ediary of cells mainly phagocytic cells (poly- 
morphnuclear cells, macrophages) probably as result of opsonization and other  
not yet fully determ ined  mechanisms 31-33. A n ti - in f lam m ato ry  and im m une-  
modulatory properties have also been largely re lated to the N-terminal moiety  of
hLF 15;17;34-36
hLF1-11, derived from the active N-terminal moiety of hLF, has been tested in vitro 
and in vivo  showing broad spectrum activity against the pathogens commonly  
involved in infections a fter HSCT, both bacterial and fungal, similar to human  
lactoferrin. The activity in preclinical studies was even superior to that  of hLF 37. 
In vivo animal experiments indicated that hLF1-11 is highly effective against 
Staphylococcus aureus, Listeria monocytogenes and antibiotic resistant Acinetobacter 
baumannii, reducing bacterial loads in infected organs by 2 to 3 log 20;23;24;37. 
Furthermore, hLF1-11 was effective against invasive infections fluconazole resistant 
and sensitive Candida species even in neutropenic and lymphopenic mice 21;22;38. 
Regarding im m une-m odulatory  properties, as for the antimicrobial activity, the 
activity of hLF1-11 is expected to be similar albeit more potent than those reported  
for hLF, although this has to be studied in more detail.
In this study, for the first t ime, the antimicrobial peptide hLF1-11 has been tested  
in healthy volunteers and autologous HSCT recipients. In both populations the  drug 
was well to lerated  with  few  possibly related side effects. The reported events 
consisted predominantly of discomfort at the  injection site, commonly reported  
with intravenous drugs. No changes on electrocardiography and in particular no 
increase in QT interval was seen. All adverse events w ere  mild in intensity, reversible 
without clinical sequel, not necessitating any intervention. No signs of cytotoxicity  
w ere seen, consistent with earl ier in vitro  data 39, and in HSCT recipients no changes 
in engraftm ent occurred. Pharmacodynamic evaluation revealed no apparent  
changes in the cytokine profiles, suggesting that the im m une-m odulatory  effects  
of hLF1-11 do not result in an unexpected increase in pro-inflammatory responses.
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During multiple dosing, elevations in transaminase levels w ere  detected and 
considered related to the  study drug in five subjects, because use of other drugs or 
alcohol was not allowed during the study, although elevations w ere  observed on 
placebo as well. Similar abnormalit ies were  observed in one patient receiving the 5 
mg dose, followed by spontaneous and complete recovery. According to the  
CTCv3.0 26, the maximum elevation was observed once in one patient and was 
m oderate  (grade 2 /3 ) .  Since this patient was receiving a number of other drugs 
known to affect transaminases (Figure 1), this occurred afte r  single dose and no 
effects on transaminases had been reported during single dosing in healthy  
volunteers but mild elevations had been recorded after multiple dosing, we  
considered this event as possibly-related to trea tm ent.  A safety advisory board 
( independent of investigators) also evaluated the liver enzyme results of all studies 
and could not establish a definite relationship betw een  hLF1-11 and elevated  
transaminases, although it did not rule out such an effect and advised that  a lower 
dose (0.5 mg) should be used in the next, multiple dosing study in patients with  
close monitoring of liver parameters. This lower dose is expected not to interfere  
with the antimicrobial activity of hLF1-11, shown in preclinical data to be active in 
the |ig /kg range 22. Moreover, a recent study emphasized that even at very low 
concentrations AMPs with  strong mem brane-binding activity could disrupt bacteria  
by reaching higher m em brane-bound concentrations than intuitively expected 40. 
One im portant  evaluation that is missing in our studies is the pharmacokinetics of 
hLF1-11, as to date the detection of the peptide is impossible to quantify in humans, 
which makes the  safety evaluations all the more important. Inability to measure  
hLF1-11 in plasma is partly due to the  doses being so small (0 .005-5  mg) that the  
concentrations in plasma are undetectable by usual methods. In animals, 
99mTc-labelled hLF1-11 was rapidly removed from the circulation mainly via the liver 
and to a lesser extent via the kidneys. The quantity of 99mTc-labelled peptide in the  
liver remained stable during the first hour a fter injection, while the plasma half-life 
(in mice) was estimated at approximately 30 min, yet this may be a underestimation 
since some of the peptide may be receptor bound and an unknown amount may be 
quickly metabolized. Studies are ongoing with  internally labeled (C14 and tritium)  
peptide to determ ine distribution and metabolism in animals, while the  
quantification in humans remains undetermined. Nevertheless, the results of this 
new antimicrobial in preclinical studies merit  fur ther  investigations on the  
applicability of hLF1-11 in humans, particularly in patients with  hematological 
malignancies, and w ere  the motivation for the current studies.
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8
Figure 1 Serum alanine aminotransferase (ALT) levels in hematopoietic stem 
cell transplantation patients.
A L T
The drugs d e p ic te d  in f ig u re  are  th e  drugs used by th e  p a t ie n t e xp e rie n c in g  e le va te d  tran sam inases. 
Day 0 = day o f  h e m a to p o ie tic  s tem  cell tra n s p la n ta t io n . HDM : h ig h -dose  m e lph a lan .
Conclusions
The new antimicrobial drug hLF1-11 was well-to lerated  in healthy volunteers with  
repeated daily doses up to 5 mg. Owing to elevations in transaminase levels being 
possibly related to trea tm en t  caution is warranted  in fur ther  studies, although this 
potential effect was regarded not clinically serious and reversible w ithout  
intervention in all cases to date. Nevertheless, as a precaution, fu r ther  testing will 
be conducted with a lower dose of 0 .5  mg in the  forthcoming multiple dosing study 
in HSCT patients.
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Abstract
Background
A sho rt peptide de riva tive  o f human lac to fe rrin , hLF1-11, has been developed as an 
an ti-m icrob ia l peptide fo r  p rophy lac tic  and the ra pe u tic  use in the  se tting  of 
hem atopo ie tic  stem cell transp lan ta tion  (SCT). It's  e fficacy in animal m odels has 
suggested add itiona l im m une enhancing p roperties  on top  o f the  an ti-m icrob ia l 
ac tiv ity . Because o ther im m unolog ica l processes during SCT, like gra ft-versus-host 
disease (GvHD), could also be in fluenced by the  peptide, we wanted to  tes t the  in 
vitro  e ffec ts  o f hLF1-11 on im m une cells involved in transp lan t im m unology. 
Methods
Peripheral b lood m ononuclear cells (PBMCs) were ob ta ined from  b u ffy  coats of 
healthy human vo lunteers. T lym phocytes, na tural k ille r (NK) cells, and dend ritic  
cells (DC) were isolated using standard procedures. The e ffec ts  o f d iffe re n t 
concen tra tions o f hLF1-11 (range 0-100 |ag/ml) w ere  stud ied in standardized 
experim enta l m odels on p ro life ra tion , d iffe re n tia tio n  and activa tion  o f these 
d iffe re n t im m une cells.
Results
No phenotyp ic  a lte ra tions were found in DCs cu ltu red in the  presence o f hLF1-11, 
bu t adding hLF1-11 during the  fina l step o f DC m atura tion  showed absence of 
podosom e loss, a sign o f inh ib ited  LPS-induced m atura tion . P ro life ra tion  of 
s tim u la ted NK cells and T lym phocytes was no t a ffec ted  by hLF1-11, and hLF1-11 
exposure did no t resu lt in tox ic  lysis o f these cells. NK cell cy to to x ic ity  and regu la tory 
T cell a c tiv ity  was unaltered, bu t allogeneic PBMC stim u la ted CD4+ m em ory T cells 
showed a decreased release o f p ro -in fla m m ato ry  cytokines IFNy and IL-17 (Th1 and 
Th17 pathway, respectively).
Conclusion
The in vitro  studies did no t reveal unexpected im m une responses th a t evoke 
concerns regarding the  safe ty o f hLF1-11 in the  c lin ical se tting  o f allogeneic SCT. 
The observed im m unosuppressive e ffec ts  o f the  peptide m ight prove beneficial 
w ith  regard to  acute GvHD, bu t th is  needs con firm ation . Because data on in vivo 
im m une e ffec ts  o f hLF1-11 are s till lacking caution is w arran ted  during fu tu re  
studies in SCT patients.
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Introduction
Human la c to fe rrin  (hLF) is a natural defense p ro te in  belonging to  the  innate im m une 
system, and is present in several body flu ids  and secretions as well as in the 
secondary granules o f neu troph ils  1. Lacto ferrin  and its deriva tives have p le io trop ic  
functions includ ing an ti-m icrob ia l ac tiv ity , a n ti-tu m o r activ ity , regulation o f cell 
g row th  and d iffe re n tia tio n , and m odu la tion  o f in flam m ato ry  as w ell as hum oral 
and ce llu lar im m une responses 1-4. M ost o f these prope rties  have been a ttr ib u te d  
to  the  N -term ina l m o ie ty  o f the  m olecule, which contains a high ca tion ic  charge 
responsible fo r  the  in te ractions w ith  m icrobe-associated m olecu lar patterns 
(MAMPs), heparin, and proteoglycans 5.
A short peptide derivative of human lactoferrin, hLF1-11, has been developed as an 
anti-m icrobia l peptide (AMP), which consists o f the cationic N-term inal 11 amino acids 
of hLF. Results from  animal models representing systemic fungal and bacterial infection 
have shown impressive in vivo efficacy even in the setting o f neutropenia 6;7. Because of 
its anti-m icrobia l potentia l, hLF1-11 could be a promising peptide in the trea tm ent of 
patients receiving high-dose chem otherapy and a stem cell transplantation (SCT), 
especially considering the increasing resistance against several im portan t anti-m icrobial 
drugs including quinolones, cephalosporins and azoles, which makes treating bacterial 
and fungal infections in SCT a d ifficu lt task. Being a derivative o f a 'natu ra l' human 
prote in hLF1-11 m ight have the advantage of less side effects and antim icrobial 
resistance, because AMPs are unlikely to  induce resistance because of the evolutionary 
d ifficu lty  in changing bacterial membrane structure 8.
In animal models, e fficacy o f hLF1-11 and o ther AMPs was seen at very low 
concen tra tions suggesting th a t add itiona l im m une enhancing p rope rties  m ight 
have con tribu ted  to  the  an ti-m icrob ia l e ffec ts  o f hLF1-11 6;9;10. Indeed, in vitro  data 
have already con firm ed im m unom odu la to ry  e ffec ts  o f hLF1-11 on m onocytes and 
macrophages. These cells exerted enhanced e ffe c to r functions includ ing enhanced 
recogn ition  and clearance o f pathogens and increased M AM P-induced cytokine 
p roduction  11. These e ffec ts  could play an im p o rta n t ro le by s tim u la ting  im m une 
responses in im m unocom prom ised SCT recip ients su ffe ring  from  mucosal barrier 
in ju ry  and neutropen ia.
Currently, lit t le  is known abou t the  im m unom odu la to ry  e ffec ts  o f hLF1-11 on o ther 
im m une cells like T lym phocytes, natural k ille r (NK) cells, and de nd ritic  cells (DC), 
which play a key ro le in bo th innate and adaptive im m unity . This is im p o rtan t 
because these cells are involved in a llo -reactive  im m une responses and im m une 
re co n s titu tio n 12;13. Before applying hLF1-11 in SCT, m ore data are necessary on the 
possible e ffec ts  on gra ft-ve rsus-host disease (GvHD) and gra ft-ve rsus-tum or (GvT) 
im m unity , since activa tion  or in h ib itio n  o f the  im m une system by hLF1-11 could 
have both benefic ia l and de trim en ta l consequences.
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In o rder to  fu r th e r study the  issues regarding safety, but also po ten tia l beneficial 
im m une properties o f hLF1-11, we conducted in vitro studies analyzing the effect of 
hLF1-11 on the  d iffe re n t im m une cells involved in innate and acquired im m une 
responses during cond ition ing  and SCT.
Material and methods
Lactoferrin and derived peptide hLF1-11
Human la c to fe rrin  was purchased from  Sigma A ldrich, Z w ijndrecht, the  Netherlands. 
The synthetic  peptide  corresponding to  residues 1-11 o f hLF, representing the 
cation ic dom ain o f hLF, was provided by AM -Pharm a BV, Bunnik, the  Netherlands. 
This peptide was designated hLF1-11 (am ino acids, GRRRRSVQWCA; m olecular 
mass, 1375 DA). The p u rity  o f these peptides exceeded 97%, as de term ined by 
reverse-phase h igh-perform ance liqu id  chrom atography. The peptides were stored 
and used as previously described 6.
Cell source
In all experim ents periphera l b lood m ononuclear cells (PBMCs) were used and 
isolated from  b u ffy  coats from  healthy human vo lun teers upon w ritte n  in form ed 
consent according to  the  Declaration o f Helsinki w ith  regard to  sc ien tific  use.
Dendritic cell culture
The generation and cu ltu re o f m onocyte-derived DCs has previously been described 
by Hobo et al. 14. Im m ature DCs w ere generated by cu ltu ring m onocytes in X-VIVO-15 
medium supplem ented w ith  2% human serum (HS), 500 U/ml in te rleukin  (IL)-4, and 
800 U/ml GM-CSF. A fte r 2-3 days, ha lf o f the medium was replaced w ith  fresh 
X-VIVO-15/2% HS medium, containing 1000 U/ml IL-4 and 1600 U/ml GM-CSF. During 
the culture process hLF1-11 was added at concentrations ranging from  0 to  100 |ag/ml. 
M atura tion o f DCs was induced at day 6-7 by culturing 0.5 x 106 im m ature DCs/ml in 
6-well plates in X-VIVO-15/2% HS containing 500 U/ml IL-4, 800 U/ml GM-CSF, 5 ng/ml 
IL-ip, 15 ng/m l IL-6, 20 ng/m l TNF-a, and 1.0 |ag/ml prostaglandin E2 (PGE2) or 2.5 |ag/ml 
lipopolysaccharide (LPS). A t day 8, m ature DCs were harvested and analyzed by FACS 
analysis fo r  surface m arker expression w ith  the emphasis on expression o f pattern 
recognition receptors (PRRs) including CD282 (Toll-like receptor (TLR) 2), CD284 
(TLR4), dectin-1, CD206 (mannose receptor (MR)), and CD209 (DC-SIGN).
Podosome form ation by DCs
The techn ique used has previously been described by van Helden et al. 15. Plastic- 
adherent monocytes were cultured in X-VIVO 15 medium (BioWhittaker) supplemented
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w ith  2% HS (PAA Laboratories), IL-4 (500 U/m l), and GM-CSF (800 U/m l), o r in RPMI 
1640 m edium  supplem ented w ith  10% (v/v) FCS, IL-4 (500 U/m l), and GM-CSF (800 
U/m l). Im m ature DCs (iDCs) were harvested on day 6. Day 6 iDCs were seeded on 
fib ro ne c tin -coa ted  12 mm coverslips. The cells were m ainta ined in 0.5 ml o f RPMI 
1640 supplem ented w ith  10% FCS, 1% u ltrag lu tam ine , IL-4 and GM-CSF. A fte r the 
cells had adhered (approxim ate ly 3 hrs), s tim u li were added consisting o f LPS (2 |ag/ 
ml), PGE2 (10 |ig /m l), hLF (10, 50 and 100 |ig /m l), hLF1-11 (1, 2, 5, 10, 50 en 100 |ig / 
ml), o r the  com bination  o f LPS (2 |ag/ml) and hLF o r hLF1-11 (100 |ag/ml). The iDCs 
were cu ltu red  ove rn igh t and fixed and stained the next day. The coverslips were 
then analyzed w ith  a standard fluo rescen t m icroscope and percentage o f cells 
con ta in ing podosom es was calculated.
T cell stim ulation assay
T cell iso la tion and cu ltu re  were pe rfo rm ed as described by Koenen et al. 16. Briefly, 
m em ory T cells w ere generated by dep le tion  o f CD25+ and CD45RA+ cells. To assess 
the  im pact on p ro life ra tion , measured by 3H-Thym idine incorpora tion , CD4+ T cells 
were stim ulated w ith  allogeneic stim ulator PBMCs (allo-PBMCs) or CD3/CD28 beads 
in the presence o f d iffe ren t concentrations o f hLF1-11 (range 0-100 |ag/ml). Cytokine 
production (IFNy and IL-17) was measured a fte r stim ulation o f CD4+ m em ory T cells 
w ith  allo-PBMCs in the  presence o f polarizing cytokines and 10 o r 100 |ag/ml of 
hLF1-11. Cells were analyzed by f lo w c y to m e try  on day 8 o f cu ltu re . Regulatory T 
cells (Treg), CD4+CD25high T cells, were isolated by f lo w c y to m e tr ic  cell sorting. 
These cells were s tim ula ted w ith  allo-PBMC in the  presence o f po larizing cytokines 
and 10 or 100 |ag/ml o f hLF1-11. Cells were analyzed by f lo w c y to m e try  on day 8 of 
cu ltu re  on the  expression o f Foxp3.
Natural killer cell assay
NK cells were isolated th rough  negative selection, using an an tibody cockta il of 
CD3, CD4, CD19 and CD33. NKdim cells w ere isolated from  negatively isolated NK 
cells, th rough  positive selection w ith  CD16 m icro-beads. NK cells were cu ltu red  in 
cu ltu re  m edium  (RPMI 1640 w ith  g lutam ax supplem ented w ith  pyruvate (0,02 
mM)), 100 U/m l pen ic illin , 100 |ag/ml s trep tom ycin  (Gibco, Paisley, UK) and 10% HS 
at 37°C, 95% hu m id ity  and 5% CO2, in 96 wells round b o tto m  plates (Greiner, 
Frickenhausen, Germany). The leukem ic K562 cell line, was cu ltu red  in cu ltu re  
medium  (RPMI 1640 w ith  g lutam ax supplem ented w ith  pyruvate (0,02 mM)), 100 
U/m l penic illin , 100 |ag/ml s treptom ycin  (Gibco, Paisley, UK) and 10% Fetal Calf 
Serum (FCS) at 37°C, 95% h u m id ity  and 5% CO2, in T75 tissue cu ltu re  flasks (Greiner, 
Frickenhausen, Germany). A fte r ove rn ight s tim u la tion  w ith  100 U/m l rIL-2 and 10 
ng/m l rIL-15, hLF1-11 was added to  the  cell cu ltu re  in t itra te d  concen tra tions. NK 
cell p ro life ra tion  was measured a fte r day 1, 3, 5, and 7 o f tre a tm e n t w ith  hLF1-11
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by 3H-Thymidine incorporation. The cytotoxic capacity was examined by 51Cr-release 
of 51Cr-labeled K562 cells (100 |aCi* 51Cr (Amersham, UK)), which w ere  used as target  
cells, 1000  cells/well. D ifferent e ffec to r /ta rget  (E:T) ratios w ere  tested. Cytotoxic 
capacity was shown as percentage specific lyses of the target cells. Activation of NK 
cells was determ ined by measuring the  CD69 expression on day 1, 3, 5, and 7 of 
trea tm en t  w ith  hLF1-11 using flowcytometry.
Flow cytom etry
NK, T cells and DCs w ere  phenotypically analyzed by 4- or 5-color f low  cytometry. 
The following conjugated mAbs w ere  used: CD3-(UCHT1), CD4-(MT310),  CD8-(DK25), 
CD27-(M-T271), CD45RA-(4KB5), CD45RO-(UCHL1) FITC- or PE-labeled (DAKO), 
CD25-(M-A251) PE, CD127-(M21) PE, CCR4-(1G1) PeCy7, CCR6-(11A9) PE- or biotin­
labeled, CD206-(19.2) PE, CXCR3-(1C6/CXCR3) PeCy5 (BD Biosciences), CXCR4-(12G5) 
PeCy5 (eBioscience, Uithoorn, The Netherlands), CCR7-(150503) FITC or PE, Dectin-  
1-(259931) PE (R&D Systems), CD4-(T4) ECD, CD4-(T4) PeCy5, and CD62L-(DREG54) 
ECD, CD80-(MAB104) PE, CD83-(HB15a) FITC, CD86-(HA5.2B7) PE (Beckman 
Coulter), CD209-(9E9A8) PE, CD282-(TL2.1) PE, CD284-(HTA125) PE (Biolegend), and 
isotype controls IgG1 FITC/PE dual-color control (DAKO) and IgG2b PE (Beckman 
Coulter). Intracellular analysis of Foxp3-(PCH101) FITC or PE and IL-17-(6CAP17) PE 
(eBioscience) and IFNy was perform ed after fixation and permeabilization, using Fix 
and Perm reagent (eBioscience). Before intracellular cytokine measurements, the  
cells were  stimulated for 4 hours with PMA (12.5 ng/ml) plus ionomycin (500 ng/ml) 
in the presence of Brefeldin A (5 |ag/ml; Sigma-Aldrich).
Results and discussion
hLF1-11 does not a lter surface m arker expression in m onocyte-derived DCs
DCs cultured and matured in the absence of hLF1-11 showed the  expected pattern  
with high expression of CD83, CD86, and CCR7, low and decreasing expression of 
MR, DC-SIGN, dectin-1, TLR2, and TLR4 (data not shown). Addition of hLF1-11 to the  
culture at doses up to 100 |ag/l did not result in altered expression patterns of any 
of these surface markers, although a slight but non-significant decrease in the  
expression of CCR7 was noted with  100 |ag/l hLF1-11. No differences w ere  seen 
between maturation induced by PGE2 or LPS.
These results are d ifferent from those in monocytes exposed to hLF1-11 which did 
not show an altered expression of surface markers and PRRs in the un-stimulated,  
but increased expression of TLR4 in the LPS-stimulated setting 17. This altered  
expression profi le also resulted in a more pro-in flam m atory  phenotype of these 
monocytes on M A M P  stimulation 17. The same study group reported similar results
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in macrophages cultured from monocytes during hLF1-11 exposition, showing an 
increased expression of PRRs, mainly TLR4 and dectin-1, with enhanced phagocytic 
activity 11. These contradicting results might be caused by differential effects of 
hLF1-11 on the  d ifferent cell types studied, although these cells all originate from 
the same myeloid lineage.
Because DCs play an im portant role in post SCT immunological processes like GvHD, 
immune reconstitution and GvT reactivity the current data do not seem to raise 
concerns on adverse effects of hLF1-11 regarding these processes. The DC 
phenotype remained unaltered, and preliminary data suggest inhibitory effects of 
hLF1-11 on the cytokine release of DCs (data not shown). Since the peptide is 
designed as an anti-microbial peptide for use in the early phase of SCT, where  
mainly inf lam m atory complications occur, this anti- in f lam m atory  effect might even 
proof to be beneficial.
Clearly, more studies are necessary to delineate the effects of hLF1-11 on DC 
subsets and the impact of timing, dosage, and co-stimulation of hLF1-11 exposition.  
Also, the effects of the peptide on other DC functions including cytokine release, T 
cell skewing and T cell activation remain to be determ ined in future studies.
hLF1-11 impairs LPS-mediated podosome dow n-regulation in im m ature DCs
In the assay on podosome down-regulation through a TLR4-mediated pathway, we  
found an impaired loss of podosomes on exposition to hLF and hLF1-11 (Figure 1). 
It is im portant to notice that the  DCs w ere  not cultured under the influence of 
these proteins, like in the previous DC study, as these had been added only in the 
final stimulation step. The effects suggest that hLF and hLF1-11 interfere more or 
less directly w ith  LPS signaling, but the mechanisms by which they do so are not 
easily deductable. For hLF many studies have shown a LPS-scavenging effect, purely 
based on charge-dependent interactions 18. This could be the mechanism in the 
impaired podosome loss with hLF in this assay. However, how hLF1-11 brought  
about a similar inhibitory e ffect remains speculative. hLF1-11 is thought to be too  
small a peptide for direct LPS-scavenging and it has been proposed as for other  
small cationic AMPs that cell penetration and intracellular translocation are of 
utmost importance for their biological activity although the intracellular target is 
currently not known 19. Unfortunately, w e  have not been able to perform additional  
mechanistic studies on the effects of hLF1-11 in DCs.
Podosome loss during DC maturation results in increased mobility of DCs and 
migration to lymph nodes where  mature DCs present antigen to lymphocytes and 
induce additional immune responses 20. Persisting of the podosomes under the 
influence of hLF and hLF1-11 possibly limits immune activation as has been shown 
in o ther models in which hLF reduced DC-mediated cellular immune responses and 
diseases 21;22. Theoretically inhibition of DC function during the early phase of SCT
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Figure 1 Effect of hLF1-11 on podosome fo rm ation  and expression.
100
Control LPS PGE2 hLF hLFl-11 LPS+hLF LPS+hLFl-11
(100|ig /m l) (100|ig /m l) (100|ig /m l) (100ng/m l)
Day 6 im m a tu re  DCs w e re  seeded on f ib ro n e c t in -c o a te d  12 m m  covers lips . A f te r  th e  cells had adh ere d , 
s t im u li w e re  added  co n s is tin g  o f  LPS (2 M g/m l), PGE2 (10 ^ .g /m l), hLF (100 |j.g /m l), hLF1-11 (100 ^ .g /m l), 
o r  th e  c o m b in a tio n  o f  LPS (2 M g/m l) and hLF o r hLF1-11 (100 |j.g /m l). The iDCs w e re  cu ltu re d  o v e rn ig h t 
and f ixe d  and sta ine d  th e  n e x t day. The cove rs lips  w e re  th e n  ana lyzed w ith  a s ta n d a rd  f lu o re s c e n t 
m ic ro sco p e  and pe rce n ta g e  o f  ce lls c o n ta in in g  pod osom es was ca lcu la te d . The m ean va lues o f  3 
in d e p e n d e n t e x p e rim e n ts  are show n . The LPS-induced loss o f  pod osom es was s ig n if ic a n tly  reduced  in 
th e  p resence o f  hLF and hLF1-11 (P = 0 .03  and P = 0.01 re sp e c tive ly ), acco rd in g  to  th e  Tam hane 
c o rre c tio n  fo r  m u lt ip le  te s tin g , n o t assum ing  equ a l va riances 34.
m ight prove benefic ia l as host APCs are pow erfu l inducers o f GvHD, a lthough they 
also play a ro le in the  generation o f GvT responses 23.
hLF1-11 does not a lter NK cell pro liferation and effector functions
NK cell pro life ra tion was measured after day 1, 3, 5, and 7 o f trea tm ent w ith  hLF1-11 by 
3H-Thymidine incorporation. A w ide range of hLF1-11 concentrations (0.01-5.0 Mg/ml) 
did not impact NK cell pro life ra tion (data not shown). Additional assays also revealed 
no changes in NK cell activation and cyto tox ic ity  w ith  hLF1-11 concentrations up to  1 
Mg/ml (Figure 2). In addition, no direct in vitro toxic effect o f hLF1-11 on NK cells was 
observed. These results suggest the absence of d irect effects of hLF1-11 on NK cells at 
concentrations w ith in  the therapeutic range used in animal and human studies 24.
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Figure 2 Effect of hLF1-11 on NK cell function.
The e f fe c t  o f  hLF1-11 on th e  c y to ly t ic  c a p a c ity  o f  NK ce lls  aga ins t K562 was s tu d ie d  w ith  th e  use o f 
51C r-re lease assay (A), and th e  e f fe c t  on NK ce ll a c t iv a t io n  was m easured  by th e  CD69 express ion  
(B). No s ig n ifica n t changes w e re  no tice d  using a w id e  range o f  hLF1-11 (0-1 ,0 ^ g /m l) . One re p re se n ta tive  
e x p e rim e n t o u t  o f  3 is show n.
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No o th e r data on hLF deriva tives like hLF1-11 are cu rren tly  available and few  exist 
on the  e ffec ts  o f hLF on NK cells. Damiens et al. found increased NK cell m ediated 
a n ti-tu m o r e ffec ts  against ep ithe lia l and hem atological cancer cells w ith  hLF 
concen tra tions o f 10 |ag/ml 25, bu t h igher doses o f hLF resulted in NK cell death. 
In th a t study the  a n ti- tu m o r e ffec ts  resu lted from  both d irec t m odula tion  o f NK cell 
c y to to x ic ity  and increased ta rge t cell sensitiv ity. The NK m odu la tion  was achieved 
by d irec t b ind ing o f hLF to  the  NK cells. However, the  b ind ing site o r receptor fo r 
hLF on NK cells has no t been iden tified . M ost o th e r studies regarding NK cell 
m odu la tion  involved in vivo animal m odels in which oral adm in is tra tion  o f hLF was 
investigated. These studies showed enhanced NK cell ac tiva tion  and an ti-tu m or 
a c tiv ity  resu lting from  hLF increasing the  release o f IL-18 from  in testina l ep ithe lia l 
cells 26.
The ro le o f NK cells in the  se tting  o f SCT is increasingly appreciated as they 
con tribu te  to  early im m une reco ns titu tio n  and GvT a c tiv ity  27. In th is  regard the 
absence o f in h ib ito ry  o r cy to tox ic  e ffec ts  o f hLF1-11 on these cells is reassuring, 
a lthough the  e ffec ts  o f higher doses remain to  be established.
hLF1-11 affects m em ory but not regulatory T cell function
In tw o  d iffe re n t assays the  e ffec t o f hLF1-11 on T cell p ro life ra tio n  was stud ied, and 
stim ula ted CD4+ T cells did no t display a lte red p ro life ra tio n  on exposure to  hLF1-11. 
No d irec t tox ic  e ffec t o f hLF1-11 on T cells was observed at concen tra tions lying 
w ith in  the  the ra pe u tic  range 24. M em ory CD4+ T cells s tim u la ted w ith  allo-PBMC 
exh ib ited s ign ifican tly  decreased p roduction  o f bo th IFNy and IL-17 in the  presence 
o f hLF1-11 at concen tra tions o f 10 and 100 |ag/ml (Figure 3). No e ffe c t was seen on 
regu la to ry  CD4+CD25high T cells d iffe re n tia tio n  measured by the  expression of 
Foxp3 (Figure 4).
Few studies have addressed the  e ffec ts  o f hLF on T lym phocytes and the  d iffe re n t 
subsets. Lym phocytes do express receptors fo r  hLF, and one specific receptor is 
even designated the  lym phocytic  (LC)-LfR 28. A lthough increased hLF-induced 
p ro life ra tion , CD4 expression, and IFNy p roduc tion  has been suggested in some 
studies, these results have been con trad ic ted  by others, the  substantia l diffe rences 
in m ethodo logy, use o f bovine versus human LF, and settings expla in ing these 
discrepancies 21;29;30. M ore consisten t data come from  in vivo animal studies which 
propose an im m une enhancing and T cell ac tiva ting  (both CD4 and CD8) e ffe c t of 
o ra lly  adm in is tered hLF 31. S im ilar to  NK cell ac tiva tion , as m entioned earlier, these 
e ffec ts  seem to  resu lt from  a lte red IL-18 release from  in testina l ep ithe lia l cells. 
In teresting ly, one study showed an in h ib ito ry  e ffe c t o f hLF on T cell responses w ith  
reduced p ro life ra tion , chem okine receptor expression, and Th1-cytokine release, 
com parable to, bu t less e ffic ie n t than, Cyclosporin A 32. M ore  standardized studies 
are necessary to  c la rify  the  d irec t and ind irec t e ffec ts  o f hLF and deriva tives on
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Figure 3 Effect of hLF1-11 on IFNy and IL-17 production by activated T cells.
Control hLFl-1110 ng/ml hLFl-11100 ng/ml
IFNy
C y to k in e  p ro d u c t io n  was m easured a f te r  s t im u la t io n  o f  m e m o ry  CD4+ T cells w ith  a llo -P B M C  in th e  
presence  o f  p o la r iz in g  cy to k in e s  and 10 o r 100 n g /m l o f  hLF1-11. Cells w e re  ana lyzed by f lo w c y to m e try  
on day 8 o f  cu ltu re . A s ig n if ic a n t re d u c tio n  in th e  p ro d u c t io n  o f  b o th  IL-17 and IFNy was n o tice d  in th e  
presence  o f  hLF1-11 (P = 0.01) 34. One re p re s e n ta tiv e  e x p e rim e n t is show n.
Figure 4 Effect of hLF1-11 on Foxp3 expression of regulatory T cells.
Control h LF l-1 1 10 ng/ml h LF l-1 1 100 ng/ml
Foxp3 Foxp3 Foxp3
R egula tory T cells (Treg) CD4+CD25high T cells w e re  iso la ted by flo w c y to m e tr ic  cell so rtin g  and s tim u la ted  
w ith  a llogene ic  s t im u la to r  PBMC in th e  presence o f po la riz in g  cy to k in e s  and 10 o r 100 ^ g /m l o f  hLF1-11. 
Cells w e re  analyzed by f lo w c y to m e try  on day 8 o f  c u ltu re  on th e  express ion o f  Foxp3. No changes w e re  
n o tice d  on expo su re  to  hLF1-11. O ne re p re s e n ta tiv e  e x p e rim e n t is show n.
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T cells and T ce ll-m ed ia ted im m une responses. The observed in h ib ito ry  e ffe c t of 
hLF1-11 on IFNy and IL-17 release by T lym phocytes is however reassuring, since 
both Th1 and Th17 responses have been im p lica ted in the  orig in  o f acute GvHD. 
Hence no increase in the  incidence o f acute GvHD w ould  be expected w ith  the  use 
o f th is  AMP. Nevertheless, the  e ffec ts  on GvT induction  and adaptive an ti-m icrob ia l 
im m u n ity  remain to  be de term ined, a lthough sim ilar to  Cyclosporin A, the  inh ib ition  
o f T cell responses by hLF1-11 are probably on ly tem po ra ry  and reversible. Since 
cy to tox ic  T lym phocytes (CD8+) and naïve T lym phocytes also play a crucial ro le in 
GvHD and GvT add itiona l studies should address the  e ffec ts  o f hLF1-11 on APC- 
m ediated activa tion  o f naïve T lym phoyctes.
Comprehensive summary
The curren t in vitro  studies did not reveal unexpected im m une responses o f hLF1-11 
th a t evoke concerns regarding safe ty and th e re w ith  do no t preclude fu r th e r  testing 
o f th is new an ti-m icrob ia l drug in the  c lin ical se tting  o f allogeneic SCT, especially 
considering the  fac t th a t the  peptide  hLF1-11 was tested at the  expected in vivo 
the rapeu tic  concen tra tion  o f hLF1-11. Nevertheless, because many im m unolog ical 
processes change during an allogeneic SCT, and data on in vivo e ffec ts  o f hLF1-11 
on im m une cells in humans are lacking, the re  s till needs to  be caution during fu tu re  
studies w ith  th is  an ti-m icrob ia l peptide  in pa tien ts receiving an allogeneic SCT. In 
add ition , im m unom odu la ting  e ffec ts  o f AMPs, includ ing hLF1-11, seem dependent 
on the  cell type  stud ied and the  tim ing , du ra tion  and dosage o f the  AMP tested 33. 
Nevertheless, the  observed in h ib ito ry  e ffec t o f hLF1-11 on LPS-induced DC 
m atura tion  and decreased Th1 and Th17 cytok ine release by CD4+ m em ory T cells 
also suggests possible add itiona l benefic ia l ac tiv ities  o f hLF1-11 during SCT w ith  
regards to  acute GvHD. These observations need to  be con firm ed bu t at least 
w a rran t fu r th e r  testing.
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SUMMARY AND FUTURE PERSPECTIVES
Summary
For many patients with hematological malignancies intensive therapy with 
high-dose chemotherapy alone or combined with radiotherapy followed by 
hematopoietic stem cell transplantation (SCT) is the only way to cure their disease. 
However, therapy is almost invariably complicated by the occurrence of infectious 
and non-infectious inflammatory complications, though considerable inter-individ­
ual variability is seen. Traditionally the focus has been on blood cells, or rather 
their absence, regarding the pathogenesis of these inflammatory complications. 
Fever is the most frequent complication and it generally occurs as the granulocytes 
or neutrophils reach their nadir. This complication has been christened 'febrile 
neutropenia' designating neutropenia as the most important factor in the 
occurrence of these complications. More recently greater emphasis has been 
placed on the (sub)mucosal damage of the mouth and gastro-intestinal tract 
following cytotoxic therapy, and is more generally referred to as mucosal barrier 
injury (MBI). The emphasis on MBI has helped to highlight the role of the intestinal 
innate immune system in post SCT inflammatory complications.
The mucosal barrier is extraordinarily complex plying host to more than 1014 
microbes that reside in close proximity to a single layer of intestinal epithelial cells. 
This symbiosis is normally mutually beneficial, but it requires the tight control of 
the immune system to prevent infection and microbial invasion as well as the 
occurrence of uncontrolled inflammation. Innate immunity plays a crucial role 
herein, and the perturbation of the delicate balance after cytotoxic therapy leads 
to alterations in host-microbial interactions which in turn influence early SCT 
complications that extend beyond the occurrence of infection. Especially in the 
development of graft-versus-host disease (GVHD) the occurrence of MBI, disrupted 
interactions between host and micro-organisms, and deregulated mucosal 
immunological processes play important roles. However, these new insights have 
not yet resulted in a greater acceptance of the role that MBI plays in post SCT 
complications, and research still focuses predominantly on immune cells rather 
than epithelial surfaces.
In the first part of this thesis we hypothesize that MBI is an important determinant 
of the systemic inflammatory response, as measured by C-reactive protein (CRP), 
and contributes to the occurrence of inflammatory complications following 
conditioning with chemotherapy with or without irradiation in the preparation for 
a SCT. In chapter 2 we performed a retrospective study in a homogenous group of 
autologous SCT recipients who had been given high-dose melphalan as conditioning 
regimen. We found a striking pattern of inflammation, and the occurrence of fever, 
coinciding with the occurrence of MBI, as measured by citrulline. This affected all 
patients without exception regardless of the presence or absence of bacteremia.
CHAPTER 10
With additional statistical analysis we were able to underscore this by showing that 
citrulline levels best predicted the course of CRP. Bacteremia possibly aggravated 
the inflammatory response but did not trigger it, and neutropenia did not 
significantly contribute to the inflammation at all. So we were able to strengthen 
our hypothesis and suggested that the paradigm 'febrile neutropenia' could in fact 
be replaced by a new paradigm of 'febrile mucositis'.
In chapter 3 we elaborated on this topic by studying the natural history of MBI and 
inflammation associated with another five conditioning regimens used for autologous 
and allogeneic SCT. The inclusion of a non-myeloablative regimen allowed us to 
estimate the sole impact of MBI on inflammation since treatment was accompanied 
by significantly less MBI, modest inflammation and no bacteremia, despite profound 
neutropenia. We also found a strong correlation between the degree of MBI elicited 
by the different regimen and the grade of inflammation. Moreover, we were able to 
link these findings with the occurrence of SCT complications, including the occurrence 
of bacteremia and acute lung injury. In addition we established a relationship between 
MBI and the kinetics of acute GvHD. We consider that our data underline that MBI 
plays a central role in the triad of MBI, inflammation and bacteremia. The extent of 
MBI determines the loss of physical barrier which facilitates bacteremia due to 
micro-organisms arising from the gut and the translocation of microbe-associated 
molecular patterns (MAMP). This was confirmed by the observation of a significant 
lower citrulline level in those with bacteremia as opposed to those without. In 
addition, MBI determines the magnitude of the inflammatory response. Chemotherapy 
and radiotherapy induce tissue damage and appear to 'prime' the innate immune 
system and it is the degree of activation status that ultimately determines the 
magnitude of the inflammatory responses elicited by host-microbial interactions 
once the mucosal barrier is breached.
In the second part of the thesis we performed retrospective analyses on the impact 
of single nucleotide polymorphisms (SNPs) in innate immune genes on the outcome 
of SCT, to explain partially the differences in the occurrence of post SCT complications 
and to further establish the importance of host-microbial interactions. In chapter 4 
we confirmed the impact of polymorphisms in the intracellular pattern recognition 
receptor (PRR) nucleotide-binding oligomerization containing protein (NOD)2 on the 
incidence of severe acute GvHD and 1-year treatment-related mortality in the setting 
of partially T cell-depleted myeloablative allogeneic SCT. This result contradicts the 
findings of Granell et al. who did not find an impact of these SNPs in T cell-depleted 
SCT in a Spanish cohort. The differences between the two studied cohorts emphasize 
the importance of context in judging on associations between gene polymorphisms 
and clinical outcomes. We conclude that in our particular clinical setting NOD2 
polymorphisms could be used to optimize therapy in SCT recipients. For instance 
donor selection, antimicrobial prophylaxis, and acute GvHD management could be
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tailored on the basis on the NOD2 status of both patient and potential donors. In 
addition, the large impact of NOD2 polymorphisms in SCT supports the concept that  
host-microbial interactions at the epithelial and mucosal barriers are important in 
the pathogenesis of SCT complications.
In chapter 5, w e  showed an association betw een  Candida colonization in SCT 
recipients and the newly discovered 'loss-of-function' polymorphism Y238X in the 
C-type lectin PRR dectin-1, which is involved in the  recognition of p-1,3-glucan. 
Colonization would probably have resulted in an increased incidence of candidemia  
whilst patients w ere  neutropenic and suffered from MBI had w e  not employed  
prophylaxis with fluconazole.
In both association studies the cohorts w ere  rather small w ith  consequently some 
difficulty employing multivariable analyses. Nonetheless, there  is a fair chance that  
the genetic associations we report  are genuine and clinically relevant since the 
pre-study probability of an association between these SNPs and SCT outcom e was 
high because of the existence of o ther confirmatory studies and biological 
plausibility. The biological plausibility is high since the  functions of both NOD2 and 
dectin-1 have been extensively characterized and a 'loss-of-function' phenotype  
established in the presence of the polymorphisms we studied.
Interestingly, in the analysis of SNP Y238X, we noted that Candida colonization  
seemed to increase the  incidence of acute GvHD, described in chapter 6. In 
retrospect this should not come as a total surprise since gram-negative bacilli are 
known to play a role in the developm ent of acute GvHD and antimicrobial prophylaxis 
during neutropenia reduces the incidence of acute GvHD. W e concluded that the 
presence of Candida species on the mucosa during MBI and neutropenia can 
contribute to the pathophysiology of acute GvHD, probably through activation of 
fungal PRRs by motifs possessed by the Candida species. Based on our findings we  
speculated that the common link between  Candida colonization and acute GvHD 
might be the interleukin ( IL)-23/T helper lymphocyte (Th)17 axis. Th17 is involved in 
the mucosal imm unity  to many pathogens and is implicated in the  pathogenesis of 
several auto -im m une diseases, including Crohn's disease. Mucosal immunity  
against Candida has recently been shown to be mediated by Th17, whereas systemic 
responses rely more on Th1 responses. Furthermore, a role for Th17 has recently  
been suggested in animal studies of acute GvHD pathogenesis, although thus far 
the data are inconclusive on the  exact impact in relation to Th1 responses. However,  
a link betw een  Candida colonization and T h1/Th17 has also been suggested in the 
pathogenesis of Crohn's disease. Nevertheless, the triad of Candida, acute GvHD 
and Th1/Th17 should be fu r ther  investigated which, if confirmed, could have 
clinical consequences. For instance, fluconazole prophylaxis would then be 
reconsidered for all SCT recipients, not solely to prevent systemic Candida infections 
but also to reduce acute GvHD. In addition, that proving Th17 contributes to the
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pathogenesis of acute GvHD in humans opens new avenues for the treatment of 
this complication.
In the third part of the thesis we focus on new therapeutic options for post-SCT 
complications, in essence trying to learn from the natural innate immune system, 
so to say, 'nature knows best'. Pleiotropic molecules like antimicrobial peptides 
(AMPs) are employed by the host defenses, but also have a secondary role in 
damage control and negative feedback. Hence, these molecules seem exceptionally 
suitable candidates for treating infections without increasing inflammation. In 
chapter 7 we described the theoretical background for the use of human lactoferrin 
(hLF) and its short-peptide cationic derivatives to treat SCT-related complications. 
The potential beneficial properties of hLF in SCT are diverse and include stimulation 
of growth and repair of epithelial cells, broad-spectrum antimicrobial activity, anti­
inflammatory activity and immune modulation. These properties are less well 
defined and characterized for the hLF-derived AMPs, but most AMPs contain the 
essential hLF domains necessary for interactions with microbial motifs and hLF 
receptors. One of these AMPs is human lactoferrin 1-11 (hLF1-11), developed by the 
pharmaceutical company AM-Pharma. Pre-clinical research has shown broad 
activity against pathogens involved in infections encountered in SCT recipients, 
with MICs ranging from 3.1 to 25 mg/L for different strains of bacteria and fungi 
(although in sub-physiological salt concentrations). Moreover, with animal studies 
antimicrobial activity was confirmed in vivo, even in neutropenic and immunocom­
promised subjects, at remarkably low concentrations (0.4 |ig/kg), compared with 
the in vitro  activity. hLF1-11 was well tolerated by animals, with no adverse events 
being seen after a daily dose of 10 mg/kg. These results encouraged and stimulated 
the further development of hLF1-11 for use in human subjects.
In chapter 8 we reported that the drug was well tolerated and safe after being given 
in single and sequential doses up to 5 mg to healthy volunteers. These data were 
complemented with those from our safety study of a single dose of 5 mg hLF1-11 
given intravenously to 8 SCT recipients. The drug was well tolerated and safe and no 
severe adverse events related to the study drug occurred. One concern arising from 
these studies was the increase in transaminase levels seen in both healthy volunteers 
and a single subject from our clinical trial. These abnormalities were transient, 
resolved completely, and were generally moderate, without any apparent clinical 
consequences. The use of other potentially hepatotoxic drugs probably explained the 
occurrence of the abnormalities experienced by the subject in our trial. Nevertheless, 
a safety board ordered a reduction of the dose to 0.5 mg in the planned multiple dose 
safety study in SCT recipients. However the study was cancelled when the company 
decided not to pursue the drug any further for clinical use.
The high efficacy of hLF1-11 in animal models suggested immune enhancing 
properties in addition to direct antimicrobial activity. This might give rise to safety
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concerns because in SCT im m unolog ical processes such as GvHD, im m une 
reco ns titu tio n  and gra ft-versus-leukem ia could also be in fluenced by the  peptide. 
T here fore in chapter 9 we pe rfo rm ed add itiona l in vitro  experim ents on T 
lym phocytes, natural k ille r (NK) cells, and d e nd ritic  cells (DC), all key players in 
transp lan ta tion  im m unology. There were no unexpected im m une responses to  
hLF1-11. Data on the  in vivo e ffec ts  o f hLF1-11 on NK-cells, lym phocytes, and DCs in 
humans are lacking so caution should be exercised in fu tu re  studies o f SCT recipients. 
The observed in h ib ito ry  e ffe c t o f hLF1-11 on lipopolysaccharide-induced DC 
m atura tion  and decreased Th1 and Th17 cy tok ine release by CD4+ m em ory T cells 
suggests possible add itiona l benefic ia l ac tiv ities  during SCT w ith  regards to  acute 
GvHD th a t needs con firm ation .
Future perspectives
Mucosal innate im m u n ity  plays an im p o rta n t ro le in cy to tox ic  therapy-induced MBI 
and GvHD, and hence has an im pact on SCT outcom e. Future studies are needed to 
gain fu r th e r  insights in to  the  com plex processes involved in mucosal im m unology 
so as to  develop new preventive and tre a tm e n t strateg ies fo r  im proving the 
outcom e o f SCT. W ith  the  in flam m ato ry  response during MBI being unre la ted to 
in fections as such the re  needs to  be a sh ift in focus from  in fections tow ards mucosal 
ba rrie r in te g rity  and innate im m une defenses. The in te ractions between PRRs and 
MAMPs and danger-associated m olecu lar pa tte rns (DAMPs), and the  an tim icrob ia l 
and im m unom odu la to ry  a c tiv ity  o f natural AMPs, may provide b e tte r insight in to 
the  way we approach uncon tro lled  in flam m ato ry  post SCT and indicates the 
d irec tion  in the  deve lopm ent o f tre a tm e n t strateg ies fo r acute GvHD and o ther 
com plica tions.
There fore, fu tu re  studies should address questions regarding pathogenesis, 
preven tion  and tre a tm e n t o f MBI in SCT recip ients. There is a need to  know more 
abou t w hat is happening at the  mucosal surfaces during SCT. W hich cells are 
involved in MBI and in flam m ation , - macrophages, ep ithe lia l cells, fib rob lasts , or 
endo the lia l cells? The ro le o f MAMPs needs to  be explored in m ore de ta il, and the 
thresho ld  fo r  trans loca tion  needs to  be de term ined. This also applies to  DAMPs, 
which ro le is ju s t s ta rted  to  be addressed in the  se tting  o f SCT. U ltim ate ly , the  most 
im p o rta n t question is if we can am e lio ra te  MBI and the  fo llow ing  in flam m ato ry  
response and prevent and tre a t GvHD fo r instance by using AMPs or PRR-agonists 
and antagonists.
The ro le o f c itru llin e  as a b iom arker o f cond ition ing -induced tissue damage should 
be m ore precisely defined. Prospective studies are necessary to  con firm  the  value 
o f c itru llin e  fo r  the  ind iv idual pa tien t in p red ic ting  the  occurrence and exten t of
CHAPTER 10
MBI, but more im portant subsequent complications including bacteremia and 
GvHD. In the meantime, classifying the degree of MBI of conditioning regimens, 
including the  so-called reduced intensity and non-myeloablative regimens, by 
means of measuring citrulline and/or CRP, could be used in clinical practice. For 
instance, it could help determ ine the need for antimicrobial prophylaxis, hospital 
admission, and use of preventive and therapeutic  anti- in f lam m atory therapies for 
a certain regimen.
The value of SNP screening in the  clinical setting of SCT remains to be determined,  
but looks promising. To study and detect genes of interest in the  future, tw o  general 
approaches exist, - genom e-wide association studies and a more step-wise  
approach focusing on pathogenic mechanisms. Screening individual genes or 
complete signaling pathways involved in antimicrobial peptide and cytokine  
synthesis, autophagy, PRR activation and signaling would be an attractive approach  
in SCT. The first goal is to enhance the insight into the contributing genes in the  
pathophysiology of inf lam m atory complications such as GvHD, but ult imately the  
goal is to find genetic associations which open ways for preventive or therapeutic  
interventions. The next step would then be designing prospective studies to 
determ ine clinical applicability of SNPs which are consistently and repeatedly  
associated with SCT outcome. However, studying the role of SNPs in the setting of 
SCT can only be done using large cohorts of patients, and this can only be achieved 
when individual institutions collaborate in national or international consortia.
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Voor veel patiënten met een hem ato-oncologische ziekte blijft intensieve therapie 
met chemotherapie alleen, of in combinatie met radiotherapie, gevolgd door een 
stam celtransplantatie (SCT) de enige manier om van hun ziekte te kunnen genezen. 
Echter, de behandeling wordt bijna altijd gecompliceerd door het optreden van 
infectieuze en niet-infectieuze ontstekingprocessen, hoewel er een aanzienlijke 
inter-individuele variabiliteit bestaat. Van oudsher is de focus gericht op bloedcellen, 
of liever gezegd het ontbreken daarvan, met betrekking tot de pathogenese van 
deze complicaties. Koorts is de meest frequent voorkomende reactie, die optreedt 
als de granulocyten of neutrofielen hun dieptepunt hebben bereikt. Deze 
complicatie wordt 'febriele neutropenie' genoemd. Recent is er echter meer 
interesse gekomen en onderzoek gedaan naar de rol van weefselbeschadiging na 
cytotoxische therapie bij het ontstaan van ontstekingscom plicaties na SCT, in het 
bijzonder van de slijmvliezen van de mond en het maag-darmkanaal. Deze 
chemotherapie en/of radiotherapie geïnduceerde slijm vliesschade wordt aangeduid 
als mucositis of 'mucosal barrier injury' (MBI).
De barrièrefunctie van de darmwand is buitengewoon complex, zeker als men 
beseft dat de menselijke gastheer sam enleeft met meer dan 1014 m icro-organis- 
men, het overgrote deel bestaand uit bacteriën, die slechts gescheiden worden 
door een enkele laag darm epitheelcellen. Deze samenleving is normaal gesproken 
voor zowel gastheer en micro-organismen voordelig, maar het vereist een strikte 
controle door het immuunsysteem. Enerzijds moet microbiële invasie en infectie 
voorkomen worden en anderzijds moeten commensale micro-organismen 
getolereerd worden zonder dat het leidt tot het optreden van ongecontroleerde 
ontstekingsreacties die vervolgens weer tot weefselschade kunnen leiden. De 
aangeboren immuniteit ('innate immunity') speelt een cruciale rol bij het behoud 
van deze homeostase. Bij verstoring van deze delicate balans na cytotoxische 
therapie ontstaan veranderingen in de interacties tussen gastheer en m icro-orga- 
nismen die invloed hebben op het optreden van ontstekingscom plicaties na SCT 
die verder gaan dan het optreden van infecties alleen. Helaas hebben deze nieuwe 
inzichten nog niet geresulteerd in een grotere acceptatie van de rol van MBI tijdens 
SCT, en de focus van huidig onderzoek richt zich toch nog voornam elijk op 
bloedcellen in plaats van epitheelcellen en de complexe mucosale immunologie.
In het eerste deel van dit proefschrift onderzochten wij de hypothese dat MBI, 
ontstaan na de behandeling met chemotherapie met of zonder bestraling, een 
belangrijke onafhankelijke factor is bij het optreden van systemische ontstekings- 
reacties, gemeten door middel van het C-reactief proteïne (CRP), en bijdraagt aan 
het ontstaan van ontstekingscom plicaties na SCT. In hoofdstuk 2 hebben we een 
retrospectief onderzoek verricht in een homogene groep van patiënten die een
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autologe SCT ondergingen na conditionering met een hoge dosis melfalan. We 
vonden een opvallend patroon van system ische ontsteking en optreden van koorts 
die samenhing met het optreden van significante MBI van het maag-darmkanaal. 
Dit was vastgesteld door sequentiële metingen van citrulline, een aminozuur dat 
sterk correleert met de hoeveelheid aanwezige darm epitheelcellen. Deze 
samenhang werd zonder uitzonderingen gezien bij alle patiënten, ongeacht of er 
wel of geen bacteriëmie optrad. Met aanvullende statistische analyses konden we 
de relatie tussen darmschade en ontsteking bevestigen door aan te tonen dat 
citrulline de beste voorspeller was van het CRP beloop en de hoogte van het CRP. 
Het optreden van bacteriëmie droeg mogelijk wel bij aan de mate van ontstekings- 
reactie, maar leek een secundaire en minder belangrijke factor te zijn. Belangrijker 
nog, neutropenie bleek geen significante bijdragende rol te hebben bij het optreden 
van ontsteking na SCT. Dus we waren in staat om onze hypothese te bevestigen en 
stelden daarom voor om het paradigma 'febriele neutropenie' te verlaten en te 
vervangen door het nieuw paradigma 'febriele mucositis'.
In hoofdstuk 3 hebben we het onderwerp, 'febriele mucositis', verder uitgewerkt 
door het natuurlijke beloop van MBI en ontsteking te bestuderen in nog eens vijf 
andere conditioneringregim es die gebruikt worden bij de voorbereiding voor een 
autologe of allogene SCT. Het meenemen van een zogenaamd niet-myeloablatief 
regime maakte de impact van MBI op ontsteking extra zichtbaar. Deze behandeling 
ging namelijk gepaard met slechts geringe MBI en een beperkte ontstekingsreactie, 
zonder het optreden van bacteriemie, ondanks een langdurige en diepe neutropenie. 
We vonden een sterke correlatie tussen de ernst van MBI en de hoogte van de 
systemische ontstekingsreactie. Bovendien konden we een duidelijke relatie leggen 
tussen het optreden van MBI en post SCT complicaties, zoals bacteriëmie, acute 
longschade en acute graft-versus-host disease (GvHD).
Wij zijn van mening dat onze gegevens het concept versterken dat MBI een centrale 
rol speelt in de trias van MBI, ontsteking en bacteriëmie. De mate van MBI bepaalt 
de ernst van de verstoring van de fysieke barrière, die vervolgens translocatie van 
zogenaamde microben-geassocieerde moleculaire patronen (MAMP) en 
darmbacteriën mogelijk maakt. Dit werd bevestigd door de waarneming dat 
patiënten met een bacteriemie aanzienlijk lagere citrulline waarden hadden dan 
degenen zonder bacteriëmie. Bovendien blijkt MBI de mate van de systemische 
ontstekingsreactie te beïnvloeden. Chemotherapie en radiotherapie induceren 
w eefselschade en activeren het aangeboren immuunsysteem ('primen'). Het is 
deze 'priming' die uiteindelijk de ernst van de ontstekingsreactie bepaalt.
In het tweede deel van het proefschrift hebben we diverse retrospectieve analyses 
uitgevoerd naar de impact van enkel-nucleotide polymorfismen (single nucleotide 
polymorphisms (SNP)) van genen van het aangeboren immuunsysteem op de 
uitkomsten van een SCT. Dit is enerzijds gedaan om een deel van het inter-individu-
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ele verschil in het optreden van complicaties te kunnen verklaren en anderzijds om 
het belang van eerder benoemde interacties tussen gastheer en micro-organismen 
te karakteriseren in de context van SCT. In hoofdstuk 4 hebben we de invloed van 
polymorfismen in de intracellulaire patroon herkenningreceptor (PRR) NOD2 op de 
incidentie van ernstige acute GvHD en de 1-jaars therapiegerelateerde mortaliteit 
bevestigd, maar nu binnen de context van partieel T-cel gedepleteerde allogene 
SCT. Dit resultaat was in tegenspraak met de bevindingen van een andere studie, in 
een Spaans cohort, waarbij geen effect van deze SNPs gevonden werd in een T-cel 
gedepleteerde setting. De verschillen tussen de twee bestudeerde cohorten 
benadrukken het belang van de context in de beoordeling van de gevonden 
associaties tussen gen-polym orfism en en klinische uitkomstmaten. We concluderen 
dat in onze Nijmeegse klinische setting NOD2 polymorfismen wel kunnen worden 
gebruikt om de therapie voor patiënten die SCT ondergaan te optimaliseren. Zo kan 
bijvoorbeeld de selectie van donoren, de antimicrobiële profylaxe en het beleid bij 
acute GvHD worden toegespitst op basis van de NOD2 status van zowel de patiënt 
als de donor(en). Bovendien ondersteunt de invloed van NOD2 polymorfismen op 
de uitkomstmaten van een SCT het concept dat interacties tussen gastheer en mi- 
cro-organism en ter plaatse van de epitheliale en mucosale barrières belangrijk zijn 
in de pathogenese van post-SCT complicaties.
In hoofdstuk 5 hebben we een verband kunnen aantonen tussen toegenomen 
Candida kolonisatie bij SCT patiënten en een recent ontdekt Y238X polymorfisme 
in de C-type lectine PRR, dectin-1, die betrokken is bij de herkenning van 
P-1,3-glucan. De toegenomen kolonisatie zou w aarschijnlijk hebben geresulteerd 
in een verhoogde incidentie van candidemie tijdens de fase van neutropenie en 
MBI, ware het niet dat bij vaststelling van Candida kolonisatie gestart werd met 
behandeling met oraal fluconazol.
De beide studies werden verricht in relatief kleine cohorten met daardoor enige 
beperkingen in de multivariate analyse. Niettemin achten wij de kans reëel dat de 
door ons gevonden genetische associaties daadwerkelijk bestaan en klinisch 
relevant zijn. De associaties tussen NOD2 en SCT uitkomsten zijn al aangetoond in 
vergelijkbare cohorten met patiënten die getransplanteerd werden met een 
verwante donor. Verder is de zogenaamde biologische plausibiliteit van de 
associaties hoog. Zo zijn de biologische functies bij processen, zoals ontsteking en 
infectie van zowel NOD2 als dectin-1, uitgebreid gekarakteriseerd en zijn de 
functionele gevolgen van de bestudeerde polymorfismen, beiden hebben een 
verlies van functie ('loss-of-function') tot gevolg, geassocieerd met ontregeling van 
deze processen.
Interessant is dat wij bij de analyse van SNP Y238X vaststelden dat Candida 
kolonisatie de incidentie van acute GvHD leek te verhogen, zoals beschreven in 
hoofdstuk 6. Achteraf is dit ook niet een onverwachte bevinding aangezien al veel
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langer de rol van G ram -negatieve bacteriën bij het on tstaan van acute GvHD 
bekend is en aangetoond is dat an tim ic rob ië le  pro fy laxe tijdens neu tropen ie  de 
inc identie  van acute GvHD ve rm inde rt. We concludeerden dat de aanwezigheid van 
Candida soorten op het s lijm vlies tijdens MBI en neu tropen ie  ook kan bijdragen 
aan de pathogenese van acute GvHD, w aarsch ijn lijk  door het activeren van 
receptoren die betrokken zijn bij de herkenning van gisten en schimmels. Op basis 
van onze bevindingen speculeren w ij dat m ogelijk  de nieuw  on tdek te  in te rleuk ine  
(IL)-23/T he lper lym focy t (Th)17-as het gem eenschappelijke verband kan zijn 
tussen Candida ko lon isatie  en acute GvHD. Th17 reacties zijn be trokken bij mucosale 
im m u n ite it ge rich t tegen versch illende m icro-organism en, inclusie f Candida, en zij 
spelen ook een rol bij het ontstaan van au to-im m uun ziekten, w aaronder de ziekte 
van Crohn. Bovendien is er een rol voo r Th17 gesuggereerd bij het on tstaan van 
acute GvHD in d ie r studies, a lhoewel to t  nu toe  de gegevens n ie t eenduid ig zijn 
over de exacte im pact, onder andere in verhouding to t  Th1 reacties. Bovendien is 
het verband tussen Candida ko lon isatie  en Th1/Th17 ook al eens gesuggereerd bij 
de ziekte van Crohn, een ziekte w aarb ij, net als bij GvHD, vers too rde  in teracties 
tussen gastheer en m icro-organism en een g ro te  rol spelen in de pathogenese. 
Daarom m oet de trias  van Candida, Th1/Th17 en GvHD verder onderzocht worden. 
Indien d it bevestigd w o rd t, hee ft d it klinisch consequenties. Fluconazol profylaxe 
voor alle allogene SCT pa tiën ten zou dan opn ieuw  overwogen m oeten worden, 
tijdens de SCT en het eerste jaa r erna, n ie t alleen om system ische Candida in fecties 
te voorkom en, maar ook om de inc iden tie  en ernst van acute GvHD te  verm inderen. 
Bovendien, als Th17 daadwerkelijk b lijk t bij te dragen aan de pathogenese van acute 
GvHD, dan opent d it nieuwe wegen voor de behandeling van deze com plicatie.
In het derde deel van d it p ro e fsch rift concentreerden we ons op nieuwe 
therapeutische opties voor vroege SCT com plicaties. Daarbij im iteerden we het 
na tuurlijke  aangeboren im m uunsysteem . In de na tuur komen nam elijk  veel 
an tim ic rob ië le  peptiden (AMP) voo r m et een breed scala aan functies  waartegen, 
door de eeuwen heen, k laarb lijke lijk  w e in ig  res is tentie  is on tw ikke ld  door de m i- 
cro-organism en. Vandaar dat deze peptiden geschikte kandidaten lijken te  zijn bij 
de bestrijd ing  van in fecties, zeker ook bij pa tiën ten m et een im m uunstoorn is . In 
hoofdstuk 7 beschrijven we de theore tische  achtergrond voo r het gebru ik van 
humaan la c to fe rrin e  (hLF) en de daarvan afgele ide kationische peptiden bij de 
behandeling van SCT ge re lateerde com plicaties. De po ten tiee l gunstige 
eigenschappen van hLF in SCT zijn divers en bestaan u it s tim u le ring  van de groei en 
herste l van ep itheelce llen, breedspectrum  an tim ic rob ië le  a c tiv ite it, on tstekings- 
rem m ende a c tiv ite it en im m uunm odu la tie . Deze eigenschappen zijn m inder goed 
gede fin ieerd voo r de AMPs afgele id van hLF, maar de meeste AMPs bevatten de 
essentië le dom einen van het m oederm olecuu l, die nodig zijn voor m icrobië le  
in te racties en bind ing aan hLF receptoren. Een van deze AMPs, is het humaan
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lactoferrine 1-11 (hLF1-11), ontwikkeld door het farmaceutische bedrijf AM-Pharma 
BV (Bunnik, Nederland). Uit preklinisch onderzoek is antimicrobiële activiteit 
gebleken tegen ziekteverwekkers, die betrokken zijn bij infecties die veel voorkomen 
bij SCT patiënten. In diverse in vivo dierstudies is de antimicrobiële effectiviteit van 
hLF1-11 getest en bevestigd, zelfs bij neutropene en immuungecompromitteerde 
dieren en bij opvallend lage concentraties (0,4 |ag/kg). hLF1-11, oplopend tot 
dagelijkse doseringen van 10 mg/kg, werd goed verdragen door de proefdieren, 
zonder noemenswaardige bijwerkingen. Deze resultaten hebben de weg vrijgemaakt 
voor de verdere ontwikkeling van hLF1-11 voor humaan gebruik.
In hoofdstuk 8 rapporteren wij de eerste data van hLF1-11 toegepast bij mensen. 
Dit betrof in eerste instantie veiligheidsstudies in gezonde vrijwilligers. hLF1-11, 
intraveneus toegediend met enkelvoudige en meervoudige doseringen tot 5 mg, 
werd goed verdragen en veilig bevonden in gezonde vrijwilligers. Deze gegevens 
werden aangevuld met gegevens uit onze eerste klinische studie naar de veiligheid 
van een eenmalige dosis van 5 mg intraveneus toegediend in 8 SCT patiënten. Het 
peptide werd goed verdragen en er traden geen ernstige bijwerkingen op die 
verband hielden met het studie-peptide. Een zorg die voortvloeide uit deze studies 
was het optreden van parenchymateuze levertestafwijkinen (verhoogd ASAT en 
ALAT) na hLF1-11, bij zowel gezonde vrijw illigers als ook bij één patiënt uit onze 
klinische trial. Deze levertestafwijkingen waren voorbijgaand, volledig omkeerbaar, 
mild van aard en hadden voor zover te beoordelen geen duidelijke klinische 
consequentie. Het gelijktijdig gebruik van andere potentieel hepatotoxische 
geneesmiddelen verklaart hoogstw aarschijnlijk het ontstaan van de levertestafwij- 
kingen bij de patiënt uit de klinische studie. Toch heeft een onafhankelijke veilig- 
heidscommissie de opdracht gegeven de dosis hLF1-11 te verlagen naar 0,5 mg bij 
de vervolgstudie met meervoudige doses bij SCT patiënten. Deze geplande studie 
werd helaas geannuleerd op het moment dat het bedrijf besloot af te zien van 
verdere ontwikkeling van hLF1-11 voor humaan gebruik.
De hoge effectiviteit van hLF1-11 in diermodellen heeft geleidt tot de suggestie dat 
het peptide additionele immuunstimulerende eigenschappen bezit naast de directe 
antim icrobiële activiteit. Dit roept vragen op betreffende de veiligheid van dit 
peptide bij SCT patiënten, omdat tijdens een SCT vele immunologische processen 
zoals alloreactieve T-cel reacties (GvHD, graft-versus-leukem ia) en immuunrecon- 
stitutie een rol spelen en beïnvloed kunnen worden door dit peptide. Daarom 
beschrijven we in hoofdstuk 9 de aanvullende in vitro  experimenten die uitgevoerd 
zijn met T-lym focyten, natural killer (NK) cellen en dendritische cellen (DC), 
belangrijke spelers in de transplantatie-imm unologie. Er traden geen onverwachte 
immuunreacties op na blootstelling van deze cellen aan hLF1-11. Gezien het feit dat 
gegevens over de in vivo effecten van hLF1-11 nog onbekend zijn moet voorzichtig­
heid worden betracht in toekomstige studies bij patiënten. De waargenomen
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rem m ende effecten van hLF1-11 op DC maturatie  en cytokine productie (IL-17, 
IFNy) door CD4+ T-cellen suggereren mogelijk additionele activiteiten van hLF1-11 
die van belang kunnen zijn bij de behandeling van specifieke SCT gerelateerde  
complicaties, zoals acute GvHD.
Toekomstperspectief
Het aangeboren immuunsysteem van de slijmvliezen van mond en maag-darmka-  
naal speelt een belangrijke rol bij de door cytotoxische therapie  veroorzaakte MBI  
en de daaruit volgende ontstekingscomplicaties, zoals acute longschade en GvHD.  
Deze complicaties hebben een grote invloed op de uiteindelijke uitkomst van een  
SCT. Verdere studies zijn dan ook nodig om meer inzicht te krijgen in de complexe  
processen die betrokken zijn bij de mucosale immunologie, zodat nieuwe  
preventieve en therapeutische strategieën ontwikkeld kunnen worden, w aardoor  
de morbidite it  en m orta l i te it  na een SCT verminderd kan w orden .  O m d at  de 
systemische ontstekingsreactie, die gezien w o rd t  na de conditionering voor een 
SCT, weinig relatie heeft  m et  de neutropenie en geassocieerde infecties en meer 
het gevolg blijkt te  zijn van MBI m oet er een verschuiving plaatsvinden in de focus 
naar de mucosale barrière en het aangeboren immuunsysteem. Inzichten, enerzijds 
in de interacties tussen PRRs en M AMPs en gevaar-geassocieerde moleculaire  
patronen (danger-associated molecular patterns; DAMPs) en anderzijds in de 
antimicrobiële en im m unom odulerende eigenschappen van natuurlijke kationische 
AMPs, kunnen zorgen voor n ieuwe invalshoeken bij de preventie en behandeling  
van de ontregelde ontstekingsreacties en complicaties die optreden na een SCT. 
Toekomstig onderzoek m oet zich richten op vraagstukken betreffende de 
pathogenese, preventie en behandeling van MBI bij SCT patiënten. Er is een grote  
behoefte  om te w eten w at er allemaal gebeurt ter plaatse van de mucosale 
barrières van de mond en darm in de vroege fase na cytotoxische therapie. Welke  
cellen zijn nog aanwezig na de conditionering en betrokken bij MBI en de ontste-  
kingsreactie tijdens SCT; macrofagen, epitheelcellen, fibroblasten of endotheelcel-  
len? Om dit te  bepalen zal weefselonderzoek van de mucosa tijdens mucositis 
onontbeerli jk  zijn. Verder m oet de precieze rol van de diverse M AMPs en DAMPs 
worden onderzocht, alsook de drempel voor translocatie bepaald worden.  
Uiteindelijk blijft de belangrijkste vraag hoe wij MBI en de daar op volgende ontste-  
kingsreacties en complicaties, zoals acute GvHD, kunnen voorkomen en behandelen,  
bijvoorbeeld door het toepassen van AMPs of door beïnvloeding van de activatie  
status van PRRs met agonisten of antagonisten.
De rol van citrulline als een biomarker van chemo- en radiotherapie geïnduceerde  
darmschade m oet nauwkeuriger worden vastgesteld. Prospectieve studies zijn
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uiteindelijk nodig om de waarde van citrulline te bepalen voor de individuele  
patiënt bij het voorspellen van MBI en de daaraan gerelateerde complicaties zoals 
bacteriëmie en GvHD. In de tussentijd kan men m et het meten van citrulline en CRP 
in principe alle conditioneringregimes in kaart brengen en graderen naar de impact 
op MBI en ontsteking. Die informatie kan gebruikt worden in de dagelijkse klinische 
SCT praktijk bij de keuzes die gemaakt worden betreffende het gebruik van 
antimicrobiële profylaxe, noodzaak voor opname in het ziekenhuis en totale  
parenterale voeding en het gebruik van preventieve en therapeutische ontstekings-  
rem m ende therapieën.
De waarde van het screenen op SNPs m oet voor de klinische setting van SCT nog 
worden vastgesteld, maar lijkt veelbelovend. Bij het bestuderen en ontdekken van 
genen van belang in de toekom st zijn er tw e e  algemene benaderingen mogelijk; 
enerzijds de genoomwijde associatie studies en anderzijds de m eer stapsgewijze 
benadering gericht op bekende pathogenetische mechanismen. Het onderzoeken  
van afzonderlijke genen of volledige signalering pathways betrokken bij de 
antimicrobiële peptiden, cytokine productie, autofagie, PRR activering en 
signalering zou een aantrekkelijke aanpak in SCT kunnen zijn. Het eerste doel 
daarbij is om het inzicht te vergroten in de genen die bijdragen aan het ontstaan  
van ontstekingscomplicaties zoals GvHD, maar het uiteindelijke doel is het vinden  
van genetische associaties die de weg vri jmaken voor preventieve of therapeutische  
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m oeten zijn naar de klinische toepasbaarheid van de SNPs die geassocieerd zijn 
m et SCT uitkomsten. Echter, bij het bestuderen van de rol van deze SNPs in de 
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ALI Acute lung injury
ALL Acute lymphoblastic leukemia
ALT Alanine aminotransferase
AML Acute myeloid leukemia
AMP Antimicrobial peptide
ANC Absolute neutrophil count
APC Antigen presenting cell
ARDS Acute respiratory distress syndrome
AST Aspartate aminotransferase
ATG Antithym ocyte globulin
AUC Area under the curve
BEAM BCNU, etoposide, cytarabine, melphalan
BMI Body mass index
BOOP Bronchiolitis obliterans organizing pneumonia
BPI Bactericidal/permeability-increasing protein
Bus Busulphan
CD Cluster of differentiation
CLL Chronic lymphocytic leukemia
CLR C-type lectin receptor





CTC Common toxicity criteria
Cyclo Cyclophosphamide
DAMP Danger-associated molecular pattern
DC Dendritic cell
DFS Disease-free survival
DLI Donor lymphocyte infusion
EDGE Environmentally determ ined genetic expression
ELISA Enzyme-linked immunosorbent assay
Flu Fludarabine
G-CSF Granulocyte-colony stimulating factor
GvHD Graft-versus-host disease
GvL Graft-versus-leukemia
GWAS G enom e-wide association study
hBD2 Human beta defensin 2
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LisT of ABBREviATioNs
HD-5 Alfa defensin 5
HD-6 Alfa defensin 6
HDM High dose melphalan
HET Heterozygote
hLF Human lactoferrin
hLF1-11 Human lactoferrin 1-11
HLA Human leukocyte antigen
HOM Homozygote
IBD Inflam m atory bowel disease
Ida Idarubicin
IDR Innate defense regulator
IEC Intestinal epithelial cell
IFNy Interferon gamma
IL Interleukin
IPS Idiopathic pneumonia syndrome





M A M P Microbe-associated molecular pattern
MBI Mucosal barrier injury
MBL Mannose-binding lectin
MDP M uram yl dipeptide
MDS Myelodysplastic syndrome
MHC M ajor histocompatibility complex
MiHag M ino r histocompatibility antigen
M M Multip le  myeloma
NF-kB Nuclear factor kappa B
NHL Non-Hodgkin lymphoma
NK Natural killer cell
NLR Nod-like receptor
NMA Non-myeloablative
NNMSS Nijmegen Nursing Mucositis Scoring System
NOD2 Nucleotide-binding oligomerization domain containing protein 2
NRM Non-relapse morta lity
OS Overall survival
OVS Oral viridans streptococcus




PMBC Peripheral blood mononuclear cell
PRR Pattern recognition receptor
RLR RIG-like receptor
ROS Reactive oxygen species
RRM Relapse-related mortality
SAE Serious adverse event
(H)SCT (Hematopoietic) stem cell transplantation
SIRS Systemic inf lamm atory response syndrome
SNP Single nucleotide polymorphism
TBI Total body irradiation
Th T helper lymphocyte
TLR Toll-like receptor
TNFa Tumor necrosis factor alfa
Treg Regulatory T cell
TRM Treatm ent-re lated  morta lity
ULN Upper limited of normal
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